Medtronic (MDT) 10-Q 3 Mar 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jan. 27, 2017	Mar. 01, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	Medtronic plc
Entity Central Index Key	1,613,103
Document Period End Date	Jan. 27, 2017
Current Fiscal Year End Date	--04-28
Document Type	10-Q
Amendment Flag	false
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Ordinary Shares Outstanding		1,368,884,991
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,017

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Millions	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016
Income Statement [Abstract]
Net sales	$ 7,283,000,000	$ 6,934,000,000	$ 21,794,000,000	$ 21,266,000,000
Costs and expenses:
Cost of products sold	2,268,000,000	2,141,000,000	6,855,000,000	6,779,000,000
Research and development expense	530,000,000	546,000,000	1,640,000,000	1,649,000,000
Selling, general, and administrative expense	2,388,000,000	2,317,000,000	7,232,000,000	7,109,000,000
Special charge	100,000,000	0	100,000,000	0
Restructuring charges, net	21,000,000	19,000,000	162,000,000	159,000,000
Certain litigation charges	218,000,000	0	300,000,000	26,000,000
Acquisition-related items	68,000,000	63,000,000	148,000,000	183,000,000
Amortization of intangible assets	497,000,000	484,000,000	1,484,000,000	1,448,000,000
Other expense, net	46,000,000	9,000,000	174,000,000	127,000,000
Operating profit	1,147,000,000	1,355,000,000	3,699,000,000	3,786,000,000
Interest income	(88,000,000)	(99,000,000)	(272,000,000)	(321,000,000)
Interest expense	268,000,000	275,000,000	804,000,000	905,000,000
Interest expense, net	180,000,000	176,000,000	532,000,000	584,000,000
Income from operations before income taxes	967,000,000	1,179,000,000	3,167,000,000	3,202,000,000
Provision for income taxes	147,000,000	84,000,000	307,000,000	767,000,000
Net income	820,000,000	1,095,000,000	2,860,000,000	2,435,000,000
Net loss attributable to noncontrolling interests	(1,000,000)	0	(5,000,000)	0
Net income attributable to Medtronic	$ 821,000,000	$ 1,095,000,000	$ 2,865,000,000	$ 2,435,000,000
Basic earnings per share (usd per share)	$ 0.60	$ 0.78	$ 2.07	$ 1.72
Diluted earnings per share (usd per share)	$ 0.59	$ 0.77	$ 2.05	$ 1.70
Basic weighted average shares outstanding (shares)	1,372.2	1,406.6	1,381.9	1,412.5
Diluted weighted average shares outstanding (shares)	1,383.1	1,422.2	1,394.7	1,429.2
Cash dividends declared per ordinary share (usd per share)	$ 0.43	$ 0.38	$ 1.29	$ 1.140

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016
Statement of Comprehensive Income [Abstract]
Net income	$ 820	$ 1,095	$ 2,860	$ 2,435
Other comprehensive loss, net of tax:
Unrealized (loss) gain on available-for-sale securities, net of tax (benefit) expense of $(40), $(34), $(3), and $(149) respectively	(115)	(61)	(40)	(268)
Currency adjustment, net	(553)	(1,454)	(1,239)	(1,513)
Net change in retirement obligations, net of tax expense of $5, $10, $15, and $30, respectively	22	27	66	62
Unrealized gain (loss) on derivatives, net of tax expense (benefit) of $55, $(3), 113 and $(36), respectively	95	(6)	202	(62)
Other comprehensive loss	(551)	(1,494)	(1,011)	(1,781)
Comprehensive income (loss) including noncontrolling interests	269	(399)	1,849	654
Comprehensive loss attributable to noncontrolling interests	(1)	0	(5)	0
Comprehensive income (loss) attributable to Medtronic	$ 270	$ (399)	$ 1,854	$ 654

Consolidated Statements of Com4

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016
Other Comprehensive Income (Loss), Tax
Unrealized (loss) gain on available-for-sale securities, tax (benefit) expense	$ (40)	$ (34)	$ (3)	$ (149)
Net change in retirement obligations, tax expense	5	10	15	30
Unrealized gain (loss) on derivatives, tax expense (benefit)	$ 55	$ (3)	$ 113	$ (36)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Jan. 27, 2017	Apr. 29, 2016
Current assets:
Cash and cash equivalents	$ 2,768	$ 2,876
Investments	8,690	9,758
Accounts receivable, less allowances of $168 and $161, respectively	5,453	5,562
Inventories	3,720	3,473
Other current assets	1,792	1,931
Total current assets	22,423	23,600
Property, plant, and equipment	10,436	9,714
Accumulated depreciation	(5,489)	(4,873)
Property, plant, and equipment, net	4,947	4,841
Goodwill	41,224	41,500
Other intangible assets, net	26,209	26,899
Tax assets	1,484	1,383
Other assets	1,291	1,421
Total assets	97,578	99,644
Current liabilities:
Current debt obligations	6,226	993
Accounts payable	1,557	1,709
Accrued compensation	1,521	1,712
Accrued income taxes	821	566
Other accrued expenses	2,547	2,185
Total current liabilities	12,672	7,165
Long-term debt	25,923	30,109
Accrued compensation and retirement benefits	1,610	1,759
Accrued income taxes	2,527	2,903
Deferred tax liabilities	3,643	3,729
Other liabilities	1,710	1,916
Total liabilities	48,085	47,581
Commitments and contingencies
Shareholders’ equity:
Ordinary shares— par value $0.0001	0	0
Retained earnings	52,266	53,931
Accumulated other comprehensive loss	(2,879)	(1,868)
Total shareholders’ equity	49,387	52,063
Noncontrolling interests	106	0
Total equity	49,493	52,063
Total liabilities and equity	$ 97,578	$ 99,644

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Jan. 27, 2017	Apr. 29, 2016
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 168	$ 161
Ordinary shares, par value (usd per share)	$ 0.0001	$ 0.0001

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016
Operating Activities:
Net income	$ 2,860	$ 2,435
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,199	2,112
Amortization of debt discount and issuance costs	21	22
Acquisition-related items	(43)	216
Provision for doubtful accounts	31	43
Deferred income taxes	(404)	(291)
Stock-based compensation	272	291
Other, net	(113)	(117)
Change in operating assets and liabilities, net of acquisitions:
Accounts receivable, net	18	86
Inventories	(261)	(388)
Accounts payable and accrued liabilities	(124)	177
Other operating assets and liabilities	495	(399)
Certain litigation charges	300	26
Certain litigation payments	(144)	(321)
Net cash provided by operating activities	5,107	3,892
Investing Activities:
Acquisitions, net of cash acquired	(1,328)	(1,132)
Additions to property, plant, and equipment	(924)	(693)
Purchases of investments	(3,354)	(4,509)
Sales and maturities of investments	4,286	4,017
Other investing activities, net	21	(11)
Net cash used in investing activities	(1,299)	(2,328)
Financing Activities:
Acquisition-related contingent consideration	(58)	(21)
Change in current debt obligations, net	1,118	1,223
Repayment of short-term borrowings (maturities greater than 90 days)	(2)	(48)
Proceeds from short-term borrowings (maturities greater than 90 days)	4	139
Issuance of long-term debt	131	0
Payments on long-term debt	(361)	(1,612)
Dividends to shareholders	(1,782)	(1,608)
Issuance of ordinary shares	309	360
Repurchase of ordinary shares	(3,409)	(2,170)
Other financing activities	80	60
Net cash used in financing activities	(3,970)	(3,677)
Effect of exchange rate changes on cash and cash equivalents	54	(9)
Net change in cash and cash equivalents	(108)	(2,122)
Cash and cash equivalents at beginning of period	2,876	4,843
Cash and cash equivalents at end of period	2,768	2,721
Supplemental Cash Flow Information
Cash paid for income taxes	474	1,236
Cash paid for interest	$ 626	$ 707

Basis of Presentation

Basis of Presentation	9 Months Ended
	Jan. 27, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, comprehensive income, financial condition, and cash flows in conformity with U.S. GAAP. In the opinion of management, the consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) for the periods presented. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended April 29, 2016 . The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation. The Company’s fiscal years 2017 , 2016 , and 2015 will end or ended on April 28, 2017 , April 29, 2016 , and April 24, 2015 , respectively.

New Accounting Pronouncements

New Accounting Pronouncements	9 Months Ended
	Jan. 27, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recently Adopted In April 2015, the Financial Accounting Standards Board (FASB) issued accounting guidance that requires debt issuance costs to be presented in the balance sheet as a direct deduction from the related debt liability. Prior to this amendment, debt issuance costs were recognized as an asset in the balance sheet and did not offset the related debt liability. The Company retrospectively adopted this guidance in the first quarter of fiscal year 2017. Its adoption resulted in a reduction of both assets and liabilities of $138 million on the Company's consolidated balance sheet at April 29, 2016 as previously filed in the 2016 Annual Report on Form 10-K. Not Yet Adopted In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019 using one of two prescribed retrospective methods. The Company is evaluating the impact of the amended revenue recognition guidance on the Company’s consolidated financial statements. In January 2016, the FASB issued guidance which requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The guidance also includes a simplified impairment assessment of equity investments without readily determinable fair values and presentation and disclosure changes. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019. The Company is evaluating the impact of the equity investment guidance on the Company's consolidated financial statements. In February 2016, the FASB issued guidance which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. The guidance is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements and is effective for the Company beginning in the first quarter of fiscal year 2020. Early adoption is permitted. The Company is evaluating the impact of the lease guidance on the Company's consolidated financial statements. In March 2016, the FASB issued guidance to simplify the accounting for share-based payment transactions by requiring all excess tax benefits and deficiencies to be recognized in income tax expense or benefit in earnings; eliminating the requirement to classify the excess tax benefit and deficiencies as additional paid-in capital. For the three and nine months ended January 27, 2017, the Company recognized $5 million and $80 million , respectively, of excess tax benefits in additional paid-in capital. Under the new guidance, an entity makes an accounting policy election to either estimate the expected forfeiture awards or account for forfeitures as they occur. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2018. In October 2016, the FASB issued guidance that requires the tax effect of inter-entity transactions, other than sales of inventory, to be recognized when the transaction occurs. This would eliminate the exception under the current guidance in which the tax effects of inter-entity asset transactions are deferred until the transferred asset is sold to a third party or otherwise recovered through use. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019. The Company is evaluating the impact of the inter-entity transaction guidance on the Company's consolidated financial statements.

Acquisitions and Acquisition-Re

Acquisitions and Acquisition-Related Items	9 Months Ended
	Jan. 27, 2017
Business Combinations [Abstract]
Acquisitions and Acquisition-Related Items	Acquisitions and Acquisition-Related Items The Company had various acquisitions during the first three quarters of fiscal year 2017 . The Company accounted for the acquisitions noted below as business combinations using the acquisition method of accounting. In accordance with authoritative guidance on business combination accounting, the assets and liabilities of the businesses acquired were recorded and consolidated on the acquisition date at their respective fair values. The pro forma impact of these acquisitions was not significant, either individually or in the aggregate, to the results of the Company for the three and nine months ended January 27, 2017 and January 29, 2016 . The results of operations related to each business acquired have been included in the Company's consolidated statements of income since the date each business was acquired. The preliminary fair values of the assets acquired and liabilities assumed during the nine months ended January 27, 2017 were as follows: (in millions) HeartWare International, Inc. Smith & Nephew's Gynecology Business All Other Total Other current assets $ 351 $ — $ 17 $ 368 Property, plant, and equipment 13 3 4 20 Other intangible assets 625 167 65 857 Goodwill 479 180 113 772 Other assets 55 — 15 70 Total assets acquired 1,523 350 214 2,087 Current liabilities 144 — 9 153 Deferred tax liabilities 60 — 9 69 Long-term debt 245 — — 245 Other liabilities 2 — 4 6 Total liabilities assumed 451 — 22 473 Net assets acquired $ 1,072 $ 350 $ 192 $ 1,614 HeartWare International, Inc. On August 23, 2016, the Company's Cardiac and Vascular Group acquired HeartWare International, Inc. (HeartWare), a medical device company that develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients around the world suffering from advanced heart failure. Total consideration for the transaction was approximately $1.1 billion . Based upon a preliminary acquisition valuation, the Company acquired $602 million of technology-based and customer-related intangible assets and $23 million of tradenames, with estimated useful lives of 15 and 5 years, respectively, and $479 million of goodwill. The acquired goodwill is not deductible for tax purposes. In addition, the Company acquired $245 million of debt through the acquisition, of which the Company redeemed $203 million as part of a cash tender offer in August 2016. The remaining $42 million of debt acquired is due December 2017 and is recorded within current debt obligations on the consolidated balance sheets. Smith & Nephew's Gynecology Business On August 5, 2016, the Company's Minimally Invasive Therapies Group acquired Smith & Nephew's gynecology business, which expands and strengthens Medtronic's minimally invasive surgical offerings and further complements its existing global gynecology business. Total consideration for the transaction was approximately $350 million , which primarily related to an upfront payment. Based upon a preliminary acquisition valuation, the Company acquired $167 million of other intangible assets, which primarily consisted of customer-related and technology related intangible assets with useful lives of 13 years, and $180 million of goodwill. The acquired goodwill is deductible for tax purposes. For information on the Company's fiscal year 2016 acquisitions, refer to Note 2 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2016 . Acquisition-Related Items During the three and nine months ended January 27, 2017 , the Company recognized acquisition-related items expense of $68 million and $148 million , primarily due to expenses incurred in connection with the Covidien integration and expenses incurred in connection with the HeartWare acquisition. For the nine months ended January 27, 2017 , these expenses were partially offset by the change in fair value of contingent consideration as a result of revised revenue forecasts and anticipated regulatory milestones. During the three and nine months ended January 29, 2016 , the Company recognized acquisition-related items expense of $63 million and $183 million , respectively, primarily due to expenses incurred in connection with the Covidien integration, partially offset by the change in fair value of contingent consideration. Contingent Consideration Certain of the Company’s business combinations involve the potential for the payment of future consideration upon the achievement of certain product development milestones and/or various other favorable operating conditions. Payment of the additional consideration is generally contingent on the acquired business reaching certain performance milestones, including attaining specified revenue levels or achieving product development milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period using Level 3 inputs, and the change in fair value is recognized within acquisition-related items in the consolidated statements of income. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based considerations). Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected revenues are based on the Company’s most recent internal operational budgets and long-range strategic plans. Changes in projected revenues, probabilities of payment, discount rates, and projected payment dates may result in adjustments to the fair value measurement. The recurring Level 3 fair value measurements of contingent consideration include the following significant unobservable inputs: Fair Value at (in millions) January 27, 2017 Valuation Technique Unobservable Input Range Discount rate 11% - 32.5% Revenue-based payments $111 Discounted cash flow Probability of payment 30% - 100% Projected fiscal year of payment 2017 - 2025 Discount rate 0.3% - 5.5% Product development-based payments $151 Discounted cash flow Probability of payment 75% - 100% Projected fiscal year of payment 2017 - 2025 The fair value of contingent consideration at January 27, 2017 and April 29, 2016 was $262 million and $377 million , respectively. At January 27, 2017 , $200 million was reflected in other liabilities and $62 million was reflected in other accrued expenses in the consolidated balance sheets. At April 29, 2016 , $311 million was reflected in other liabilities and $66 million was reflected in other accrued expenses in the consolidated balance sheet. Contingent consideration payments related to the acquisition date fair value are reported as financing activities in the consolidated statements of cash flows. Amounts paid in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows. The following table provides a reconciliation of the beginning and ending balances of contingent consideration: Three months ended Nine months ended (in millions) January 27, 2017 January 29, 2016 January 27, 2017 January 29, 2016 Beginning Balance $ 285 $ 368 $ 377 $ 264 Purchase price contingent consideration (4 ) 14 28 149 Payments (23 ) (2 ) (62 ) (22 ) Change in fair value 4 (9 ) (81 ) (20 ) Ending Balance $ 262 $ 371 $ 262 $ 371

Special Charge

Special Charge	9 Months Ended
	Jan. 27, 2017
Commitments and Contingencies Disclosure [Abstract]
Special Charge	Special Charge During the three and nine months ended January 27, 2017 , continuing the Company's commitment to improve the health of people and communities throughout the world, the Company made a $100 million charitable cash contribution to meet the multi-year funding needs of the Medtronic Foundation, a related party non-profit organization. During the three and nine months ended January 29, 2016 , the Company did no t recognize a special charge.

Restructuring Charges

Restructuring Charges	9 Months Ended
	Jan. 27, 2017
Restructuring and Related Activities [Abstract]
Restructuring Charges	Restructuring Charges Cost Synergies Initiative The cost synergies initiative is the Company's restructuring program primarily related to the integration of Covidien. This initiative is expected to contribute to the approximately $850 million in cost synergies expected to be achieved as a result of the integration of the Covidien acquisition through fiscal year 2018, including administrative office optimization, manufacturing and supply chain infrastructure, certain program cancellations, and reduction of general and administrative redundancies. Restructuring charges are expected to be primarily related to employee termination costs and costs related to manufacturing and facility closures and are expected to be incurred on a quarterly basis throughout fiscal year 2017 and in future fiscal years as cost synergy strategies are finalized. A summary of the restructuring accrual, recorded within other accrued expenses and other liabilities in the consolidated balance sheets, and related activity is presented below: (in millions) Employee Termination Costs Asset Write-downs Other Costs Total April 29, 2016 $ 213 $ — $ 37 $ 250 Restructuring charges 152 18 44 214 Payments/write-downs (146 ) (18 ) (49 ) (213 ) Reversal of excess accrual (40 ) — (2 ) (42 ) January 27, 2017 $ 179 $ — $ 30 $ 209 As part of the cost synergies initiative, for the three and nine months ended January 27, 2017 , the Company recognized $56 million and $214 million in restructuring charges, respectively, which were partially offset by reversals of excess restructuring reserves of $35 million and $42 million , respectively. Reversals of restructuring reserves relate to certain employees identified for termination finding other positions within the Company and employee termination costs being less than initially estimated. In addition, for the three months and nine months ended January 27, 2017 , asset write-downs included $1 million and $8 million , respectively, related to property, plant, and equipment impairments. For the nine months ended January 27, 2017 , asset write-downs also included $10 million related to inventory write-offs of discontinued product lines, which were recognized within cost of products sold in the consolidated statements of income. As part of the cost synergies initiative, for the three and nine months ended January 29, 2016 , the Company recognized $55 million and $208 million in restructuring charges, respectively, which were partially offset by reversals of excess restructuring reserves of $19 million and $32 million , respectively. Reversals of restructuring reserves primarily relate to certain employees identified for termination finding other positions within the Company. For the three and nine months ended January 29, 2016 , restructuring charges consisted primarily of employee termination costs. In addition, for the three months and nine months ended January 29, 2016 , asset write-downs included $3 million and $13 million , respectively, related to property, plant, and equipment impairments. For the nine months ended January 29, 2016 , asset write-downs also included $9 million related to inventory write-offs of discontinued product lines, which were recognized within cost of products sold in the consolidated statements of income.

Financial Instruments

Financial Instruments	9 Months Ended
	Jan. 27, 2017
Investments [Abstract]
Financial Instruments	Financial Instruments The Company holds investments consisting primarily of marketable debt and equity securities. The authoritative guidance is principally applied to financial assets and liabilities, such as marketable equity securities and debt and equity securities, that are classified and accounted for as trading and available-for-sale and are measured on a recurring basis. The Company also holds cost method, equity method, and other investments which are measured at fair value on a nonrecurring basis. For information on the valuation techniques and inputs used in the fair value measurements, refer to Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2016. The following table summarizes the Company's investments by significant investment category and the consolidated balance sheet classification at January 27, 2017 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 577 $ 1 $ (12 ) $ 566 $ 566 $ — Marketable equity securities 102 21 (3 ) 120 — 120 Total Level 1 679 22 (15 ) 686 566 120 Level 2: Corporate debt securities 4,637 49 (35 ) 4,651 4,651 — U.S. government and agency securities 973 1 (15 ) 959 959 — Mortgage-backed securities 761 6 (20 ) 747 747 — Foreign government and agency securities 50 — (1 ) 49 49 — Other asset-backed securities 198 1 — 199 199 — Debt funds 1,743 — (224 ) 1,519 1,519 — Total Level 2 8,362 57 (295 ) 8,124 8,124 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 47 — (3 ) 44 — 44 Total Level 3 48 — (3 ) 45 — 45 Total available-for-sale securities $ 9,089 $ 79 $ (313 ) $ 8,855 $ 8,690 $ 165 Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 589 — — N/A — 589 Total Level 3 589 — — N/A — 589 Total cost method, equity method, and other investments $ 589 $ — $ — N/A $ — $ 589 Total investments $ 9,678 $ 79 $ (313 ) $ 8,855 $ 8,690 $ 754 The following table summarizes the Company's investments by significant investment category and the related consolidated balance sheet classification at April 29, 2016 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 792 $ 14 $ (1 ) $ 805 $ 805 $ — Marketable equity securities 75 21 (11 ) 85 — 85 Total Level 1 867 35 (12 ) 890 805 85 Level 2: Corporate debt securities 3,935 85 (24 ) 3,996 3,996 — U.S. government and agency securities 902 2 — 904 904 — Mortgage-backed securities 1,016 17 (18 ) 1,015 1,015 — Other asset-backed securities 192 3 — 195 195 — Debt funds 3,040 5 (281 ) 2,764 2,764 — Total Level 2 9,085 112 (323 ) 8,874 8,874 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 47 — (3 ) 44 — 44 Total Level 3 48 — (3 ) 45 — 45 Total available-for-sale securities $ 10,000 $ 147 $ (338 ) $ 9,809 $ 9,679 $ 130 Trading securities: Level 1: Exchange-traded funds 65 15 (1 ) 79 79 — Total Level 1 65 15 (1 ) 79 79 — Total trading securities $ 65 $ 15 $ (1 ) $ 79 $ 79 $ — Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 506 — — N/A — 506 Total Level 3 506 — — N/A — 506 Total cost method, equity method, and other investments $ 506 $ — $ — N/A $ — $ 506 Total investments $ 10,571 $ 162 $ (339 ) $ 9,888 $ 9,758 $ 636 Marketable Debt and Equity Securities The following tables represent the gross unrealized losses and fair values of the Company’s available-for-sale securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at January 27, 2017 and April 29, 2016 : January 27, 2017 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 1,568 $ (30 ) $ 82 $ (5 ) Auction rate securities — — 44 (3 ) Mortgage-backed securities 402 (8 ) 133 (12 ) U.S. government and agency securities 1,011 (27 ) — — Foreign government and agency securities 49 (1 ) — — Debt funds 227 (8 ) 1,091 (216 ) Marketable equity securities 17 (1 ) 1 (2 ) Total $ 3,274 $ (75 ) $ 1,351 $ (238 ) April 29, 2016 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 756 $ (18 ) $ 136 $ (6 ) Auction rate securities — — 44 (3 ) Mortgage-backed securities 196 (5 ) 92 (5 ) U.S. government and agency securities 308 (4 ) 67 (5 ) Debt funds 670 (26 ) 1,601 (256 ) Marketable equity securities 45 (11 ) — — Total $ 1,975 $ (64 ) $ 1,940 $ (275 ) The following table represents the range of the unobservable inputs utilized in the fair value measurement of the auction rate securities classified as Level 3 at January 27, 2017 : Valuation Technique Unobservable Input Range (Weighted Average) Auction rate securities Discounted cash flow Years to principal recovery 2 yrs. - 12 yrs. (3 yrs.) Illiquidity premium 6% The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the end of the fiscal quarter in which the actual event or change in circumstances that caused the transfer occurs. There were no transfers between Level 1, Level 2, or Level 3 during the three and nine months ended January 27, 2017 and January 29, 2016 . When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. The following tables provide a reconciliation of the beginning and ending balances of items measured at fair value on a recurring basis that used significant unobservable inputs (Level 3): Three months ended January 27, 2017 (in millions) Total Level 3 Corporate debt Auction rate October 28, 2016 $ 45 $ 1 $ 44 Total unrealized (losses) gains included in other comprehensive income — — — January 27, 2017 $ 45 $ 1 $ 44 Three months ended January 29, 2016 (in millions) Total Level 3 Corporate debt Auction rate October 30, 2015 $ 103 $ 1 $ 102 Total unrealized (losses) gains included in other comprehensive income — — — January 29, 2016 $ 103 $ 1 $ 102 Nine months ended January 27, 2017 (in millions) Total Level 3 Corporate Debt Auction Rate April 29, 2016 $ 45 $ 1 $ 44 Total unrealized (losses) gains included in other comprehensive income — — — January 27, 2017 $ 45 $ 1 $ 44 Nine months ended January 29, 2016 (in millions) Total Level 3 Corporate Debt Auction Rate April 24, 2015 $ 106 $ 1 $ 105 Total unrealized (losses) gains included in other comprehensive income (3 ) — (3 ) January 29, 2016 $ 103 $ 1 $ 102 Activity related to the Company’s investment portfolio is as follows: Three months ended January 27, 2017 January 29, 2016 (in millions) Debt (1) Equity (2) Debt (1) Equity (2) Proceeds from sales $ 661 $ 1 $ 1,261 $ 4 Gross realized gains 10 — 2 4 Gross realized losses (7 ) — (9 ) — Impairment losses recognized — (10 ) — (2 ) Nine months ended January 27, 2017 January 29, 2016 (in millions) Debt (1) Equity (2) Debt (1) Equity (2) Proceeds from sales $ 4,203 $ 83 $ 3,979 $ 38 Gross realized gains 74 29 11 36 Gross realized losses (56 ) — (21 ) — Impairment losses recognized — (20 ) — (43 ) (1) Includes available-for-sale debt securities. (2) Includes marketable equity securities, cost method, equity method, exchange-traded funds, and other investments. Credit losses represent the difference between the present value of cash flows expected to be collected on certain mortgage-backed securities and auction rate securities and the amortized cost of these securities. Based on the Company’s assessment of the credit quality of the underlying collateral and credit support available to each of the remaining securities in which the Company is invested, the Company believes it has recognized all necessary other-than-temporary impairments, as the Company does not have the intent to sell, nor is it more likely than not that the Company will be required to sell, before recovery of the amortized cost. At January 27, 2017 and April 29, 2016 , the credit loss portion of other-than-temporary impairments on debt securities was no t significant. The total reductions of available-for-sale debt securities sold during the three and nine months ended January 27, 2017 and January 29, 2016 , were no t significant. The total other-than-temporary impairment losses on available-for-sale debt securities for the three and nine months ended January 27, 2017 and January 29, 2016 were no t significant. The January 27, 2017 balance of available-for-sale debt securities, excluding debt funds which have no single maturity date, by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) January 27, 2017 Due in one year or less $ 1,185 Due after one year through five years 2,905 Due after five years through ten years 3,043 Due after ten years 83 Total $ 7,216 The Company holds investments in marketable equity securities, which are classified as other assets in the consolidated balance sheets. The aggregate carrying amount of these investments was $120 million and $85 million at January 27, 2017 and April 29, 2016 , respectively. The Company did no t recognize any significant impairment charges related to marketable equity securities during the three and nine months ended January 27, 2017 , nor during the three months ended January 29, 2016 . During the nine months ended January 29, 2016 , the Company determined that the fair values of certain marketable equity securities were below the carrying values and that the carrying values of these investments were not expected to be recoverable within a reasonable period of time. As a result, the Company recognized $20 million in impairment charges for the nine months ended January 29, 2016 , which were recognized within other expense, net in the consolidated statements of income. Cost method, equity method, and other investments The Company holds investments in equity and other securities that are accounted for using the cost or equity method, which are classified as other assets in the consolidated balance sheets. At January 27, 2017 and April 29, 2016 , the aggregate carrying amount of equity and other securities without a quoted market price and accounted for using the cost or equity method was $589 million and $506 million , respectively. Cost and equity method investments are measured at fair value on a nonrecurring basis. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. If there are identified events or changes in circumstances that may have a material adverse effect on the fair value of the investment, the investment is assessed for impairment. Cost method investments fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value, as the investments are in privately-held entities without quoted market prices. To determine the fair value of these investments, the Company uses all pertinent financial information available related to the entities, including financial statements and market participant valuations from recent and proposed equity offerings. During the three and nine months ended January 27, 2017 and January 29, 2016 , the Company determined that the fair values of certain cost method investments were below their carrying values and that the carrying values of these investments were not expected to be recoverable within a reasonable period of time. As a result, the Company recognized $10 million and $20 million in impairment charges during the three and nine months ended January 27, 2017 , respectively, which were recognized in other expense, net in the consolidated statements of income. The Company recognized $2 million and $23 million in impairment charges during the three and nine months ended January 29, 2016 , respectively, which were recognized in other expense, net in the consolidated statements of income.

Financing Arrangements

Financing Arrangements	9 Months Ended
	Jan. 27, 2017
Debt Disclosure [Abstract]
Financing Arrangements	Financing Arrangements Commercial Paper The Company maintains a commercial paper program that allows the Company to have a maximum of $3.5 billion in commercial paper outstanding. Commercial paper outstanding at January 27, 2017 was $1.1 billion . No amounts were outstanding at April 29, 2016 . During the three and nine months ended January 27, 2017 , the weighted average original maturity of the commercial paper outstanding was approximately 40 days and 38 days, respectively, and the weighted average interest rate was 0.87 percent and 0.82 percent, respectively. The issuance of commercial paper proportionately reduced the amount of credit available under the Company’s existing Credit Facility, as defined below. Line of Credit The Company has a $3.5 billion five year credit facility (Credit Facility) which provides back-up funding for the commercial paper program described above. At January 27, 2017 and April 29, 2016 , no amounts were outstanding. Interest rates are determined by a pricing matrix based on the Company’s long-term debt ratings, which are assigned by Standard & Poor’s Ratings Services and Moody’s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The Credit Facility agreement also contains customary covenants, all of which the Company remained in compliance with at January 27, 2017 . Long-Term Debt Long-term debt consisted of the following: (in millions, except interest rates) Maturity by Fiscal Year January 27, 2017 April 29, 2016 6.000 percent ten-year 2008 CIFSA senior notes 2018 $ — $ 1,150 1.500 percent three-year 2015 senior notes 2018 1,000 1,000 1.375 percent five-year 2013 senior notes 2018 1,000 1,000 5.600 percent ten-year 2009 senior notes 2019 400 400 4.450 percent ten-year 2010 senior notes 2020 766 766 2.500 percent five-year 2015 senior notes 2020 2,500 2,500 Floating rate five-year 2015 senior notes 2020 500 500 4.200 percent ten-year 2010 CIFSA senior notes 2021 600 600 4.125 percent ten-year 2011 senior notes 2021 500 500 3.125 percent ten-year 2012 senior notes 2022 675 675 3.150 percent seven-year 2015 senior notes 2022 2,500 2,500 3.200 percent ten-year 2012 CIFSA senior notes 2023 650 650 2.750 percent ten-year 2013 senior notes 2023 530 530 2.950 percent ten-year 2013 CIFSA senior notes 2024 310 310 3.625 percent ten-year 2014 senior notes 2024 850 850 3.500 percent ten-year 2015 senior notes 2025 4,000 4,000 4.375 percent twenty-year 2015 senior notes 2035 2,382 2,382 6.550 percent thirty-year 2008 CIFSA senior notes 2038 374 374 6.500 percent thirty-year 2009 senior notes 2039 300 300 5.550 percent thirty-year 2010 senior notes 2040 500 500 4.500 percent thirty-year 2012 senior notes 2042 400 400 4.000 percent thirty-year 2013 senior notes 2043 325 325 4.625 percent thirty-year 2014 senior notes 2044 650 650 4.625 percent thirty-year 2015 senior notes 2045 4,000 4,000 Three-year term loan 2018 — 3,000 Interest rate swaps (Note 8) 2018 - 2022 41 89 Capital lease obligations 2018 - 2025 24 26 Bank borrowings 2018-2021 142 56 Debt premium 2018-2045 128 214 Deferred financing costs (1) 2018-2045 (124 ) (138 ) Long-term debt $ 25,923 $ 30,109 (1) The Company retrospectively adopted the guidance to simplify the presentation of deferred issuance costs in the quarter ended July 29, 2016. As a result, deferred issuance costs have been reclassified from other assets to long-term debt. See Note 2 to the consolidated financial statements for additional information. Senior Notes The Company had outstanding unsecured senior obligations (collectively, the Senior Notes), with a principal value of $27.4 billion at both January 27, 2017 and April 29, 2016 . The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The indentures under which the Senior Notes were issued contain customary covenants, all of which the Company remained in compliance with at January 27, 2017 . The Company used the net proceeds from the sale of the Senior Notes primarily for general corporate uses, which includes the repayment of other indebtedness of the Company and to fund the acquisition of Covidien in fiscal year 2015. For additional information regarding the terms of these agreements, refer to Note 7 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2016 . Financial Instruments Not Measured at Fair Value At January 27, 2017 , the estimated fair value of the Company’s Senior Notes, including the current portion, was $28.6 billion compared to a principal value of $27.4 billion . At April 29, 2016 , the estimated fair value was $29.8 billion compared to a principal value of $27.4 billion . The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and derivative/hedging activity.

Derivatives and Currency Exchan

Derivatives and Currency Exchange Risk Management	9 Months Ended
	Jan. 27, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Currency Exchange Risk Management	Derivatives and Currency Exchange Risk Management The Company uses operational and economic hedges, as well as currency exchange rate derivative contracts and interest rate derivative instruments, to manage the impact of currency exchange and interest rate changes on earnings and cash flows. In addition, the Company uses cross currency interest rate swaps to manage currency risk related to certain debt. In order to minimize earnings and cash flow volatility resulting from currency exchange rate changes, the Company enters into derivative instruments, principally forward currency exchange rate contracts. These contracts are designed to hedge anticipated foreign currency transactions and changes in the value of specific assets and liabilities. At inception of the contract, the derivative is designated as either a freestanding derivative or a cash flow hedge. The primary currencies of the derivative instruments are the Euro and Japanese Yen. The Company does not enter into currency exchange rate derivative contracts for speculative purposes. The gross notional amount of all currency exchange rate derivative instruments outstanding at January 27, 2017 and April 29, 2016 was $10.9 billion and $10.8 billion , respectively. The information that follows explains the various types of derivatives and financial instruments used by the Company, reasons the Company uses such instruments, and the impact such instruments have on the Company’s consolidated balance sheets, statements of income, and statements of cash flows. Freestanding Derivative Contracts Freestanding derivative contracts are used to offset the Company’s exposure to the change in value of specific foreign currency denominated assets and liabilities and to offset variability of cash flows associated with forecasted transactions denominated in a foreign currency. The gross notional amount of these contracts, not designated as hedging instruments, outstanding at January 27, 2017 and April 29, 2016 , was $5.1 billion and $5.0 billion , respectively. The amounts and classification of the gains in the consolidated statements of income related to derivative instruments, not designated as hedging instruments, for the three and nine months ended January 27, 2017 and January 29, 2016 were as follows: Three months ended Nine months ended (in millions) Classification January 27, 2017 January 29, 2016 January 27, 2017 January 29, 2016 Currency exchange rate contracts gains Other expense, net $ 67 $ 19 $ 27 $ 35 Cash Flow Hedges Currency Exchange Rate Risk Forward contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. No gains or losses relating to ineffectiveness of foreign currency cash flow hedges were recognized in earnings during the three and nine months ended January 27, 2017 and January 29, 2016 . No components of the hedge contracts were excluded in the measurement of hedge ineffectiveness and no hedges were derecognized or discontinued during the three and nine months ended January 27, 2017 and January 29, 2016 . The gross notional amount of these contracts, designated as cash flow hedges, outstanding at both January 27, 2017 and April 29, 2016 , was $5.7 billion and will mature within the subsequent three -year period. The amount of gross gains (losses), classification of the gains (losses) in the consolidated statements of income, and the accumulated other comprehensive (loss) income (AOCI) related to the effective portion of currency exchange rate contract derivative instruments designated as cash flow hedges for the three and nine months ended January 27, 2017 and January 29, 2016 were as follows: Three months ended January 27, 2017 Recognized in OCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ 190 Other expense, net $ 68 Total $ 190 $ 68 Three months ended January 29, 2016 Recognized in OCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ 104 Other expense, net $ 111 Cost of products sold (9 ) Total $ 104 $ 102 Nine months ended January 27, 2017 Recognized in OCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ 378 Other expense, net $ 89 Total $ 378 $ 89 Nine months ended January 29, 2016 Recognized in OCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ 108 Other expense, net $ 295 Cost of products sold (45 ) Total $ 108 $ 250 Forecasted Debt Issuance Interest Rate Risk Forward starting interest rate derivative instruments designated as cash flow hedges are designed to manage the exposure to interest rate volatility with regard to future issuances of fixed-rate debt. No gains or losses relating to ineffectiveness of forward starting interest rate derivative instruments were recognized in interest expense, net during the three and nine months ended January 27, 2017 and January 29, 2016 . No components of the hedge contracts were excluded in the measurement of hedge ineffectiveness during the three and nine months ended January 27, 2017 and January 29, 2016 . At January 27, 2017 , the Company had $300 million of fixed pay, forward starting interest rate swaps with a weighted average fixed-rate of 3.10 percent in anticipation of planned debt issuances in fiscal year 2017. For the three and nine months ended January 27, 2017 and January 29, 2016 , the reclassification of the effective portion of the net losses on forward starting interest rate derivative instruments from accumulated other comprehensive loss to interest expense, net was no t significant. The unrealized losses on outstanding forward starting interest rate swap derivative instruments at January 27, 2017 and April 29, 2016 were $26 million and $48 million , respectively. Unrealized losses on outstanding forward starting interest rate swap derivative instruments were recorded in other liabilities, with the offset recorded in accumulated other comprehensive loss in the consolidated balance sheets. For the three months ended January 27, 2017 and January 29, 2016 , the Company recognized $28 million and $(14) million , respectively, of unrealized gains (losses) in accumulated other comprehensive loss . For the nine months ended January 27, 2017 and January 29, 2016 , the Company recognized $22 million and $30 million , respectively, of unrealized gains in accumulated other comprehensive loss . At January 27, 2017 and April 29, 2016 , the Company had $112 million and $(90) million , respectively, in after-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in accumulated other comprehensive loss . The Company expects that $120 million of after-tax net unrealized gains at January 27, 2017 will be recognized in the consolidated statements of income over the next 12 months. Fair Value Hedges Interest rate derivative instruments designated as fair value hedges are designed to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, the Company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. At January 27, 2017 and April 29, 2016 , the Company had interest rate swaps in gross notional amounts of $1.2 billion , designated as fair value hedges of underlying fixed-rate senior note obligations. For additional information regarding the terms of the Company’s interest rate swap agreements, refer to Note 8 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2016 . At January 27, 2017 , the market value of outstanding interest rate swap agreements was a net $41 million unrealized gain, and the market value of the hedged item was a net $41 million unrealized loss. The amounts were recorded in other assets with the offsets recorded in long-term debt and current debt obligations in the consolidated balance sheet. During the three and nine months ended January 27, 2017 and January 29, 2016 , the Company did no t have any significant ineffective fair value hedging instruments. In addition, during the three and nine months ended January 27, 2017 and January 29, 2016 , the Company did no t recognize any significant gains or losses on firm commitments that no longer qualify as fair value hedges. Balance Sheet Presentation The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at January 27, 2017 and April 29, 2016 . The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not and are further segregated by type of contract within those two categories. January 27, 2017 Asset Derivatives Liability Derivatives (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments: Currency exchange rate contracts Other current assets $ 217 Other accrued expenses $ 33 Interest rate contracts Other assets 41 Other liabilities 26 Currency exchange rate contracts Other assets 79 Other liabilities 11 Total derivatives designated as hedging instruments $ 337 $ 70 Derivatives not designated as hedging instruments: Currency exchange rate contracts Other current assets $ 35 Other accrued expenses $ 42 Cross currency interest rate contracts Other current assets 1 Other accrued expenses — Cross currency interest rate contracts Other assets 6 Other liabilities 11 Total derivatives not designated as hedging instruments $ 42 $ 53 Total derivatives $ 379 $ 123 April 29, 2016 Asset Derivatives Liability Derivatives (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments: Currency exchange rate contracts Other current assets $ 123 Other accrued expenses $ 89 Interest rate contracts Other assets 89 Other liabilities 48 Currency exchange rate contracts Other assets 9 Other liabilities 54 Total derivatives designated as hedging instruments $ 221 $ 191 Derivatives not designated as hedging instruments: Commodity derivatives Other current assets $ — Other accrued expenses $ 1 Currency exchange rate contracts Other current assets 13 Other accrued expenses 23 Cross currency interest rate contracts Other assets 14 Other liabilities 4 Total derivatives not designated as hedging instruments $ 27 $ 28 Total derivatives $ 248 $ 219 The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis. January 27, 2017 April 29, 2016 (in millions) Level 1 Level 2 Level 1 Level 2 Derivative assets $ 331 $ 48 $ 145 $ 103 Derivative liabilities 86 37 166 53 The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. January 27, 2017 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 332 $ (83 ) $ (123 ) $ 126 Interest rate contracts 41 (12 ) (6 ) 23 Cross currency interest rate contracts 6 (3 ) — 3 $ 379 $ (98 ) $ (129 ) $ 152 Derivative liabilities: Currency exchange rate contracts $ (86 ) $ 71 $ — $ (15 ) Interest rate contracts (26 ) 24 — (2 ) Cross currency interest rate contracts (11 ) 3 — (8 ) $ (123 ) $ 98 $ — $ (25 ) Total $ 256 $ — $ (129 ) $ 127 April 29, 2016 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 145 $ (98 ) $ (1 ) $ 46 Interest rate contracts 89 (20 ) — 69 Cross currency interest rate contracts 14 — — 14 $ 248 $ (118 ) $ (1 ) $ 129 Derivative liabilities: Currency exchange rate contracts $ (166 ) $ 85 $ 26 $ (55 ) Interest rate contracts (48 ) 34 — (14 ) Cross currency interest rate contracts (4 ) — — (4 ) Commodity contracts (1 ) — — (1 ) $ (219 ) $ 119 $ 26 $ (74 ) Total $ 29 $ 1 $ 25 $ 55

Inventories

Inventories	9 Months Ended
	Jan. 27, 2017
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete, or slow-moving based on changes in customer demand, technology developments, and other economic factors. Inventory balances were as follows: (in millions) January 27, 2017 April 29, 2016 Finished goods $ 2,381 $ 2,242 Work in-process 536 499 Raw materials 803 732 Total $ 3,720 $ 3,473

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	9 Months Ended
	Jan. 27, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill The changes in the carrying amount of goodwill by reporting unit for the nine months ended January 27, 2017 were as follows: (in millions) Cardiac and Vascular Group Minimally Invasive Therapies Group Restorative Therapies Group Diabetes Group Total April 29, 2016 $ 6,243 $ 23,784 $ 9,620 $ 1,853 $ 41,500 Goodwill as a result of acquisitions 509 230 33 — 772 Currency adjustment, net (55 ) (924 ) (69 ) — (1,048 ) January 27, 2017 $ 6,697 $ 23,090 $ 9,584 $ 1,853 $ 41,224 The Company assesses goodwill for impairment annually in the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Impairment testing for goodwill is performed at the reporting unit level. The test for impairment of goodwill requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis. The Company did no t recognize any goodwill impairment during the three or nine months ended January 27, 2017 or January 29, 2016 . Intangible Assets The gross carrying amount and accumulated amortization of intangible assets at January 27, 2017 and April 29, 2016 were as follows: January 27, 2017 April 29, 2016 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 18,708 $ (2,132 ) $ 18,596 $ (1,331 ) Purchased technology and patents 12,208 (3,582 ) 11,397 (2,976 ) Trademarks and tradenames 832 (471 ) 854 (403 ) Other 78 (39 ) 72 (31 ) Total $ 31,826 $ (6,224 ) $ 30,919 $ (4,741 ) Indefinite-lived: IPR&D $ 607 $ 721 The Company assesses definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset (asset group) may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable, the Company calculates the excess of an intangible asset's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. The Company did no t recognize any intangible asset impairments during the three or nine months ended January 27, 2017 or January 29, 2016 . The Company assesses indefinite-lived intangibles for impairment annually in the third quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The indefinite-lived intangibles impairment test requires the Company to perform an assessment involving several estimates about fair value. The Company calculates the excess of indefinite-lived intangibles asset fair values over their carrying values utilizing a discounted future cash flow analysis. During the three and nine months ended January 27, 2017 and January 29, 2016 , the Company did no t recognize any significant indefinite-lived intangibles impairments. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of such clinical trials, delays or failures to obtain required market clearances or other failures to achieve a commercially viable product, and as a result, may recognize impairment losses in the future. Amortization Expense Intangible asset amortization expense for the three and nine months ended January 27, 2017 was $497 million and $1.5 billion , respectively, and for the three and nine months ended January 29, 2016 was $ 484 million and $ 1.4 billion , respectively. At January 27, 2017 , the estimated aggregate amortization expense by fiscal year based on the current carrying value of definite-lived intangible assets is as follows: (in millions) Amortization Expense Remaining 2017 $ 499 2018 1,971 2019 1,877 2020 1,829 2021 1,812 2022 1,768

Income Taxes

Income Taxes	9 Months Ended
	Jan. 27, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company’s effective tax rate for the three and nine months ended January 27, 2017 was 15.2 percent and 9.7 percent, respectively, compared to 7.1 percent and 24.0 percent for the three and nine months ended January 29, 2016 , respectively. The change in the effective tax rate for the three and nine months ended January 27, 2017 was primarily due to certain tax adjustments, the impact of special charges, restructuring charges, net, certain litigation charges, acquisition-related items, the finalization of certain tax returns, changes to certain deferred income tax balances and uncertain tax position reserves, the permanent extension of the U.S. federal research and development tax credit during the third quarter of fiscal year 2016, and year over year changes in operational results by jurisdiction. During the three months ended January 27, 2017 , the Company recognized a charge of $86 million associated with the IRS’s disallowance of the utilization of certain net operating losses, and the recording of a valuation allowance against the net operating loss deferred tax asset. During the nine months ended January 27, 2017 , the Company also recognized a $371 million charge associated with the expected resolution with the IRS for the Ardian, CoreValve, Inc. and Ablation Frontiers, Inc. acquisition-related issues and the allocation of income between Medtronic, Inc. and its wholly owned subsidiary operating in Puerto Rico for certain businesses. This resolution does not include the businesses that are the subject of the Medtronic, Inc. U.S. Tax Court case for fiscal years 2005 and 2006. The Company also recognized a $29 million charge in connection with the redemption of an intercompany minority interest. These charges were partially offset by a $431 million tax benefit recognized as the result of the resolution of Covidien's previously disclosed Tyco International plc intercompany debt issues with the U.S. Tax Court and the Appeals Division of the IRS. During the three months ended January 29, 2016 , the Company recognized a $25 million tax benefit associated with the disposition of a wholly owned U.S. subsidiary. During the nine months ended January 29, 2016 , the Company recognized a net tax charge of $417 million . The net tax charge primarily related to U.S. income tax expense resulting from the Company's completion of an internal reorganization of the ownership of certain legacy Covidien businesses that reduced the cash and investments held by the Company's U.S.-controlled non-U.S. subsidiaries, which was partially offset by the tax benefit associated with the disposition of a wholly owned U.S. subsidiary. During the nine months ended January 27, 2017 , the Company's gross unrecognized tax benefits decreased from $2.7 billion to $2.0 billion . In addition, the Company has accrued gross interest and penalties of $345 million at January 27, 2017 . If all of the Company’s unrecognized tax benefits were recognized, approximately $1.9 billion would impact the Company’s effective tax rate. The Company has recorded all of the gross unrecognized tax benefits as a non-current liability within accrued income taxes on the consolidated balance sheet. The Company will continue to recognize interest and penalties related to income tax matters within provision for income taxes in the consolidated statements of income and record the liability within accrued income taxes on the consolidated balance sheet. See Note 16 to the consolidated financial statements for additional information regarding the status of current tax audits and proceedings.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Jan. 27, 2017
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Earnings per share is calculated using the two-class method, as the Company's A Preferred Shares are considered participating securities. Accordingly, earnings are allocated to both ordinary shares and participating securities in determining earnings per ordinary share. Due to the limited number of A Preferred Shares outstanding, this allocation had no effect on ordinary earnings per share; therefore, it is not presented below. Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted average number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock options and other stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. The table below sets forth the computation of basic and diluted earnings per share: Three months ended Nine months ended (in millions, except per share data) January 27, 2017 January 29, 2016 January 27, 2017 January 29, 2016 Numerator: Net income attributable to ordinary shareholders $ 821 $ 1,095 $ 2,865 $ 2,435 Denominator: Basic – weighted average shares outstanding 1,372.2 1,406.6 1,381.9 1,412.5 Effect of dilutive securities: Employee stock options 7.9 12.0 9.2 12.5 Employee restricted stock units 3.0 3.5 3.4 4.1 Other — 0.1 0.2 0.1 Diluted – weighted average shares outstanding 1,383.1 1,422.2 1,394.7 1,429.2 Basic earnings per share $ 0.60 $ 0.78 $ 2.07 $ 1.72 Diluted earnings per share $ 0.59 $ 0.77 $ 2.05 $ 1.70 The calculation of weighted average diluted shares outstanding excludes options to purchase approximately 10 million and 6 million ordinary shares for the three and nine months ended January 27, 2017 , respectively, and approximately 5 million and 4 million ordinary shares for the three and nine months ended January 29, 2016 , respectively, because their effect would be anti-dilutive on the Company’s earnings per share.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Jan. 27, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock awards, and employee stock purchase plan shares recognized for the three and nine months ended January 27, 2017 and January 29, 2016 : Three months ended Nine months ended (in millions) January 27, 2017 January 29, 2016 January 27, 2017 January 29, 2016 Stock options $ 37 $ 43 $ 128 $ 162 Restricted stock awards 40 33 128 113 Employee stock purchase plan shares 5 5 16 15 Total stock-based compensation expense $ 82 $ 81 $ 272 $ 290 Cost of products sold $ 12 $ 12 $ 38 $ 38 Research and development expense 10 8 32 28 Selling, general, and administrative expense 55 47 179 162 Restructuring charges, net — 2 2 16 Acquisition-related items 5 12 21 46 Total stock-based compensation expense $ 82 $ 81 $ 272 $ 290 Income tax benefits (23 ) (23 ) (77 ) (86 ) Total stock-based compensation expense, net of tax $ 59 $ 58 $ 195 $ 204

Retirement Benefit Plans

Retirement Benefit Plans	9 Months Ended
	Jan. 27, 2017
Compensation and Retirement Disclosure [Abstract]
Retirement Benefit Plans	Retirement Benefit Plans The Company sponsors various retirement benefit plans, including defined benefit pension plans (pension benefits), post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the defined benefit pension plans included the following components for the three and nine months ended January 27, 2017 and January 29, 2016 : U.S. Pension Benefits Non-U.S. Pension Benefits Three months ended Three months ended (in millions) January 27, 2017 January 29, 2016 January 27, 2017 January 29, 2016 Service cost $ 29 $ 30 $ 19 $ 22 Interest cost 27 31 6 9 Expected return on plan assets (47 ) (45 ) (12 ) (13 ) Amortization of net actuarial loss 23 24 4 6 Net periodic benefit cost $ 32 $ 40 $ 17 $ 24 U.S. Pension Benefits Non-U.S. Pension Benefits Nine months ended Nine months ended (in millions) January 27, 2017 January 29, 2016 January 27, 2017 January 29, 2016 Service cost $ 87 $ 90 $ 57 $ 66 Interest cost 81 93 18 27 Expected return on plan assets (141 ) (135 ) (36 ) (39 ) Amortization of net actuarial loss 69 72 12 18 Net periodic benefit cost $ 96 $ 120 $ 51 $ 72

Accumulated Other Comprehensive

Accumulated Other Comprehensive (Loss) Income and Supplemental Equity Disclosure	9 Months Ended
	Jan. 27, 2017
Equity [Abstract]
Accumulated Other Comprehensive (Loss) Income and Supplemental Equity Disclosure	Accumulated Other Comprehensive (Loss) Income and Supplemental Equity Disclosure Changes in AOCI by component are as follows: (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities (1) Cumulative Translation Adjustments (2) Net Change in Retirement Obligations (3) Unrealized Gain (Loss) on Derivatives (4) Total Accumulated Other Comprehensive (Loss) Income April 29, 2016, net of tax $ (107 ) $ (474 ) $ (1,197 ) $ (90 ) $ (1,868 ) Other comprehensive income (loss) before reclassifications, before tax (20 ) (1,239 ) — 400 (859 ) Tax expense (5 ) — — (145 ) (150 ) Other comprehensive income (loss) before reclassifications, net of tax (25 ) (1,239 ) — 255 (1,009 ) Reclassifications, before tax (23 ) — 81 (85 ) (27 ) Tax (expense) benefit 8 — (15 ) 32 25 Reclassifications, net of tax (15 ) — 66 (53 ) (2 ) Other comprehensive income (loss), net of tax (40 ) (1,239 ) 66 202 (1,011 ) January 27, 2017, net of tax $ (147 ) $ (1,713 ) $ (1,131 ) $ 112 $ (2,879 ) (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities (1) Cumulative Translation Adjustments (2) Net Change in Retirement Obligations (3) Unrealized Gain (Loss) on Derivatives (4) Total Accumulated Other Comprehensive (Loss) Income April 24, 2015, net of tax $ 14 $ (277 ) $ (1,131 ) $ 210 $ (1,184 ) Other comprehensive (loss) income before reclassifications, before tax (399 ) (1,513 ) 2 134 (1,776 ) Tax benefit (expense) 143 — — (50 ) 93 Other comprehensive (loss) income before reclassifications, net of tax (256 ) (1,513 ) 2 84 (1,683 ) Reclassifications, before tax (18 ) — 90 (232 ) (160 ) Tax benefit (expense) 6 — (30 ) 86 62 Reclassifications, net of tax (12 ) — 60 (146 ) (98 ) Other comprehensive (loss) income, net of tax (268 ) (1,513 ) 62 (62 ) (1,781 ) January 29, 2016, net of tax $ (254 ) $ (1,790 ) $ (1,069 ) $ 148 $ (2,965 ) (1) Represents net realized gains (losses) on sales of available-for-sale securities that were reclassified from AOCI to other expense, net (see Note 6 ). (2) Taxes are not provided on cumulative translation adjustments as substantially all translation adjustments relate to earnings that are intended to be indefinitely reinvested outside the U.S. (3) Includes net amortization of prior service costs and actuarial losses included in net periodic benefit cost (see Note 14 ). (4) Relates to currency cash flow hedges that were reclassified from AOCI to other expense, net or cost of products sold and forward starting interest rate derivative instruments that were reclassified from AOCI to interest expense, net (see Note 8 ). The supplemental equity schedule below presents changes in the Company's noncontrolling interests and total shareholders' equity for the nine months ended January 27, 2017 . (in millions) Total Shareholders' Equity Noncontrolling Interests Total Equity April 29, 2016 $ 52,063 $ — $ 52,063 Net income 2,865 (5 ) 2,860 Other comprehensive loss (1,011 ) — (1,011 ) Dividends to shareholders (1,782 ) — (1,782 ) Issuance of shares under stock purchase and award plans 309 — 309 Repurchase of ordinary shares (3,409 ) — (3,409 ) Tax benefit from exercise of stock-based awards 80 — 80 Stock-based compensation 272 — 272 Additions of noncontrolling ownership interests — 111 111 January 27, 2017 $ 49,387 $ 106 $ 49,493

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jan. 27, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company and its affiliates are involved in a number of legal actions involving product liability, intellectual property disputes, shareholder related matters, environmental proceedings, income tax disputes, and governmental proceedings and investigations in the United States and around the world, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company’s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of these legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues or limit the Company's ability to conduct business in applicable jurisdictions. The Company records a liability in the consolidated financial statements for loss contingencies related to legal actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. At January 27, 2017 and April 29, 2016 , accrued certain litigation charges were approximately $1.2 billion and $1.0 billion , respectively. The ultimate cost to the Company with respect to accrued certain litigation charges could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, or cash flows. The Company includes accrued certain litigation charges in other accrued expenses and other liabilities on the consolidated balance sheets. In addition to litigation contingencies, the Company also has certain income tax and guarantee obligations that may potentially result in future charges. While it is not possible to predict the outcome for most of the matters discussed below, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, or cash flows. Product Liability Matters Sprint Fidelis In 2007, a putative class action was filed in the Ontario Superior Court of Justice in Canada seeking damages for personal injuries allegedly related to the Company's Sprint Fidelis family of defibrillation leads. On October 20, 2009, the court certified a class proceeding but denied class certification on plaintiffs' claim for punitive damages. Pretrial proceedings are underway. The Company has not recognized an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter. INFUSE Litigation The Company estimates law firms representing approximately 6,000 claimants have asserted or intend to assert personal injury claims against Medtronic in the U.S. state and federal courts involving the INFUSE bone graft product. As of March 1, 2017, the Company has reached agreements to settle approximately 4,300 of these claims, and certain of the remaining claims could proceed to trial beginning in calendar year 2017. The Company's accrued expenses for this matter are included within accrued certain litigation charges in other accrued expenses and other liabilities on the consolidated balance sheets as discussed above. Other INFUSE Litigation On June 5, 2014, Humana, Inc. filed a lawsuit for unspecified monetary damages in the U.S. District Court for the Western District of Tennessee, alleging that Medtronic, Inc. violated federal racketeering (RICO) law and various state laws, by conspiring with physicians to promote unapproved uses of INFUSE. In September of 2015 the Court granted Medtronic’s motion to dismiss the primary allegations, including the RICO claims, in Humana’s complaint. In April of 2016 the Court denied Humana's motion to file an amended complaint. The Company has not recognized an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter. Pelvic Mesh Litigation The Company, through the acquisition of Covidien, is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of Covidien supplied pelvic mesh products to one of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In July 2015, the Company and Bard agreed that Bard would pay the Company $121 million towards the settlement of 11,000 of these claims. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately 15,800 claimants have asserted or may assert claims involving products manufactured by Covidien’s subsidiaries. As of March 1, 2017, the Company has reached agreements to settle approximately 11,300 of these claims. The Company's accrued expenses for this matter are included within accrued certain litigation charges in other accrued expenses and other liabilities on the consolidated balance sheets as discussed above. Patent Litigation Ethicon On December 14, 2011, Ethicon filed an action against Covidien in the U.S. District Court for the Southern District of Ohio, alleging patent infringement and seeking monetary damages and injunctive relief. On January 22, 2014, the district court entered summary judgment in Covidien's favor, and the majority of this ruling was affirmed by the Federal Circuit on August 7, 2015. Following appeal, the case was remanded back to the District Court with respect to one patent. On January 21, 2016, Covidien filed a second action in the U.S. District Court for the Southern District of Ohio, seeking a declaration of non-infringement with respect to a second set of patents held by Ethicon. The court consolidated this second action with the remaining patent issues from the first action. In addition to claims of non-infringement, the Company asserts affirmative defenses of invalidity for each of the patents-in-suit. The case is currently in the fact discovery stage. The Company has not recognized an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter. Shareholder Related Matters INFUSE On March 12, 2012, Charlotte Kokocinski (Kokocinski) filed a shareholder derivative action against both Medtronic, Inc. and certain of its current and former officers and directors in the U.S. District Court for the District of Minnesota, setting forth certain allegations, including a claim that defendants violated various purported duties in connection with the INFUSE bone graft product and otherwise. On March 25, 2013, the Court dismissed the case without prejudice, and Kokocinski subsequently filed an amended complaint. On March 30, 2015, the Court granted defendants’ motion to dismiss the amended complaint, dismissing the case with prejudice. Kokocinski sought reconsideration of that decision, and, on September 30, 2015, the Court denied Kokocinski’s request for reconsideration. Kokocinski has appealed the Court’s decision to the U.S. Court of Appeals for the Eighth Circuit. On March 1, 2017, the Eighth Circuit Court of Appeals affirmed the lower Court. West Virginia Pipe Trades and Phil Pace, on June 27, 2013 and July 3, 2013, respectively, filed putative class action complaints against Medtronic, Inc. and certain of its officers in the U.S. District Court for the District of Minnesota, alleging that the defendants made false and misleading public statements regarding the INFUSE Bone Graft product during the period of December 8, 2010 through August 3, 2011. The matters were consolidated in September, 2013, and in the consolidated complaint plaintiffs alleged a class period of September 28, 2010 through August 3, 2011. On September 30, 2015, the Court granted defendants’ motion for summary judgment in the consolidated matters. Plaintiffs have appealed the dismissal to the U.S. Court of Appeals for the Eighth Circuit, and in December of 2016 the Eighth Circuit Court reversed and remanded the case to the District Court for further proceedings. COVIDIEN ACQUISITION On July 2, 2014, Lewis Merenstein filed a putative shareholder class action in Hennepin County, Minnesota, District Court seeking to enjoin the then-potential acquisition of Covidien. The lawsuit named Medtronic, Inc., Covidien, and each member of the Medtronic, Inc. Board of Directors at the time as defendants, and alleged that the directors breached their fiduciary duties to shareholders with regard to the then-potential acquisition. On August 21, 2014, Kenneth Steiner filed a putative shareholder class action in Hennepin County, Minnesota, District Court, also seeking an injunction to prevent the potential Covidien acquisition. In September 2014, the Merenstein and Steiner matters were consolidated and in December 2014, the plaintiffs filed a preliminary injunction motion seeking to enjoin the Covidien transaction. On December 30, 2014, a hearing was held on plaintiffs’ motion for preliminary injunction and on defendants’ motion to dismiss. On January 2, 2015, the District Court denied the plaintiffs’ motion for preliminary injunction and on January 5, 2015 issued its opinion. On March 20, 2015, the District Court issued its order and opinion granting Medtronic’s motion to dismiss the case. In May of 2015, the plaintiffs filed an appeal, and, in January of 2016, the Minnesota State Court of Appeals affirmed in part, reversed in part, and remanded the case to the District Court for further proceedings. In February of 2016, the Company petitioned the Minnesota Supreme Court to review the decision of the Minnesota State Court of Appeals, and on April 19, 2016 the Minnesota Supreme Court granted the Company’s petition on the issue of whether most of the original claims are properly characterized as direct or derivative under Minnesota law. A decision from the Minnesota Supreme Court is expected in calendar year 2017. HEARTWARE On January 22, 2016, the St. Paul Teachers’ Retirement Fund Association filed a putative class action complaint (the “Complaint”) in the United States District Court for the Southern District of New York against HeartWare on behalf of all persons and entities who purchased or otherwise acquired shares of HeartWare from June 10, 2014 through January 11, 2016 (the “Class Period”). The Complaint was amended on June 29, 2016 and claims HeartWare and one of its executives violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making false and misleading statements about, among other things, HeartWare’s response to a June 2014 FDA warning letter, the development of the Miniaturized Ventricular Assist Device (MVAD) System and the proposed acquisition of Valtech Cardio Ltd. The Complaint seeks to recover damages on behalf of all purchasers or acquirers of HeartWare’s stock during the Class Period. In August of 2016 the Company acquired HeartWare. The Company has not recognized an expense related to damages in connection with the shareholder related matters, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from these matters. Environmental Proceedings The Company, through the acquisition of Covidien, is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods. The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation, subsidiaries of Covidien, in December 2008, which included a directive to remove a significant volume of soils at the site. After a hearing on the compliance order before the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order, the Maine Board modified the MDEP order and issued a final order requiring removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills. The Company has proceeded with implementation of the investigation and remediation at the site in accordance with the MDEP order as modified by the Maine Board order. The Company has also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring Covidien to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary. On July 29, 2002, following a March 2002 trial, the District Court entered an opinion and order which held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that Covidien was liable for the cost of performing a study of the river and bay. The District Court subsequently appointed an independent study panel to oversee the study and ordered Covidien to pay costs associated with the study. A report issued by the study panel contains recommendations for a variety of potential remedial options which could be implemented individually or in a variety of combinations, and included preliminary cost estimates for a variety of potential remedial options, which the report describes as “very rough estimates of cost,” ranging from $25 million to $235 million . The report indicates that these costs are subject to uncertainties, and that before any remedial option is implemented, further engineering studies and engineering design work are necessary to determine the feasibility of the proposed remedial options. In June of 2014, a trial was held to determine if remediation was necessary and feasible, and on September 2, 2015, the District Court issued an order concluding that further engineering study and engineering design work is appropriate to determine the nature and extent of remediation in the Penobscot River and Bay. In January of 2016, the Court appointed an engineering firm to conduct the next phase of the study. The study is targeted for completion late calendar year 2017. The Company's accrued expenses for environmental proceedings are included within accrued certain litigation charges in other accrued expenses and other liabilities on the consolidated balance sheets as discussed above. Government Matters Medtronic has received subpoenas or document requests from the Attorneys General in Massachusetts, California, Oregon, Illinois, and Washington seeking information regarding sales, marketing, clinical, and other information relating to the INFUSE bone graft product. In the third quarter of fiscal year 2017, the Company accrued expenses in connection with these matters, which are included within accrued certain litigation charges in other accrued expenses and other liabilities on the consolidated balance sheets as discussed above. On May 2, 2011, the U.S. Attorney’s Office for the District of Massachusetts issued a subpoena to ev3, a subsidiary of the Company, requesting production of documents relating to sales and marketing and other issues in connection with several neurovascular products. The matters under investigation relate to activities prior to Covidien's acquisition of ev3 in 2010. ev3 complied as required with the subpoena and cooperated with the investigation. In the third quarter of fiscal year 2016, the Company accrued expenses in connection with this matter, which are included within accrued certain litigation charges in other accrued expenses and other liabilities on the consolidated balance sheets as discussed above. On September 2, 2014, the U.S. Department of Health and Human Services, Office of Inspector General and the U.S. Attorney’s Office for the Northern District of California, issued a subpoena requesting production of documents relating to sales and marketing practices associated with certain of ev3’s peripheral vascular products. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from this matter. Income Taxes In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. On December 23, 2010, the IRS issued a statutory notice of deficiency with respect to the remaining issues. Medtronic, Inc. filed a petition with the U.S. Tax Court on March 21, 2011 objecting to the deficiency. During October and November 2012, Medtronic, Inc. reached resolution with the IRS on various matters, including the deductibility of a settlement payment. Medtronic, Inc. and the IRS agreed to hold one issue, the calculation of amounts eligible for the one-time repatriation holiday, because such specific issue was being addressed by other taxpayers in litigation with the IRS. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court proceeding with respect to this issue began on February 3, 2015 and ended on March 12, 2015. On June 9, 2016, the U.S. Tax court issued its opinion with respect to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for fiscal years 2005 and 2006. The U.S. Tax Court generally rejected the IRS’s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. During November 2016, Medtronic and the IRS entered into a Stipulation of Settled Issues with the Tax Court which resolved the one-time repatriation holiday as an outstanding issue unless, either party concludes to appeal the Tax Court Opinion and a final decision is inconsistent with the U.S. Tax Court Opinion. The U.S. Tax Court entered their final decision on January 25, 2017. An appeal of the U.S. Tax Court Opinion must be filed within 90 days of such date. In October 2011, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2007 and 2008. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. During the first quarter of fiscal year 2016, the Company finalized its agreement with the IRS on the proposed adjustments associated with the tax effects of the Company's acquisition of Kyphon Inc. (Kyphon). The settlement was consistent with the certain tax adjustment recorded during the fourth quarter of fiscal year 2015. During the first quarter of fiscal year 2017, an expected settlement was reached with the IRS for all outstanding issues for fiscal years 2007 and 2008 except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. In April 2014, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2009, 2010, and 2011. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. During the first quarter of fiscal year 2017, an expected settlement was reached with the IRS for all outstanding issues for fiscal years 2009, 2010, and 2011 except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. The IRS continues to audit Medtronic, Inc.'s U.S. federal income tax returns for the fiscal years 2012 through 2014. Covidien and the IRS have concluded and reached agreement on its audit of Covidien’s U.S. federal income tax returns for the 2008 and 2009 tax years. The IRS continues to audit Covidien’s U.S. federal income tax returns for the years 2010 through 2012. The IRS concluded its field examination of certain of Tyco International’s U.S. federal income tax returns for the years 1997 through 2000 and proposed tax adjustments, several of which also affect Covidien’s income tax returns for certain years after 2000. Tyco International appealed certain of the tax adjustments proposed by the IRS and had resolved all but one of the matters associated with the proposed tax adjustments. The IRS asserted that substantially all of Tyco International’s intercompany debt originating during the years 1997 through 2000 should not be treated as debt for U.S. federal income tax purposes, and disallowed interest deductions related to the intercompany debt and certain tax attribute adjustments recognized on Tyco International’s U.S. income tax returns. The Company disagreed with the IRS’s proposed adjustments and, on July 22, 2013, Tyco International filed a petition with the U.S. Tax Court contesting the IRS assessment. On January 15, 2016, Tyco International, as audit managing party under the Tax Sharing Agreement, entered into Stipulations of Settled Issues with the IRS intended to resolve all Federal tax disputes related to this intercompany debt issue for the Tax Sharing Participants for the 1997 - 2000 audit cycle before the U.S. Tax Court. The Stipulations of Settled Issues were contingent upon the IRS Appeals Division applying the same settlement terms to all intercompany debt issues on appeal for subsequent audit cycles (2001 - 2007). On May 17, 2016 the IRS Office of Appeals issued fully executed Forms 870-AD that effectively settled the matters on appeal on the same terms as those set forth in the Stipulations of Settled Issues, and on May 31, 2016 the U.S. Tax Court entered decisions consistent with the Stipulations of Settled Issues. As a result, all aspects of this controversy that were before the U.S. Tax Court and Appeals Division of the IRS have been finally resolved for audit cycles from 1997-2007. See Note 11 for additional discussion of income taxes. Guarantees As a result of the acquisition of Covidien, the Company has guarantee commitments and indemnifications with Tyco International, TE Connectivity Ltd. (TE Connectivity), and Mallinckrodt plc (Mallinckrodt) which relate to certain contingent tax liabilities. On June 29, 2007, Covidien entered into the Tax Sharing Agreement, under which Covidien shares responsibility for certain of its, Tyco International’s, and TE Connectivity’s income tax liabilities for periods prior to Covidien’s 2007 separation from Tyco International (2007 separation). Covidien, Tyco International, and TE Connectivity share 42 percent , 27 percent , and 31 percent , respectively, of U.S. income tax liabilities that arise from adjustments made by tax authorities to Covidien's, Tyco International’s, and TE Connectivity’s U.S. income tax returns, certain income tax liabilities arising from adjustments made by tax authorities to intercompany transactions or similar adjustments, and certain taxes attributable to internal transactions undertaken in anticipation of the 2007 separation. If Tyco International and TE Connectivity default on their obligations to the Company under the Tax Sharing Agreement, the Company would be liable for the entire amount of these liabilities. All costs and expenses associated with the management of these tax liabilities are being shared equally among the parties. In connection with the 2007 separation, all tax liabilities associated with Covidien business became Covidien’s tax liabilities. Following Covidien’s spin-off of its Pharmaceuticals business to Covidien shareholders through a distribution of all the outstanding ordinary shares of Mallinkrodt (2013 separation), Mallinckrodt became the primary obligor to the taxing authorities for the tax liabilities attributable to its subsidiaries, a significant portion of which relate to periods prior to the 2007 separation. However, Covidien remains the sole party subject to the Tax Sharing Agreement. Accordingly, Mallinckrodt does not share in the Company’s liability to Tyco International and TE Connectivity, nor in the receivable that the Company has from Tyco International, and TE Connectivity. If any party to the Tax Sharing Agreement were to default in its obligation to another party to pay its share of the distribution taxes that arise as a result of no party’s fault, each non-defaulting party would be required to pay, equally with any other non-defaulting party, the amounts in default. In addition, if another party to the Tax Sharing Agreement that is responsible for all or a portion of an income tax liability were to default in its payment of such liability to a taxing authority, the Company could be legally liable under applicable tax law for such liabilities and be required to make additional tax payments. Accordingly, under certain circumstances, the Company may be obligated to pay amounts in excess of the Company’s agreed upon share of Covidien's, Tyco International’s and TE Connectivity’s tax liabilities. The Company has used available information to develop its best estimates for certain assets and liabilities related to periods prior to the 2007 separation, including amounts subject to or impacted by the provisions of the Tax Sharing Agreement. The actual amounts that the Company may be required to ultimately accrue or pay under the Tax Sharing Agreement, however, could vary depending upon the outcome of the unresolved tax matters. Final determination of the balances will be made in subsequent periods, primarily related to certain pre-2007 separation tax liabilities and tax years open for examination. These balances will also be impacted by the filing of final or amended income tax returns in certain jurisdictions where those returns include a combination of Tyco International, Covidien, and/or TE Connectivity legal entities for periods prior to the 2007 separation. The resolutions with the U.S. Tax Court and IRS Appeals for fiscal years 1997 through 2007 were finalized during May 2016. However, the Tax Sharing Agreement remains in place with respect to income tax liabilities that are not the subject of such resolution. In conjunction with the 2013 separation, Mallinckrodt assumed the tax liabilities that are attributable to its subsidiaries, and Covidien indemnified Mallinckrodt to the extent that such tax liabilities arising from periods prior to 2013 exceed $200 million , net of certain tax benefits realized. In addition, in connection with the 2013 separation, Covidien entered into certain other guarantee commitments and indemnifications with Mallinckrodt. See Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2016 for additional information. Except as described above in this note or for certain income tax related matters, the Company has not recognized an expense related to losses in connection with these matters because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company cannot reasonably estimate the range of loss, if any, that may result from these matters. In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of them to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising out of the Company or its affiliates’ products or the negligence of any of their personnel or claims alleging that any of their products infringe third-party patents or other intellectual property. The Company’s maximum exposure under these indemnification provisions cannot be estimated, and the Company has not accrued any liabilities within the consolidated financial statements. Historically, the Company has not experienced significant losses on these types of indemnifications.

Segment and Geographic Informat

Segment and Geographic Information	9 Months Ended
	Jan. 27, 2017
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information Segment information The Company’s management evaluates performance and allocates resources based on profit and loss from operations before income taxes and interest expense, net, not including corporate-determined charges, as presented in the table below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 29, 2016 . In the first quarter of fiscal year 2017, the Company realigned the divisions within the Restorative Therapies Group. The Restorative Therapies Group consists of the following divisions: Spine, Brain Therapies, Pain Therapies, and Specialty Therapies. Net sales of the Company’s reportable segments include end-customer revenues from the sale of products each reportable segment develops and manufactures or distributes. Net sales and income from operations before income taxes by reportable segment are as follows: Three months ended Nine months ended (in millions) January 27, 2017 January 29, 2016 January 27, 2017 January 29, 2016 Cardiac and Vascular Group $ 2,548 $ 2,410 $ 7,650 $ 7,460 Minimally Invasive Therapies Group 2,417 2,291 7,314 7,103 Restorative Therapies Group 1,817 1,759 5,415 5,335 Diabetes Group 501 474 1,415 1,368 Total net sales $ 7,283 $ 6,934 $ 21,794 $ 21,266 Three months ended Nine months ended (in millions) January 27, 2017 January 29, 2016 January 27, 2017 January 29, 2016 Cardiac and Vascular Group $ 683 $ 726 $ 2,055 $ 2,298 Minimally Invasive Therapies Group 328 282 958 963 Restorative Therapies Group 535 496 1,543 1,460 Diabetes Group 149 140 375 379 Total reportable segments’ income from operations before income taxes 1,695 1,644 4,931 5,100 Special charge (100 ) — (100 ) — Impact of inventory step-up — — (38 ) (226 ) Restructuring charges, net (1) (21 ) (19 ) (172 ) (159 ) Certain litigation charges (218 ) — (300 ) (26 ) Acquisition-related items (68 ) (63 ) (148 ) (183 ) Interest expense, net (180 ) (176 ) (532 ) (584 ) Corporate (141 ) (207 ) (474 ) (720 ) Total income from operations before income taxes $ 967 $ 1,179 $ 3,167 $ 3,202 (1) Restructuring charges, net within this table include the impact of amounts recorded within cost of products sold in the consolidated statements of income Geographic information Net sales to external customers by geography are as follows: Three months ended Nine months ended (in millions) January 27, 2017 January 29, 2016 January 27, 2017 January 29, 2016 Americas (1) $ 4,417 $ 4,229 $ 13,185 $ 13,064 EMEA (2) 1,652 1,607 4,895 4,843 Asia-Pacific 818 729 2,530 2,235 Greater China 396 369 1,184 1,124 Total net sales $ 7,283 $ 6,934 $ 21,794 $ 21,266 (1) The U.S., which is included in the Americas, had net sales to external customers of $4.1 billion and $12.3 billion for the three and nine months ended January 27, 2017 , respectively, compared to $4.0 billion and $12.2 billion for the three and nine months ended January 29, 2016 . (2) EMEA consists of Europe, Middle East, and Africa. Sales to Ireland were insignificant during all periods presented.

Guarantor Financial Information

Guarantor Financial Information	9 Months Ended
	Jan. 27, 2017
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Guarantor Financial Information	Guarantor Financial Information Medtronic plc and Medtronic Global Holdings S.C.A. (Medtronic Luxco) each have provided full and unconditional guarantees of the obligations of Medtronic, Inc. under the Senior Notes (Medtronic Senior Notes) and full and unconditional guarantees of the obligations of Covidien International Finance S.A. (CIFSA) under the Senior Notes (CIFSA Senior Notes). The guarantees of the CIFSA Senior Notes are in addition to the guarantees of the CIFSA Senior Notes by Covidien Ltd. and Covidien Group Holdings Ltd. The guarantees provided by the parent company guarantor and subsidiary guarantors are joint and several. A summary of the guarantees is as follows: Guarantees of Medtronic Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - Medtronic, Inc. • Subsidiary Guarantor - Medtronic Luxco Guarantees of CIFSA Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - CIFSA • Subsidiary Guarantors - Medtronic Luxco, Covidien Ltd., and Covidien Group Holdings Ltd. Subsequent to January 27, 2017, the Company filed a Form S-3 registration statement with the Securities and Exchange Commission to support future issuances of registered debt securities from either Medtronic Luxco or Medtronic, Inc. Medtronic plc and Medtronic, Inc. will be the parent company guarantor and subsidiary guarantor, respectively, if Medtronic Luxco issues registered debt securities. The guarantee structure of the existing Medtronic Senior Notes will apply to any registered debt securities issued by Medtronic, Inc. under this registration statement. The following presents the Company’s consolidating statements of comprehensive income for the three and nine months ended January 27, 2017 and January 29, 2016 , condensed consolidating balance sheets at January 27, 2017 and April 29, 2016 , and condensed consolidating statements of cash flows for the nine months ended January 27, 2017 and January 29, 2016 . Condensed consolidating financial information is presented on a stand-alone basis using the equity method of accounting. During the third quarter of fiscal year 2017, the Company undertook certain steps to reorganize ownership of various subsidiaries. The transactions were entirely among subsidiaries under the common control of Medtronic. This reorganization has been reflected as of the beginning of the earliest period presented. As previously disclosed, the Company made revisions to its consolidating statements of comprehensive income of the guarantees of the Medtronic Senior Notes and CIFSA Senior notes as previously presented in Note 18 in the Company’s Quarterly Report on Form 10-Q for the period ended January 29, 2016 due to an incorrect presentation of the equity in net (income) loss of subsidiaries balances for the nine months ended January 29, 2016. In the consolidating statements of comprehensive income of the guarantees of the Medtronic Senior Notes, the $7.1 billion revision resulted in additional income reported in the equity in net (income) loss of subsidiaries line item in the Subsidiary Issuer (Medtronic, Inc.) column. In the consolidating statements of comprehensive income of the guarantees of the CIFSA Senior Notes, the $7.1 billion revision resulted in reduced income reported in the equity in net (income) loss of subsidiaries line item in the Subsidiary Issuer (CIFSA) column. There is no impact to the consolidated financial statements of Medtronic plc as previously filed in the 2016 Annual Report on Form 10-K or Quarterly Reports on Form 10-Q. As previously disclosed, the Company made revisions to its condensed consolidating balance sheets of the guarantees of the Medtronic Senior Notes and CIFSA Senior Notes as previously presented in Note 19 in the Company’s Annual Report on Form 10-K for the year ended April 29, 2016 primarily due to an income statement error recognized in the second quarter of fiscal year 2016, resulting in an incorrect presentation of the investment in subsidiaries balances. In the condensed consolidating balance sheet of the guarantees of the Medtronic Senior Notes, the $5.1 billion revision increased the line items investment in subsidiaries and shareholders' equity in the Subsidiary Issuer (Medtronic, Inc.) column. In the condensed consolidating balance sheet of the guarantees of the CIFSA Senior Notes, the $5.1 billion revision decreased the line items investment in subsidiaries and shareholders' equity in the Subsidiary Issuer (CIFSA) column. There is no impact to the consolidated financial statements of Medtronic plc as previously filed in the 2016 Annual Report on Form 10-K or Quarterly Reports on Form 10-Q. As previously disclosed, the Company revised its condensed consolidating balance sheets of the guarantees of the CIFSA Notes as previously presented in Note 19 in the Company’s Annual Report on Form 10-K for the year ended April 29, 2016 due to an incorrect presentation of intercompany capital contributions. The $20.5 billion revision decreased the investment in subsidiaries and intercompany payable balances in the Parent Guarantor (Medtronic plc) column and decreased the investment in subsidiaries and shareholders’ equity balances in the Subsidiary Guarantor column in both the condensed consolidating balance sheets of the guarantees of the Medtronic Senior Notes and CIFSA Senior Notes, decreased the intercompany receivable and shareholders’ equity balances in the Subsidiary Issuer (Medtronic, Inc.) column in the condensed consolidating balance sheets of the guarantees of the Medtronic Senior Notes, and decreased the intercompany receivable and shareholders’ equity balances in the Subsidiary Non-Guarantors column. There is no impact to the consolidated financial statements of Medtronic plc as previously filed in the 2016 Annual Report on Form 10-K or Quarterly Reports on Form 10-Q. The Company made revisions to its condensed consolidating statement of cash flows of the guarantees of the Medtronic Senior Notes and CIFSA Senior Notes as previously presented in Note 18 in the Company’s Quarterly Report on Form 10-Q for the period ended January 29, 2016 due to an incorrect presentation of intercompany capital contributions. For the Medtronic Senior Notes, an approximately $1.5 billion revision to operating, investing and financing activities was made in both the Subsidiary Guarantor and Subsidiary Non-Guarantor columns. In the CIFSA Senior Notes, a $2.1 billion revision to operating, investing and financing activities was made in the Subsidiary Issuer (CIFSA), Subsidiary Guarantors, and Subsidiary Non-Guarantors columns. Additionally, a $7.3 billion revision was made to investing and financing activities in the Subsidiary Issuer (CIFSA) column and operating and investing activities in the Subsidiary Non-Guarantors column. There is no impact to the consolidated financial statements of Medtronic plc as previously filed in the 2016 Annual Report on Form 10-K or Quarterly Reports on Form 10-Q. Consolidating Statement of Comprehensive Income Three Months Ended January 27, 2017 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 298 $ — $ 7,283 $ (298 ) $ 7,283 Costs and expenses: Cost of products sold — 214 — 2,366 (312 ) 2,268 Research and development expense — 147 — 383 — 530 Selling, general, and administrative expense 4 264 — 2,120 — 2,388 Special charge — 100 — — — 100 Restructuring charges, net — 22 — (1 ) — 21 Certain litigation charges — — — 218 — 218 Acquisition-related items — 36 — 32 — 68 Amortization of intangible assets — 3 — 494 — 497 Other (income) expense, net 80 (498 ) — 464 — 46 Operating profit (loss) (84 ) 10 — 1,207 14 1,147 Interest income — (62 ) (157 ) (294 ) 425 (88 ) Interest expense 32 397 18 246 (425 ) 268 Interest expense (income), net 32 335 (139 ) (48 ) — 180 Equity in net (income) loss of subsidiaries (937 ) (561 ) (798 ) — 2,296 — Income from operations before income taxes 821 236 937 1,255 (2,282 ) 967 Provision (benefit) for income taxes — (60 ) — 207 — 147 Net income 821 296 937 1,048 (2,282 ) 820 Net loss attributable to noncontrolling interests — — — (1 ) — (1 ) Net income attributable to Medtronic 821 296 937 1,049 (2,282 ) 821 Other comprehensive income (loss), net of tax (551 ) 27 (551 ) (584 ) 1,108 (551 ) Total comprehensive income $ 270 $ 323 $ 386 $ 465 $ (1,174 ) $ 270 Consolidating Statement of Comprehensive Income Nine Months Ended January 27, 2017 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 983 $ — $ 21,793 $ (982 ) $ 21,794 Costs and expenses: Cost of products sold — 706 — 7,145 (996 ) 6,855 Research and development expense — 469 — 1,171 — 1,640 Selling, general, and administrative expense 9 828 — 6,395 — 7,232 Special charge — 100 — — — 100 Restructuring charges, net — 40 — 122 — 162 Certain litigation charges — — — 300 — 300 Acquisition-related items — 96 — 52 — 148 Amortization of intangible assets — 9 — 1,475 — 1,484 Other (income) expense, net 5 (1,830 ) — 1,999 — 174 Operating profit (loss) (14 ) 565 — 3,134 14 3,699 Interest (income) — (183 ) (477 ) (719 ) 1,107 (272 ) Interest expense 74 1,203 31 603 (1,107 ) 804 Interest (income) expense, net 74 1,020 (446 ) (116 ) — 532 Equity in net (income) of subsidiaries (2,949 ) (2,074 ) (2,503 ) — 7,526 — Income (loss) from operations before income taxes 2,861 1,619 2,949 3,250 (7,512 ) 3,167 Provision (benefit) for income taxes (4 ) (10 ) — 321 — 307 Net income (loss) 2,865 1,629 2,949 2,929 (7,512 ) 2,860 Net loss attributable to noncontrolling interests — — — (5 ) — (5 ) Net income attributable to Medtronic 2,865 1,629 2,949 2,934 (7,512 ) 2,865 Other comprehensive income (loss), net of tax (1,011 ) 168 (1,011 ) (1,085 ) 1,928 (1,011 ) Total comprehensive income $ 1,854 $ 1,797 $ 1,938 $ 1,849 $ (5,584 ) $ 1,854 Consolidating Statement of Comprehensive Income Three Months Ended January 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 350 $ — $ 6,934 $ (350 ) $ 6,934 Costs and expenses: Cost of products sold — 245 — 2,258 (362 ) 2,141 Research and development expense — 148 — 398 — 546 Selling, general, and administrative expense 2 245 — 2,070 — 2,317 Restructuring charges, net — — — 19 — 19 Acquisition-related items — 36 — 27 — 63 Amortization of intangible assets — 3 — 481 — 484 Other (income) expense, net 36 (574 ) — 547 — 9 Operating profit (loss) (38 ) 247 — 1,134 12 1,355 Interest income — (58 ) (174 ) (105 ) 238 (99 ) Interest expense 7 408 3 95 (238 ) 275 Interest expense (income), net 7 350 (171 ) (10 ) — 176 Equity in net (income) loss of subsidiaries (1,137 ) (621 ) (966 ) — 2,724 — Income from operations before income taxes 1,092 518 1,137 1,144 (2,712 ) 1,179 Provision (benefit) for income taxes (3 ) (16 ) 2 101 — 84 Net income 1,095 534 1,135 1,043 (2,712 ) 1,095 Other comprehensive income (loss), net of tax (1,494 ) (80 ) (1,494 ) (1,510 ) 3,084 (1,494 ) Total comprehensive income $ (399 ) $ 454 $ (359 ) $ (467 ) $ 372 $ (399 ) Consolidating Statement of Comprehensive Income Nine Months Ended January 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 1,085 $ — $ 21,266 $ (1,085 ) $ 21,266 Costs and expenses: Cost of products sold — 753 — 7,089 (1,063 ) 6,779 Research and development expense — 464 — 1,185 — 1,649 Selling, general, and administrative expense 7 756 — 6,346 — 7,109 Restructuring charges, net — 4 — 155 — 159 Certain litigation charges, net — — — 26 — 26 Acquisition-related items — 91 — 92 — 183 Amortization of intangible assets — 9 — 1,439 — 1,448 Other (income) expense, net 86 (1,502 ) — 1,543 — 127 Operating profit (loss) (93 ) 510 — 3,391 (22 ) 3,786 Interest income — (179 ) (531 ) (328 ) 717 (321 ) Interest expense 12 1,307 6 297 (717 ) 905 Interest (income) expense, net 12 1,128 (525 ) (31 ) — 584 Equity in net income of subsidiaries (2,529 ) (2,562 ) (2,006 ) — 7,097 — Income from operations before income taxes 2,424 1,944 2,531 3,422 (7,119 ) 3,202 Provision (benefit) for income taxes (11 ) (94 ) 2 870 — 767 Net income 2,435 2,038 2,529 2,552 (7,119 ) 2,435 Other comprehensive income (loss), net of tax (1,781 ) (337 ) (1,781 ) (1,876 ) 3,994 (1,781 ) Total comprehensive income $ 654 $ 1,701 $ 748 $ 676 $ (3,125 ) $ 654 Condensed Consolidating Balance Sheet January 27, 2017 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 40 $ — $ 2,728 $ — $ 2,768 Investments — — — 8,690 — 8,690 Accounts receivable, net — — — 5,453 — 5,453 Inventories — 162 — 3,658 (100 ) 3,720 Intercompany receivable 48 — — 13,720 (13,768 ) — Other current assets 6 184 — 1,602 — 1,792 Total current assets 54 386 — 35,851 (13,868 ) 22,423 Property, plant, and equipment, net — 1,251 — 3,696 — 4,947 Goodwill — — — 41,224 — 41,224 Other intangible assets, net — 22 — 26,187 — 26,209 Tax assets — 675 — 809 — 1,484 Investment in subsidiaries 54,344 72,458 41,130 — (167,932 ) — Intercompany loans receivable 3,000 8,716 22,906 31,042 (65,664 ) — Other assets — 428 — 863 — 1,291 Total assets $ 57,398 $ 83,936 $ 64,036 $ 139,672 $ (247,464 ) $ 97,578 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Current debt obligations $ — $ 3,500 $ 1,099 $ 1,627 $ — $ 6,226 Accounts payable — 309 — 1,248 — 1,557 Intercompany payable 17 12,353 — 1,398 (13,768 ) — Accrued compensation 6 597 — 918 — 1,521 Accrued income taxes 12 26 — 783 — 821 Other accrued expenses — 579 — 1,968 — 2,547 Total current liabilities 35 17,364 1,099 7,942 (13,768 ) 12,672 Long-term debt — 23,617 — 2,306 — 25,923 Accrued compensation and retirement benefits — 1,185 — 425 — 1,610 Accrued income taxes 10 1,642 — 875 — 2,527 Long-term intercompany loans payable 7,966 10,235 15,595 31,868 (65,664 ) — Deferred tax liabilities — — — 3,643 — 3,643 Other liabilities — 198 — 1,512 — 1,710 Total liabilities 8,011 54,241 16,694 48,571 (79,432 ) 48,085 Shareholders’ equity 49,387 29,695 47,342 90,995 (168,032 ) 49,387 Noncontrolling interests — — — 106 — 106 Total equity 49,387 29,695 47,342 91,101 (168,032 ) 49,493 Total liabilities and equity $ 57,398 $ 83,936 $ 64,036 $ 139,672 $ (247,464 ) $ 97,578 Condensed Consolidating Balance Sheet April 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 55 $ — $ 2,821 $ — $ 2,876 Investments — — — 9,758 — 9,758 Accounts receivable, net — — — 5,562 — 5,562 Inventories — 162 — 3,511 (200 ) 3,473 Intercompany receivable 403 141,368 — 162,278 (304,049 ) — Other current assets 24 271 — 1,636 — 1,931 Total current assets 427 141,856 — 185,566 (304,249 ) 23,600 Property, plant, and equipment, net — 1,139 — 3,702 — 4,841 Goodwill — — — 41,500 — 41,500 Other intangible assets, net — 31 — 26,868 — 26,899 Tax assets — 690 — 693 — 1,383 Investment in subsidiaries 52,608 68,903 49,698 — (171,209 ) — Intercompany loans receivable 3,000 8,884 10,203 18,140 (40,227 ) — Other assets — 506 — 915 — 1,421 Total assets $ 56,035 $ 222,009 $ 59,901 $ 277,384 $ (515,685 ) $ 99,644 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Current debt obligations $ — $ 500 $ — $ 493 $ — $ 993 Accounts payable — 288 — 1,421 — 1,709 Intercompany payable — 151,687 — 152,362 (304,049 ) — Accrued compensation 32 616 — 1,064 — 1,712 Accrued income taxes 11 — — 555 — 566 Other accrued expenses 1 243 — 1,941 — 2,185 Total current liabilities 44 153,334 — 157,836 (304,049 ) 7,165 Long-term debt — 26,646 — 3,463 — 30,109 Accrued compensation and retirement benefits — 1,258 — 501 — 1,759 Accrued income taxes 10 1,422 — 1,471 — 2,903 Long-term intercompany loans payable 3,918 10,128 14,297 11,884 (40,227 ) — Deferred tax liabilities — — — 3,729 — 3,729 Other liabilities — 202 — 1,714 — 1,916 Total liabilities 3,972 192,990 14,297 180,598 (344,276 ) 47,581 Total shareholders' equity 52,063 29,019 45,604 96,786 (171,409 ) 52,063 Total liabilities and shareholders' equity $ 56,035 $ 222,009 $ 59,901 $ 277,384 $ (515,685 ) $ 99,644 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 27, 2017 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 834 $ 933 $ 306 $ 3,034 $ — $ 5,107 Investing Activities: Acquisitions, net of cash acquired — (940 ) — (388 ) — (1,328 ) Additions to property, plant, and equipment — (257 ) — (667 ) — (924 ) Purchases of investments — — — (3,516 ) 162 (3,354 ) Sales and maturities of investments — 210 — 4,238 (162 ) 4,286 Net (increase) decrease in intercompany loans — 168 (2,703 ) (2,902 ) 5,437 — Capital contribution paid — (241 ) — — 241 — Other investing activities, net — — — 21 — 21 Net cash provided by (used in) investing activities — (1,060 ) (2,703 ) (3,214 ) 5,678 (1,299 ) Financing Activities: Acquisition-related contingent consideration — — — (58 ) — (58 ) Change in current debt obligations, net — — 1,099 19 — 1,118 Repayment of current debt obligations (maturities greater than 90 days) — — — (2 ) — (2 ) Proceeds from current debt obligations (maturities greater than 90 days) — — — 4 — 4 Issuance of long-term debt — — — 131 — 131 Payments on long-term debt — (29 ) — (332 ) — (361 ) Dividends to shareholders (1,782 ) — — — — (1,782 ) Issuance of ordinary shares 309 — — — — 309 Repurchase of ordinary shares (3,409 ) — — — — (3,409 ) Net intercompany loan borrowings (repayments) 4,048 107 1,298 (16 ) (5,437 ) — Capital contribution received — — — 241 (241 ) — Other financing activities — 34 — 46 — 80 Net cash provided by (used in) financing activities (834 ) 112 2,397 33 (5,678 ) (3,970 ) Effect of exchange rate changes on cash and cash equivalents — — — 54 — 54 Net change in cash and cash equivalents — (15 ) — (93 ) — (108 ) Cash and cash equivalents at beginning of period — 55 — 2,821 — 2,876 Cash and cash equivalents at end of period $ — $ 40 $ — $ 2,728 $ — $ 2,768 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (15 ) $ 839 $ 525 $ 2,551 $ (8 ) $ 3,892 Investing Activities: Acquisitions, net of cash acquired — — — (1,132 ) — (1,132 ) Additions to property, plant, and equipment — (210 ) — (483 ) — (693 ) Purchases of investments — — — (4,509 ) — (4,509 ) Sales and maturities of investments — — — 4,017 — 4,017 Net (increase) decrease in intercompany loans — (975 ) (539 ) (2,544 ) 4,058 — Capital contribution paid — — (1,500 ) — 1,500 — Other investing activities, net — — — (11 ) — (11 ) Net cash provided by (used in) investing activities — (1,185 ) (2,039 ) (4,662 ) 5,558 (2,328 ) Financing Activities: Acquisition-related contingent consideration — — — (21 ) — (21 ) Change in current debt obligations, net — — 1,201 22 — 1,223 Repayment of current debt obligations (maturities greater than 90 days) — — (48 ) — — (48 ) Proceeds from current debt obligations (maturities greater than 90 days) — — 139 — — 139 Payments on long-term debt — (600 ) — (1,012 ) — (1,612 ) Dividends to shareholders (1,608 ) — — — — (1,608 ) Issuance of ordinary shares 360 — — — — 360 Repurchase of ordinary shares (2,170 ) — — — — (2,170 ) Net intercompany loan borrowings (repayments) 3,110 (96 ) 53 991 (4,058 ) — Intercompany dividend paid — — — (8 ) 8 — Capital contribution received — — — 1,500 (1,500 ) — Other financing activities 60 — — — — 60 Net cash (used in) provided by financing activities (248 ) (696 ) 1,345 1,472 (5,550 ) (3,677 ) Effect of exchange rate changes on cash and cash equivalents — — — (9 ) — (9 ) Net change in cash and cash equivalents (263 ) (1,042 ) (169 ) (648 ) — (2,122 ) Cash and cash equivalents at beginning of period 263 1,071 170 3,339 — 4,843 Cash and cash equivalents at end of period $ — $ 29 $ 1 $ 2,691 $ — $ 2,721 Consolidating Statement of Comprehensive Income Three Months Ended January 27, 2017 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 7,283 $ — $ 7,283 Costs and expenses: Cost of products sold — — — 2,268 — 2,268 Research and development expense — — — 530 — 530 Selling, general, and administrative expense 4 — — 2,384 — 2,388 Special charge — — — 100 — 100 Restructuring charges, net — — — 21 — 21 Certain litigation charges — — — 218 — 218 Acquisition-related items — — — 68 — 68 Amortization of intangible assets — — — 497 — 497 Other expense, net 80 — — (34 ) — 46 Operating profit (loss) (84 ) — — 1,231 — 1,147 Interest income — (23 ) (158 ) (108 ) 201 (88 ) Interest expense 32 26 18 393 (201 ) 268 Interest expense (income), net 32 3 (140 ) 285 — 180 Equity in net (income) loss of subsidiaries (937 ) (386 ) (797 ) — 2,120 — Income from operations before income taxes 821 383 937 946 (2,120 ) 967 Provision (benefit) for income taxes — — — 147 — 147 Net income 821 383 937 799 (2,120 ) 820 Net loss attributable to noncontrolling interests — — — (1 ) — (1 ) Net income attributable to Medtronic 821 383 937 800 (2,120 ) 821 Other comprehensive income (loss), net of tax (551 ) (82 ) (551 ) (551 ) 1,184 (551 ) Total comprehensive income $ 270 $ 301 $ 386 $ 249 $ (936 ) $ 270 Consolidating Statement of Comprehensive Income Nine Months Ended January 27, 2017 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 21,794 $ — $ 21,794 Costs and expenses: Cost of products sold — — — 6,855 — 6,855 Research and development expense — — — 1,640 — 1,640 Selling, general, and administrative expense 9 1 2 7,220 — 7,232 Special charge — — — 100 — 100 Restructuring charges, net — — — 162 — 162 Certain litigation charges — — — 300 — 300 Acquisition-related items — — — 148 — 148 Amortization of intangible assets — — — 1,484 — 1,484 Other (income) expense, net 5 1 — 168 — 174 Operating profit (loss) (14 ) (2 ) (2 ) 3,717 — 3,699 Interest income — (71 ) (482 ) (315 ) 596 (272 ) Interest expense 74 81 30 1,215 (596 ) 804 Interest expense (income), net 74 10 (452 ) 900 — 532 Equity in net (income) loss of subsidiaries (2,949 ) (1,630 ) (2,499 ) — 7,078 — Income from operations before income taxes 2,861 1,618 2,949 2,817 (7,078 ) 3,167 Provision (benefit) for income taxes (4 ) — — 311 — 307 Net income 2,865 1,618 2,949 2,506 (7,078 ) 2,860 Net loss attributable to noncontrolling interests — — — (5 ) — (5 ) Net income attributable to Medtronic 2,865 1,618 2,949 2,511 (7,078 ) 2,865 Other comprehensive loss, net of tax (1,011 ) (63 ) (1,011 ) (1,011 ) 2,085 (1,011 ) Total comprehensive income (loss) $ 1,854 $ 1,555 $ 1,938 $ 1,500 $ (4,993 ) $ 1,854 Consolidating Statement of Comprehensive Income Three Months Ended January 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 6,934 $ — $ 6,934 Costs and expenses: Cost of products sold — — — 2,141 — 2,141 Research and development expense — — — 546 — 546 Selling, general, and administrative expense 2 — — 2,315 — 2,317 Restructuring charges, net — — — 19 — 19 Acquisition-related items — — — 63 — 63 Amortization of intangible assets — — — 484 — 484 Other (income) expense, net 36 — — (27 ) — 9 Operating profit (loss) (38 ) — — 1,393 — 1,355 Interest income — (104 ) (174 ) (103 ) 282 (99 ) Interest expense 7 32 3 515 (282 ) 275 Interest expense (income), net 7 (72 ) (171 ) 412 — 176 Equity in net (income) loss of subsidiaries (1,137 ) (476 ) (966 ) — 2,579 — Income from operations before income taxes 1,092 548 1,137 981 (2,579 ) 1,179 Provision (benefit) for income taxes (3 ) — — 87 — 84 Net income 1,095 548 1,137 894 (2,579 ) 1,095 Other comprehensive income (loss), net of tax (1,494 ) (61 ) (1,494 ) (1,494 ) 3,049 (1,494 ) Total comprehensive income $ (399 ) $ 487 $ (357 ) $ (600 ) $ 470 $ (399 ) Consolidating Statement of Comprehensive Income Nine Months Ended January 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 21,266 $ — $ 21,266 Costs and expenses: Cost of products sold — — — 6,779 — 6,779 Research and development expense — — — 1,649 — 1,649 Selling, general, and administrative expense 7 — 3 7,099 — 7,109 Restructuring charges, net — — — 159 — 159 Certain litigation charges, net — — — 26 — 26 Acquisition-related items — — — 183 — 183 Amortization of intangible assets — — — 1,448 — 1,448 Other (income) expense, net 86 1 11 29 — 127 Operating profit (loss) (93 ) (1 ) (14 ) 3,894 — 3,786 Interest income — (421 ) (533 ) (329 ) 962 (321 ) Interest expense 12 98 6 1,751 (962 ) 905 Interest expense (income), net 12 (323 ) (527 ) 1,422 — 584 Equity in net (income) loss of subsidiaries (2,529 ) (558 ) (2,016 ) — 5,103 — Income from operations before income taxes 2,424 880 2,529 2,472 (5,103 ) 3,202 Provision (benefit) for income taxes (11 ) — — 778 — 767 Net income 2,435 880 2,529 1,694 (5,103 ) 2,435 Other comprehensive income (loss), net of tax (1,781 ) 767 (1,781 ) (1,781 ) 2,795 (1,781 ) Total comprehensive income $ 654 $ 1,647 $ 748 $ (87 ) $ (2,308 ) $ 654 Condensed Consolidating Balance Sheet January 27, 2017 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 81 $ — $ 2,687 $ — $ 2,768 Investments — — — 8,690 — 8,690 Accounts receivable, net — — — 5,453 — 5,453 Inventories — — — 3,720 — 3,720 Intercompany receivable 48 — 60 17 (125 ) — Other current assets 6 — — 1,786 — 1,792 Total current assets 54 81 60 22,353 (125 ) 22,423 Property, plant, and equipment, net — — — 4,947 — 4,947 Goodwill — — — 41,224 — 41,224 Other intangible assets, net — — — 26,209 — 26,209 Tax assets — — — 1,484 — 1,484 Investment in subsidiaries 54,344 21,293 39,803 — (115,440 ) — Intercompany loans receivable 3,000 5,639 24,173 19,444 (52,256 ) — Other assets — — — 1,291 — 1,291 Total assets $ 57,398 $ 27,013 $ 64,036 $ 116,952 $ (167,821 ) $ 97,578 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Current debt obligations $ — $ 1,188 $ 1,099 $ 3,939 $ — $ 6,226 Accounts payable — — — 1,557 — 1,557 Intercompany payable 17 — — 108 (125 ) — Accrued compensation 6 — — 1,515 — 1,521 Accrued income taxes 12 — — 809 — 821 Other accrued expenses — 32 — 2,515 — 2,547 Total current liabilities 35 1,220 1,099 10,443 (125 ) 12,672 Long-term debt — 2,139 — 23,784 — 25,923 Accrued compensation and retirement benefits — — — 1,610 — 1,610 Accrued income taxes 10 — — 2,517 — 2,527 Long-term intercompany loans payable 7,966 5,116 15,596 23,578 (52,256 ) — Deferred tax liabilities — — — 3,643 — 3,643 Other liabilities — — — 1,710 — 1,710 Total liabilities 8,011 8,475 16,695 67,285 (52,381 ) 48,085 Shareholders’ equity 49,387 18,538 47,341 49,561 (115,440 ) 49,387 Noncontrolling interests — — — 106 — 106 Total equity 49,387 18,538 47,341 49,667 (115,440 ) 49,493 Total liabilities and equity $ 57,398 $ 27,013 $ 64,036 $ 116,952 $ (167,821 ) $ 97,578 Condensed Consolidating Balance Sheet April 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 208 $ — $ 2,668 $ — $ 2,876 Investments — — — 9,758 — 9,758 Accounts receivable, net — — — 5,562 — 5,562 Inventories — — — 3,473 — 3,473 Intercompany receivable 403 — 61 — (464 ) — Other current assets 24 — — 1,907 — 1,931 Total current assets 427 208 61 23,368 (464 ) 23,600 Property, plant, and equipment, net — — 1 4,840 — 4,841 Goodwill — — — 41,500 — 41,500 Other intangible assets, net — — — 26,899 — 26,899 Tax assets — — — 1,383 — 1,383 Investment in subsidiaries 52,608 36,476 48,375 — (137,459 ) — Intercompany loans receivable 3,000 8,253 11,465 27,724 (50,442 ) — Other assets — — — 1,421 — 1,421 Total assets $ 56,035 $ 44,937 $ 59,902 $ 127,135 $ (188,365 ) $ 99,644 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Current debt obligations $ — $ — $ — $ 993 $ — $ 993 Accounts payable — — — 1,709 — 1,709 Intercompany payable — — — 464 (464 ) — Accrued compensation 32 — — 1,680 — 1,712 Accrued income taxes 11 — — 555 — 566 Other accrued expenses 1 24 — 2,160 — 2,185 Total current liabilities 44 24 — 7,561 (464 ) 7,165 Long-term debt — 3,382 — 26,727 — 30,109 Accrued compensation and retirement benefits — — — 1,759 — 1,759 Accrued income taxes 10 — — 2,893 — 2,903 Long-term intercompany loans payable 3,918 14,689 14,298 17,537 (50,442 ) — Deferred tax liabilities — — — 3,729 — 3,729 Other liabilities — — — 1,916 — 1,916 Total liabilities 3,972 18,095 14,298 62,122 (50,906 ) 47,581 Total shareholders' equity 52,063 26,842 45,604 65,013 (137,459 ) 52,063 Total liabilities and shareholders' equity $ 56,035 $ 44,937 $ 59,902 $ 127,135 $ (188,365 ) $ 99,644 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 27, 2017 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 834 $ (53 ) $ 160 $ 4,166 $ — $ 5,107 Investing Activities: Acquisitions, net of cash acquired — — — (1,328 ) — (1,328 ) Additions to property, plant, and equipment — — — (924 ) — (924 ) Purchases of investments — — — (3,354 ) — (3,354 ) Sales and maturities of investments — — — 4,286 — 4,286 Net (increase) decrease in intercompany loans receivable — 2,614 (2,557 ) 1,774 (1,831 ) — Intercompany dividend received — 920 — — (920 ) — Capital contribution paid — (537 ) — — 537 — Other investing activities, net — — — 21 — 21 Net cash provided by (used in) investing activities — 2,997 (2,557 ) 475 (2,214 ) (1,299 ) Financing Activities: Acquisition-related contingent consideration — — — (58 ) — (58 ) Change in current debt obligations, net — — 1,099 19 — 1,118 Repayment of current debt obligations (maturities greater than 90 days) — — — (2 ) — (2 ) Proceeds from current debt obligations (maturities greater than 90 days) — — — 4 — 4 Issuance of long-term debt — — — 131 — 131 Payments on long-term debt — — — (361 ) — (361 ) Dividends to shareholders (1,782 ) — — — — (1,782 ) Issuance of ordinary shares 309 — — — — 309 Repurchase of ordinary shares (3,409 ) — — — — (3,409 ) Net intercompany loan borrowings (repayments) 4,048 (3,071 ) 1,298 (4,106 ) 1,831 — Intercompany dividend paid — — — (920 ) 920 — Capital contribution received — — — 537 (537 ) — Other financing activities — — — 80 — 80 Net cash provided by (used in) financing activities (834 ) (3,071 ) 2,397 (4,676 ) 2,214 (3,970 ) Effect of exchange rate changes on cash and cash equivalents — — — 54 — 54 Net change in cash and cash equivalents — (127 ) — 19 — (108 ) Cash and cash equivalents at beginning of period — 208 — 2,668 — 2,876 Cash and cash equivalents at end of period $ — $ 81 $ — $ 2,687 $ — $ 2,768 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Jan. 27, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, comprehensive income, financial condition, and cash flows in conformity with U.S. GAAP. In the opinion of management, the consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) for the periods presented. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended April 29, 2016 .
Consolidation	The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation.
Fiscal Period	The Company’s fiscal years 2017 , 2016 , and 2015 will end or ended on April 28, 2017 , April 29, 2016 , and April 24, 2015 , respectively.
New Accounting Pronouncements	Recently Adopted In April 2015, the Financial Accounting Standards Board (FASB) issued accounting guidance that requires debt issuance costs to be presented in the balance sheet as a direct deduction from the related debt liability. Prior to this amendment, debt issuance costs were recognized as an asset in the balance sheet and did not offset the related debt liability. The Company retrospectively adopted this guidance in the first quarter of fiscal year 2017. Its adoption resulted in a reduction of both assets and liabilities of $138 million on the Company's consolidated balance sheet at April 29, 2016 as previously filed in the 2016 Annual Report on Form 10-K. Not Yet Adopted In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019 using one of two prescribed retrospective methods. The Company is evaluating the impact of the amended revenue recognition guidance on the Company’s consolidated financial statements. In January 2016, the FASB issued guidance which requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The guidance also includes a simplified impairment assessment of equity investments without readily determinable fair values and presentation and disclosure changes. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019. The Company is evaluating the impact of the equity investment guidance on the Company's consolidated financial statements. In February 2016, the FASB issued guidance which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. The guidance is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements and is effective for the Company beginning in the first quarter of fiscal year 2020. Early adoption is permitted. The Company is evaluating the impact of the lease guidance on the Company's consolidated financial statements. In March 2016, the FASB issued guidance to simplify the accounting for share-based payment transactions by requiring all excess tax benefits and deficiencies to be recognized in income tax expense or benefit in earnings; eliminating the requirement to classify the excess tax benefit and deficiencies as additional paid-in capital. For the three and nine months ended January 27, 2017, the Company recognized $5 million and $80 million , respectively, of excess tax benefits in additional paid-in capital. Under the new guidance, an entity makes an accounting policy election to either estimate the expected forfeiture awards or account for forfeitures as they occur. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2018. In October 2016, the FASB issued guidance that requires the tax effect of inter-entity transactions, other than sales of inventory, to be recognized when the transaction occurs. This would eliminate the exception under the current guidance in which the tax effects of inter-entity asset transactions are deferred until the transferred asset is sold to a third party or otherwise recovered through use. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019. The Company is evaluating the impact of the inter-entity transaction guidance on the Company's consolidated financial statements.

Acquisitions and Acquisition-27

Acquisitions and Acquisition-Related Items (Tables)	9 Months Ended
	Jan. 27, 2017
Business Acquisition [Line Items]
Fair Value Measurements, Contingent Consideration, Significant Unobservable Inputs	The recurring Level 3 fair value measurements of contingent consideration include the following significant unobservable inputs: Fair Value at (in millions) January 27, 2017 Valuation Technique Unobservable Input Range Discount rate 11% - 32.5% Revenue-based payments $111 Discounted cash flow Probability of payment 30% - 100% Projected fiscal year of payment 2017 - 2025 Discount rate 0.3% - 5.5% Product development-based payments $151 Discounted cash flow Probability of payment 75% - 100% Projected fiscal year of payment 2017 - 2025
Reconciliation of Beginning and Ending Balances of Contingent Consideration Associated with Acquisitions	The following table provides a reconciliation of the beginning and ending balances of contingent consideration: Three months ended Nine months ended (in millions) January 27, 2017 January 29, 2016 January 27, 2017 January 29, 2016 Beginning Balance $ 285 $ 368 $ 377 $ 264 Purchase price contingent consideration (4 ) 14 28 149 Payments (23 ) (2 ) (62 ) (22 ) Change in fair value 4 (9 ) (81 ) (20 ) Ending Balance $ 262 $ 371 $ 262 $ 371
2017 Acquisitions [Member]
Business Acquisition [Line Items]
Fair Value of Assets Acquired and Liabilities Assumed	The preliminary fair values of the assets acquired and liabilities assumed during the nine months ended January 27, 2017 were as follows: (in millions) HeartWare International, Inc. Smith & Nephew's Gynecology Business All Other Total Other current assets $ 351 $ — $ 17 $ 368 Property, plant, and equipment 13 3 4 20 Other intangible assets 625 167 65 857 Goodwill 479 180 113 772 Other assets 55 — 15 70 Total assets acquired 1,523 350 214 2,087 Current liabilities 144 — 9 153 Deferred tax liabilities 60 — 9 69 Long-term debt 245 — — 245 Other liabilities 2 — 4 6 Total liabilities assumed 451 — 22 473 Net assets acquired $ 1,072 $ 350 $ 192 $ 1,614

Restructuring Charges (Tables)

Restructuring Charges (Tables)	9 Months Ended
	Jan. 27, 2017
Cost Synergies Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	A summary of the restructuring accrual, recorded within other accrued expenses and other liabilities in the consolidated balance sheets, and related activity is presented below: (in millions) Employee Termination Costs Asset Write-downs Other Costs Total April 29, 2016 $ 213 $ — $ 37 $ 250 Restructuring charges 152 18 44 214 Payments/write-downs (146 ) (18 ) (49 ) (213 ) Reversal of excess accrual (40 ) — (2 ) (42 ) January 27, 2017 $ 179 $ — $ 30 $ 209

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Jan. 27, 2017
Investments [Abstract]
Investments by Category and Related Balance Sheet Classification	The following table summarizes the Company's investments by significant investment category and the consolidated balance sheet classification at January 27, 2017 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 577 $ 1 $ (12 ) $ 566 $ 566 $ — Marketable equity securities 102 21 (3 ) 120 — 120 Total Level 1 679 22 (15 ) 686 566 120 Level 2: Corporate debt securities 4,637 49 (35 ) 4,651 4,651 — U.S. government and agency securities 973 1 (15 ) 959 959 — Mortgage-backed securities 761 6 (20 ) 747 747 — Foreign government and agency securities 50 — (1 ) 49 49 — Other asset-backed securities 198 1 — 199 199 — Debt funds 1,743 — (224 ) 1,519 1,519 — Total Level 2 8,362 57 (295 ) 8,124 8,124 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 47 — (3 ) 44 — 44 Total Level 3 48 — (3 ) 45 — 45 Total available-for-sale securities $ 9,089 $ 79 $ (313 ) $ 8,855 $ 8,690 $ 165 Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 589 — — N/A — 589 Total Level 3 589 — — N/A — 589 Total cost method, equity method, and other investments $ 589 $ — $ — N/A $ — $ 589 Total investments $ 9,678 $ 79 $ (313 ) $ 8,855 $ 8,690 $ 754 The following table summarizes the Company's investments by significant investment category and the related consolidated balance sheet classification at April 29, 2016 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 792 $ 14 $ (1 ) $ 805 $ 805 $ — Marketable equity securities 75 21 (11 ) 85 — 85 Total Level 1 867 35 (12 ) 890 805 85 Level 2: Corporate debt securities 3,935 85 (24 ) 3,996 3,996 — U.S. government and agency securities 902 2 — 904 904 — Mortgage-backed securities 1,016 17 (18 ) 1,015 1,015 — Other asset-backed securities 192 3 — 195 195 — Debt funds 3,040 5 (281 ) 2,764 2,764 — Total Level 2 9,085 112 (323 ) 8,874 8,874 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 47 — (3 ) 44 — 44 Total Level 3 48 — (3 ) 45 — 45 Total available-for-sale securities $ 10,000 $ 147 $ (338 ) $ 9,809 $ 9,679 $ 130 Trading securities: Level 1: Exchange-traded funds 65 15 (1 ) 79 79 — Total Level 1 65 15 (1 ) 79 79 — Total trading securities $ 65 $ 15 $ (1 ) $ 79 $ 79 $ — Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 506 — — N/A — 506 Total Level 3 506 — — N/A — 506 Total cost method, equity method, and other investments $ 506 $ — $ — N/A $ — $ 506 Total investments $ 10,571 $ 162 $ (339 ) $ 9,888 $ 9,758 $ 636
Available-For-Sale Securities in Continuous Unrealized Loss Position	The following tables represent the gross unrealized losses and fair values of the Company’s available-for-sale securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at January 27, 2017 and April 29, 2016 : January 27, 2017 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 1,568 $ (30 ) $ 82 $ (5 ) Auction rate securities — — 44 (3 ) Mortgage-backed securities 402 (8 ) 133 (12 ) U.S. government and agency securities 1,011 (27 ) — — Foreign government and agency securities 49 (1 ) — — Debt funds 227 (8 ) 1,091 (216 ) Marketable equity securities 17 (1 ) 1 (2 ) Total $ 3,274 $ (75 ) $ 1,351 $ (238 ) April 29, 2016 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 756 $ (18 ) $ 136 $ (6 ) Auction rate securities — — 44 (3 ) Mortgage-backed securities 196 (5 ) 92 (5 ) U.S. government and agency securities 308 (4 ) 67 (5 ) Debt funds 670 (26 ) 1,601 (256 ) Marketable equity securities 45 (11 ) — — Total $ 1,975 $ (64 ) $ 1,940 $ (275 )
Unobservable Inputs Utilized in the Fair Value Measurement of Auction Rate Securities Classified as Level 3	The following table represents the range of the unobservable inputs utilized in the fair value measurement of the auction rate securities classified as Level 3 at January 27, 2017 : Valuation Technique Unobservable Input Range (Weighted Average) Auction rate securities Discounted cash flow Years to principal recovery 2 yrs. - 12 yrs. (3 yrs.) Illiquidity premium 6%
Reconciliation of Beginning and Ending Balances of Items Measured at Fair Value on a Recurring Basis that Used Significant Unobservable Inputs (Level 3)	The following tables provide a reconciliation of the beginning and ending balances of items measured at fair value on a recurring basis that used significant unobservable inputs (Level 3): Three months ended January 27, 2017 (in millions) Total Level 3 Corporate debt Auction rate October 28, 2016 $ 45 $ 1 $ 44 Total unrealized (losses) gains included in other comprehensive income — — — January 27, 2017 $ 45 $ 1 $ 44 Three months ended January 29, 2016 (in millions) Total Level 3 Corporate debt Auction rate October 30, 2015 $ 103 $ 1 $ 102 Total unrealized (losses) gains included in other comprehensive income — — — January 29, 2016 $ 103 $ 1 $ 102 Nine months ended January 27, 2017 (in millions) Total Level 3 Corporate Debt Auction Rate April 29, 2016 $ 45 $ 1 $ 44 Total unrealized (losses) gains included in other comprehensive income — — — January 27, 2017 $ 45 $ 1 $ 44 Nine months ended January 29, 2016 (in millions) Total Level 3 Corporate Debt Auction Rate April 24, 2015 $ 106 $ 1 $ 105 Total unrealized (losses) gains included in other comprehensive income (3 ) — (3 ) January 29, 2016 $ 103 $ 1 $ 102
Activity Related to the Company's Investment Portfolio	Activity related to the Company’s investment portfolio is as follows: Three months ended January 27, 2017 January 29, 2016 (in millions) Debt (1) Equity (2) Debt (1) Equity (2) Proceeds from sales $ 661 $ 1 $ 1,261 $ 4 Gross realized gains 10 — 2 4 Gross realized losses (7 ) — (9 ) — Impairment losses recognized — (10 ) — (2 ) Nine months ended January 27, 2017 January 29, 2016 (in millions) Debt (1) Equity (2) Debt (1) Equity (2) Proceeds from sales $ 4,203 $ 83 $ 3,979 $ 38 Gross realized gains 74 29 11 36 Gross realized losses (56 ) — (21 ) — Impairment losses recognized — (20 ) — (43 ) (1) Includes available-for-sale debt securities. (2) Includes marketable equity securities, cost method, equity method, exchange-traded funds, and other investments.
Available-for-sale Debt Securities Contractual Maturities	The January 27, 2017 balance of available-for-sale debt securities, excluding debt funds which have no single maturity date, by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) January 27, 2017 Due in one year or less $ 1,185 Due after one year through five years 2,905 Due after five years through ten years 3,043 Due after ten years 83 Total $ 7,216

Financing Arrangements (Tables)

Financing Arrangements (Tables)	9 Months Ended
	Jan. 27, 2017
Debt Disclosure [Abstract]
Long-term Debt	Long-term debt consisted of the following: (in millions, except interest rates) Maturity by Fiscal Year January 27, 2017 April 29, 2016 6.000 percent ten-year 2008 CIFSA senior notes 2018 $ — $ 1,150 1.500 percent three-year 2015 senior notes 2018 1,000 1,000 1.375 percent five-year 2013 senior notes 2018 1,000 1,000 5.600 percent ten-year 2009 senior notes 2019 400 400 4.450 percent ten-year 2010 senior notes 2020 766 766 2.500 percent five-year 2015 senior notes 2020 2,500 2,500 Floating rate five-year 2015 senior notes 2020 500 500 4.200 percent ten-year 2010 CIFSA senior notes 2021 600 600 4.125 percent ten-year 2011 senior notes 2021 500 500 3.125 percent ten-year 2012 senior notes 2022 675 675 3.150 percent seven-year 2015 senior notes 2022 2,500 2,500 3.200 percent ten-year 2012 CIFSA senior notes 2023 650 650 2.750 percent ten-year 2013 senior notes 2023 530 530 2.950 percent ten-year 2013 CIFSA senior notes 2024 310 310 3.625 percent ten-year 2014 senior notes 2024 850 850 3.500 percent ten-year 2015 senior notes 2025 4,000 4,000 4.375 percent twenty-year 2015 senior notes 2035 2,382 2,382 6.550 percent thirty-year 2008 CIFSA senior notes 2038 374 374 6.500 percent thirty-year 2009 senior notes 2039 300 300 5.550 percent thirty-year 2010 senior notes 2040 500 500 4.500 percent thirty-year 2012 senior notes 2042 400 400 4.000 percent thirty-year 2013 senior notes 2043 325 325 4.625 percent thirty-year 2014 senior notes 2044 650 650 4.625 percent thirty-year 2015 senior notes 2045 4,000 4,000 Three-year term loan 2018 — 3,000 Interest rate swaps (Note 8) 2018 - 2022 41 89 Capital lease obligations 2018 - 2025 24 26 Bank borrowings 2018-2021 142 56 Debt premium 2018-2045 128 214 Deferred financing costs (1) 2018-2045 (124 ) (138 ) Long-term debt $ 25,923 $ 30,109 (1) The Company retrospectively adopted the guidance to simplify the presentation of deferred issuance costs in the quarter ended July 29, 2016. As a result, deferred issuance costs have been reclassified from other assets to long-term debt. See Note 2 to the consolidated financial statements for additional information.

Derivatives and Currency Exch31

Derivatives and Currency Exchange Risk Management (Tables)	9 Months Ended
	Jan. 27, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Amount and Location of Gains (Losses) in Statements of Income, Derivative Instruments Not Designated as Hedging Instruments	The amounts and classification of the gains in the consolidated statements of income related to derivative instruments, not designated as hedging instruments, for the three and nine months ended January 27, 2017 and January 29, 2016 were as follows: Three months ended Nine months ended (in millions) Classification January 27, 2017 January 29, 2016 January 27, 2017 January 29, 2016 Currency exchange rate contracts gains Other expense, net $ 67 $ 19 $ 27 $ 35
Amount and Location of Gains (Losses) in Statements of Income and OCI, Derivative Instruments Designated as Cash Flow Hedges	The amount of gross gains (losses), classification of the gains (losses) in the consolidated statements of income, and the accumulated other comprehensive (loss) income (AOCI) related to the effective portion of currency exchange rate contract derivative instruments designated as cash flow hedges for the three and nine months ended January 27, 2017 and January 29, 2016 were as follows: Three months ended January 27, 2017 Recognized in OCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ 190 Other expense, net $ 68 Total $ 190 $ 68 Three months ended January 29, 2016 Recognized in OCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ 104 Other expense, net $ 111 Cost of products sold (9 ) Total $ 104 $ 102 Nine months ended January 27, 2017 Recognized in OCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ 378 Other expense, net $ 89 Total $ 378 $ 89 Nine months ended January 29, 2016 Recognized in OCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ 108 Other expense, net $ 295 Cost of products sold (45 ) Total $ 108 $ 250
Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets	The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at January 27, 2017 and April 29, 2016 . The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not and are further segregated by type of contract within those two categories. January 27, 2017 Asset Derivatives Liability Derivatives (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments: Currency exchange rate contracts Other current assets $ 217 Other accrued expenses $ 33 Interest rate contracts Other assets 41 Other liabilities 26 Currency exchange rate contracts Other assets 79 Other liabilities 11 Total derivatives designated as hedging instruments $ 337 $ 70 Derivatives not designated as hedging instruments: Currency exchange rate contracts Other current assets $ 35 Other accrued expenses $ 42 Cross currency interest rate contracts Other current assets 1 Other accrued expenses — Cross currency interest rate contracts Other assets 6 Other liabilities 11 Total derivatives not designated as hedging instruments $ 42 $ 53 Total derivatives $ 379 $ 123 April 29, 2016 Asset Derivatives Liability Derivatives (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments: Currency exchange rate contracts Other current assets $ 123 Other accrued expenses $ 89 Interest rate contracts Other assets 89 Other liabilities 48 Currency exchange rate contracts Other assets 9 Other liabilities 54 Total derivatives designated as hedging instruments $ 221 $ 191 Derivatives not designated as hedging instruments: Commodity derivatives Other current assets $ — Other accrued expenses $ 1 Currency exchange rate contracts Other current assets 13 Other accrued expenses 23 Cross currency interest rate contracts Other assets 14 Other liabilities 4 Total derivatives not designated as hedging instruments $ 27 $ 28 Total derivatives $ 248 $ 219
Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis. January 27, 2017 April 29, 2016 (in millions) Level 1 Level 2 Level 1 Level 2 Derivative assets $ 331 $ 48 $ 145 $ 103 Derivative liabilities 86 37 166 53
Offsetting Assets	The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. January 27, 2017 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 332 $ (83 ) $ (123 ) $ 126 Interest rate contracts 41 (12 ) (6 ) 23 Cross currency interest rate contracts 6 (3 ) — 3 $ 379 $ (98 ) $ (129 ) $ 152 Derivative liabilities: Currency exchange rate contracts $ (86 ) $ 71 $ — $ (15 ) Interest rate contracts (26 ) 24 — (2 ) Cross currency interest rate contracts (11 ) 3 — (8 ) $ (123 ) $ 98 $ — $ (25 ) Total $ 256 $ — $ (129 ) $ 127 April 29, 2016 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 145 $ (98 ) $ (1 ) $ 46 Interest rate contracts 89 (20 ) — 69 Cross currency interest rate contracts 14 — — 14 $ 248 $ (118 ) $ (1 ) $ 129 Derivative liabilities: Currency exchange rate contracts $ (166 ) $ 85 $ 26 $ (55 ) Interest rate contracts (48 ) 34 — (14 ) Cross currency interest rate contracts (4 ) — — (4 ) Commodity contracts (1 ) — — (1 ) $ (219 ) $ 119 $ 26 $ (74 ) Total $ 29 $ 1 $ 25 $ 55
Offsetting Liabilities	The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. January 27, 2017 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 332 $ (83 ) $ (123 ) $ 126 Interest rate contracts 41 (12 ) (6 ) 23 Cross currency interest rate contracts 6 (3 ) — 3 $ 379 $ (98 ) $ (129 ) $ 152 Derivative liabilities: Currency exchange rate contracts $ (86 ) $ 71 $ — $ (15 ) Interest rate contracts (26 ) 24 — (2 ) Cross currency interest rate contracts (11 ) 3 — (8 ) $ (123 ) $ 98 $ — $ (25 ) Total $ 256 $ — $ (129 ) $ 127 April 29, 2016 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 145 $ (98 ) $ (1 ) $ 46 Interest rate contracts 89 (20 ) — 69 Cross currency interest rate contracts 14 — — 14 $ 248 $ (118 ) $ (1 ) $ 129 Derivative liabilities: Currency exchange rate contracts $ (166 ) $ 85 $ 26 $ (55 ) Interest rate contracts (48 ) 34 — (14 ) Cross currency interest rate contracts (4 ) — — (4 ) Commodity contracts (1 ) — — (1 ) $ (219 ) $ 119 $ 26 $ (74 ) Total $ 29 $ 1 $ 25 $ 55

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Jan. 27, 2017
Inventory Disclosure [Abstract]
Inventory Balances	Inventory balances were as follows: (in millions) January 27, 2017 April 29, 2016 Finished goods $ 2,381 $ 2,242 Work in-process 536 499 Raw materials 803 732 Total $ 3,720 $ 3,473

Goodwill and Other Intangible33

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Jan. 27, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The changes in the carrying amount of goodwill by reporting unit for the nine months ended January 27, 2017 were as follows: (in millions) Cardiac and Vascular Group Minimally Invasive Therapies Group Restorative Therapies Group Diabetes Group Total April 29, 2016 $ 6,243 $ 23,784 $ 9,620 $ 1,853 $ 41,500 Goodwill as a result of acquisitions 509 230 33 — 772 Currency adjustment, net (55 ) (924 ) (69 ) — (1,048 ) January 27, 2017 $ 6,697 $ 23,090 $ 9,584 $ 1,853 $ 41,224
Gross Carrying Amount of Indefinite-Lived Intangible Assets	The gross carrying amount and accumulated amortization of intangible assets at January 27, 2017 and April 29, 2016 were as follows: January 27, 2017 April 29, 2016 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 18,708 $ (2,132 ) $ 18,596 $ (1,331 ) Purchased technology and patents 12,208 (3,582 ) 11,397 (2,976 ) Trademarks and tradenames 832 (471 ) 854 (403 ) Other 78 (39 ) 72 (31 ) Total $ 31,826 $ (6,224 ) $ 30,919 $ (4,741 ) Indefinite-lived: IPR&D $ 607 $ 721
Gross Carrying Amount and Accumulated Amortization of Definite-Lived Intangible Assets	The gross carrying amount and accumulated amortization of intangible assets at January 27, 2017 and April 29, 2016 were as follows: January 27, 2017 April 29, 2016 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 18,708 $ (2,132 ) $ 18,596 $ (1,331 ) Purchased technology and patents 12,208 (3,582 ) 11,397 (2,976 ) Trademarks and tradenames 832 (471 ) 854 (403 ) Other 78 (39 ) 72 (31 ) Total $ 31,826 $ (6,224 ) $ 30,919 $ (4,741 ) Indefinite-lived: IPR&D $ 607 $ 721
Estimated Future Aggregate Amortization Expense, Definite-Lived Intangible Assets	At January 27, 2017 , the estimated aggregate amortization expense by fiscal year based on the current carrying value of definite-lived intangible assets is as follows: (in millions) Amortization Expense Remaining 2017 $ 499 2018 1,971 2019 1,877 2020 1,829 2021 1,812 2022 1,768

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Jan. 27, 2017
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The table below sets forth the computation of basic and diluted earnings per share: Three months ended Nine months ended (in millions, except per share data) January 27, 2017 January 29, 2016 January 27, 2017 January 29, 2016 Numerator: Net income attributable to ordinary shareholders $ 821 $ 1,095 $ 2,865 $ 2,435 Denominator: Basic – weighted average shares outstanding 1,372.2 1,406.6 1,381.9 1,412.5 Effect of dilutive securities: Employee stock options 7.9 12.0 9.2 12.5 Employee restricted stock units 3.0 3.5 3.4 4.1 Other — 0.1 0.2 0.1 Diluted – weighted average shares outstanding 1,383.1 1,422.2 1,394.7 1,429.2 Basic earnings per share $ 0.60 $ 0.78 $ 2.07 $ 1.72 Diluted earnings per share $ 0.59 $ 0.77 $ 2.05 $ 1.70

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Jan. 27, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Components and Classification of Stock-based Compensation Expense	The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock awards, and employee stock purchase plan shares recognized for the three and nine months ended January 27, 2017 and January 29, 2016 : Three months ended Nine months ended (in millions) January 27, 2017 January 29, 2016 January 27, 2017 January 29, 2016 Stock options $ 37 $ 43 $ 128 $ 162 Restricted stock awards 40 33 128 113 Employee stock purchase plan shares 5 5 16 15 Total stock-based compensation expense $ 82 $ 81 $ 272 $ 290 Cost of products sold $ 12 $ 12 $ 38 $ 38 Research and development expense 10 8 32 28 Selling, general, and administrative expense 55 47 179 162 Restructuring charges, net — 2 2 16 Acquisition-related items 5 12 21 46 Total stock-based compensation expense $ 82 $ 81 $ 272 $ 290 Income tax benefits (23 ) (23 ) (77 ) (86 ) Total stock-based compensation expense, net of tax $ 59 $ 58 $ 195 $ 204

Retirement Benefit Plans (Table

Retirement Benefit Plans (Tables)	9 Months Ended
	Jan. 27, 2017
Compensation and Retirement Disclosure [Abstract]
Components of Net Periodic Benefit Cost	The net periodic benefit cost of the defined benefit pension plans included the following components for the three and nine months ended January 27, 2017 and January 29, 2016 : U.S. Pension Benefits Non-U.S. Pension Benefits Three months ended Three months ended (in millions) January 27, 2017 January 29, 2016 January 27, 2017 January 29, 2016 Service cost $ 29 $ 30 $ 19 $ 22 Interest cost 27 31 6 9 Expected return on plan assets (47 ) (45 ) (12 ) (13 ) Amortization of net actuarial loss 23 24 4 6 Net periodic benefit cost $ 32 $ 40 $ 17 $ 24 U.S. Pension Benefits Non-U.S. Pension Benefits Nine months ended Nine months ended (in millions) January 27, 2017 January 29, 2016 January 27, 2017 January 29, 2016 Service cost $ 87 $ 90 $ 57 $ 66 Interest cost 81 93 18 27 Expected return on plan assets (141 ) (135 ) (36 ) (39 ) Amortization of net actuarial loss 69 72 12 18 Net periodic benefit cost $ 96 $ 120 $ 51 $ 72

Accumulated Other Comprehensi37

Accumulated Other Comprehensive (Loss) Income and Supplemental Equity Disclosure (Tables)	9 Months Ended
	Jan. 27, 2017
Equity [Abstract]
Changes in AOCI by Component	Changes in AOCI by component are as follows: (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities (1) Cumulative Translation Adjustments (2) Net Change in Retirement Obligations (3) Unrealized Gain (Loss) on Derivatives (4) Total Accumulated Other Comprehensive (Loss) Income April 29, 2016, net of tax $ (107 ) $ (474 ) $ (1,197 ) $ (90 ) $ (1,868 ) Other comprehensive income (loss) before reclassifications, before tax (20 ) (1,239 ) — 400 (859 ) Tax expense (5 ) — — (145 ) (150 ) Other comprehensive income (loss) before reclassifications, net of tax (25 ) (1,239 ) — 255 (1,009 ) Reclassifications, before tax (23 ) — 81 (85 ) (27 ) Tax (expense) benefit 8 — (15 ) 32 25 Reclassifications, net of tax (15 ) — 66 (53 ) (2 ) Other comprehensive income (loss), net of tax (40 ) (1,239 ) 66 202 (1,011 ) January 27, 2017, net of tax $ (147 ) $ (1,713 ) $ (1,131 ) $ 112 $ (2,879 ) (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities (1) Cumulative Translation Adjustments (2) Net Change in Retirement Obligations (3) Unrealized Gain (Loss) on Derivatives (4) Total Accumulated Other Comprehensive (Loss) Income April 24, 2015, net of tax $ 14 $ (277 ) $ (1,131 ) $ 210 $ (1,184 ) Other comprehensive (loss) income before reclassifications, before tax (399 ) (1,513 ) 2 134 (1,776 ) Tax benefit (expense) 143 — — (50 ) 93 Other comprehensive (loss) income before reclassifications, net of tax (256 ) (1,513 ) 2 84 (1,683 ) Reclassifications, before tax (18 ) — 90 (232 ) (160 ) Tax benefit (expense) 6 — (30 ) 86 62 Reclassifications, net of tax (12 ) — 60 (146 ) (98 ) Other comprehensive (loss) income, net of tax (268 ) (1,513 ) 62 (62 ) (1,781 ) January 29, 2016, net of tax $ (254 ) $ (1,790 ) $ (1,069 ) $ 148 $ (2,965 ) (1) Represents net realized gains (losses) on sales of available-for-sale securities that were reclassified from AOCI to other expense, net (see Note 6 ). (2) Taxes are not provided on cumulative translation adjustments as substantially all translation adjustments relate to earnings that are intended to be indefinitely reinvested outside the U.S. (3) Includes net amortization of prior service costs and actuarial losses included in net periodic benefit cost (see Note 14 ). (4) Relates to currency cash flow hedges that were reclassified from AOCI to other expense, net or cost of products sold and forward starting interest rate derivative instruments that were reclassified from AOCI to interest expense, net (see Note 8 ).
Supplemental Equity Schedule	The supplemental equity schedule below presents changes in the Company's noncontrolling interests and total shareholders' equity for the nine months ended January 27, 2017 . (in millions) Total Shareholders' Equity Noncontrolling Interests Total Equity April 29, 2016 $ 52,063 $ — $ 52,063 Net income 2,865 (5 ) 2,860 Other comprehensive loss (1,011 ) — (1,011 ) Dividends to shareholders (1,782 ) — (1,782 ) Issuance of shares under stock purchase and award plans 309 — 309 Repurchase of ordinary shares (3,409 ) — (3,409 ) Tax benefit from exercise of stock-based awards 80 — 80 Stock-based compensation 272 — 272 Additions of noncontrolling ownership interests — 111 111 January 27, 2017 $ 49,387 $ 106 $ 49,493

Segment and Geographic Inform38

Segment and Geographic Information (Tables)	9 Months Ended
	Jan. 27, 2017
Segment Reporting [Abstract]
Net Sales by Segment	Net sales and income from operations before income taxes by reportable segment are as follows: Three months ended Nine months ended (in millions) January 27, 2017 January 29, 2016 January 27, 2017 January 29, 2016 Cardiac and Vascular Group $ 2,548 $ 2,410 $ 7,650 $ 7,460 Minimally Invasive Therapies Group 2,417 2,291 7,314 7,103 Restorative Therapies Group 1,817 1,759 5,415 5,335 Diabetes Group 501 474 1,415 1,368 Total net sales $ 7,283 $ 6,934 $ 21,794 $ 21,266
Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated	Three months ended Nine months ended (in millions) January 27, 2017 January 29, 2016 January 27, 2017 January 29, 2016 Cardiac and Vascular Group $ 683 $ 726 $ 2,055 $ 2,298 Minimally Invasive Therapies Group 328 282 958 963 Restorative Therapies Group 535 496 1,543 1,460 Diabetes Group 149 140 375 379 Total reportable segments’ income from operations before income taxes 1,695 1,644 4,931 5,100 Special charge (100 ) — (100 ) — Impact of inventory step-up — — (38 ) (226 ) Restructuring charges, net (1) (21 ) (19 ) (172 ) (159 ) Certain litigation charges (218 ) — (300 ) (26 ) Acquisition-related items (68 ) (63 ) (148 ) (183 ) Interest expense, net (180 ) (176 ) (532 ) (584 ) Corporate (141 ) (207 ) (474 ) (720 ) Total income from operations before income taxes $ 967 $ 1,179 $ 3,167 $ 3,202 (1) Restructuring charges, net within this table include the impact of amounts recorded within cost of products sold in the consolidated statements of income
Net Sales to External Customers by Geography	Net sales to external customers by geography are as follows: Three months ended Nine months ended (in millions) January 27, 2017 January 29, 2016 January 27, 2017 January 29, 2016 Americas (1) $ 4,417 $ 4,229 $ 13,185 $ 13,064 EMEA (2) 1,652 1,607 4,895 4,843 Asia-Pacific 818 729 2,530 2,235 Greater China 396 369 1,184 1,124 Total net sales $ 7,283 $ 6,934 $ 21,794 $ 21,266 (1) The U.S., which is included in the Americas, had net sales to external customers of $4.1 billion and $12.3 billion for the three and nine months ended January 27, 2017 , respectively, compared to $4.0 billion and $12.2 billion for the three and nine months ended January 29, 2016 . (2) EMEA consists of Europe, Middle East, and Africa. Sales to Ireland were insignificant during all periods presented.

Guarantor Financial Informati39

Guarantor Financial Information (Tables)	9 Months Ended
	Jan. 27, 2017
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Consolidating Statement of Comprehensive Income	Consolidating Statement of Comprehensive Income Three Months Ended January 27, 2017 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 298 $ — $ 7,283 $ (298 ) $ 7,283 Costs and expenses: Cost of products sold — 214 — 2,366 (312 ) 2,268 Research and development expense — 147 — 383 — 530 Selling, general, and administrative expense 4 264 — 2,120 — 2,388 Special charge — 100 — — — 100 Restructuring charges, net — 22 — (1 ) — 21 Certain litigation charges — — — 218 — 218 Acquisition-related items — 36 — 32 — 68 Amortization of intangible assets — 3 — 494 — 497 Other (income) expense, net 80 (498 ) — 464 — 46 Operating profit (loss) (84 ) 10 — 1,207 14 1,147 Interest income — (62 ) (157 ) (294 ) 425 (88 ) Interest expense 32 397 18 246 (425 ) 268 Interest expense (income), net 32 335 (139 ) (48 ) — 180 Equity in net (income) loss of subsidiaries (937 ) (561 ) (798 ) — 2,296 — Income from operations before income taxes 821 236 937 1,255 (2,282 ) 967 Provision (benefit) for income taxes — (60 ) — 207 — 147 Net income 821 296 937 1,048 (2,282 ) 820 Net loss attributable to noncontrolling interests — — — (1 ) — (1 ) Net income attributable to Medtronic 821 296 937 1,049 (2,282 ) 821 Other comprehensive income (loss), net of tax (551 ) 27 (551 ) (584 ) 1,108 (551 ) Total comprehensive income $ 270 $ 323 $ 386 $ 465 $ (1,174 ) $ 270 Consolidating Statement of Comprehensive Income Nine Months Ended January 27, 2017 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 983 $ — $ 21,793 $ (982 ) $ 21,794 Costs and expenses: Cost of products sold — 706 — 7,145 (996 ) 6,855 Research and development expense — 469 — 1,171 — 1,640 Selling, general, and administrative expense 9 828 — 6,395 — 7,232 Special charge — 100 — — — 100 Restructuring charges, net — 40 — 122 — 162 Certain litigation charges — — — 300 — 300 Acquisition-related items — 96 — 52 — 148 Amortization of intangible assets — 9 — 1,475 — 1,484 Other (income) expense, net 5 (1,830 ) — 1,999 — 174 Operating profit (loss) (14 ) 565 — 3,134 14 3,699 Interest (income) — (183 ) (477 ) (719 ) 1,107 (272 ) Interest expense 74 1,203 31 603 (1,107 ) 804 Interest (income) expense, net 74 1,020 (446 ) (116 ) — 532 Equity in net (income) of subsidiaries (2,949 ) (2,074 ) (2,503 ) — 7,526 — Income (loss) from operations before income taxes 2,861 1,619 2,949 3,250 (7,512 ) 3,167 Provision (benefit) for income taxes (4 ) (10 ) — 321 — 307 Net income (loss) 2,865 1,629 2,949 2,929 (7,512 ) 2,860 Net loss attributable to noncontrolling interests — — — (5 ) — (5 ) Net income attributable to Medtronic 2,865 1,629 2,949 2,934 (7,512 ) 2,865 Other comprehensive income (loss), net of tax (1,011 ) 168 (1,011 ) (1,085 ) 1,928 (1,011 ) Total comprehensive income $ 1,854 $ 1,797 $ 1,938 $ 1,849 $ (5,584 ) $ 1,854 Consolidating Statement of Comprehensive Income Three Months Ended January 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 350 $ — $ 6,934 $ (350 ) $ 6,934 Costs and expenses: Cost of products sold — 245 — 2,258 (362 ) 2,141 Research and development expense — 148 — 398 — 546 Selling, general, and administrative expense 2 245 — 2,070 — 2,317 Restructuring charges, net — — — 19 — 19 Acquisition-related items — 36 — 27 — 63 Amortization of intangible assets — 3 — 481 — 484 Other (income) expense, net 36 (574 ) — 547 — 9 Operating profit (loss) (38 ) 247 — 1,134 12 1,355 Interest income — (58 ) (174 ) (105 ) 238 (99 ) Interest expense 7 408 3 95 (238 ) 275 Interest expense (income), net 7 350 (171 ) (10 ) — 176 Equity in net (income) loss of subsidiaries (1,137 ) (621 ) (966 ) — 2,724 — Income from operations before income taxes 1,092 518 1,137 1,144 (2,712 ) 1,179 Provision (benefit) for income taxes (3 ) (16 ) 2 101 — 84 Net income 1,095 534 1,135 1,043 (2,712 ) 1,095 Other comprehensive income (loss), net of tax (1,494 ) (80 ) (1,494 ) (1,510 ) 3,084 (1,494 ) Total comprehensive income $ (399 ) $ 454 $ (359 ) $ (467 ) $ 372 $ (399 ) Consolidating Statement of Comprehensive Income Nine Months Ended January 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ 1,085 $ — $ 21,266 $ (1,085 ) $ 21,266 Costs and expenses: Cost of products sold — 753 — 7,089 (1,063 ) 6,779 Research and development expense — 464 — 1,185 — 1,649 Selling, general, and administrative expense 7 756 — 6,346 — 7,109 Restructuring charges, net — 4 — 155 — 159 Certain litigation charges, net — — — 26 — 26 Acquisition-related items — 91 — 92 — 183 Amortization of intangible assets — 9 — 1,439 — 1,448 Other (income) expense, net 86 (1,502 ) — 1,543 — 127 Operating profit (loss) (93 ) 510 — 3,391 (22 ) 3,786 Interest income — (179 ) (531 ) (328 ) 717 (321 ) Interest expense 12 1,307 6 297 (717 ) 905 Interest (income) expense, net 12 1,128 (525 ) (31 ) — 584 Equity in net income of subsidiaries (2,529 ) (2,562 ) (2,006 ) — 7,097 — Income from operations before income taxes 2,424 1,944 2,531 3,422 (7,119 ) 3,202 Provision (benefit) for income taxes (11 ) (94 ) 2 870 — 767 Net income 2,435 2,038 2,529 2,552 (7,119 ) 2,435 Other comprehensive income (loss), net of tax (1,781 ) (337 ) (1,781 ) (1,876 ) 3,994 (1,781 ) Total comprehensive income $ 654 $ 1,701 $ 748 $ 676 $ (3,125 ) $ 654 Consolidating Statement of Comprehensive Income Three Months Ended January 27, 2017 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 7,283 $ — $ 7,283 Costs and expenses: Cost of products sold — — — 2,268 — 2,268 Research and development expense — — — 530 — 530 Selling, general, and administrative expense 4 — — 2,384 — 2,388 Special charge — — — 100 — 100 Restructuring charges, net — — — 21 — 21 Certain litigation charges — — — 218 — 218 Acquisition-related items — — — 68 — 68 Amortization of intangible assets — — — 497 — 497 Other expense, net 80 — — (34 ) — 46 Operating profit (loss) (84 ) — — 1,231 — 1,147 Interest income — (23 ) (158 ) (108 ) 201 (88 ) Interest expense 32 26 18 393 (201 ) 268 Interest expense (income), net 32 3 (140 ) 285 — 180 Equity in net (income) loss of subsidiaries (937 ) (386 ) (797 ) — 2,120 — Income from operations before income taxes 821 383 937 946 (2,120 ) 967 Provision (benefit) for income taxes — — — 147 — 147 Net income 821 383 937 799 (2,120 ) 820 Net loss attributable to noncontrolling interests — — — (1 ) — (1 ) Net income attributable to Medtronic 821 383 937 800 (2,120 ) 821 Other comprehensive income (loss), net of tax (551 ) (82 ) (551 ) (551 ) 1,184 (551 ) Total comprehensive income $ 270 $ 301 $ 386 $ 249 $ (936 ) $ 270 Consolidating Statement of Comprehensive Income Nine Months Ended January 27, 2017 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 21,794 $ — $ 21,794 Costs and expenses: Cost of products sold — — — 6,855 — 6,855 Research and development expense — — — 1,640 — 1,640 Selling, general, and administrative expense 9 1 2 7,220 — 7,232 Special charge — — — 100 — 100 Restructuring charges, net — — — 162 — 162 Certain litigation charges — — — 300 — 300 Acquisition-related items — — — 148 — 148 Amortization of intangible assets — — — 1,484 — 1,484 Other (income) expense, net 5 1 — 168 — 174 Operating profit (loss) (14 ) (2 ) (2 ) 3,717 — 3,699 Interest income — (71 ) (482 ) (315 ) 596 (272 ) Interest expense 74 81 30 1,215 (596 ) 804 Interest expense (income), net 74 10 (452 ) 900 — 532 Equity in net (income) loss of subsidiaries (2,949 ) (1,630 ) (2,499 ) — 7,078 — Income from operations before income taxes 2,861 1,618 2,949 2,817 (7,078 ) 3,167 Provision (benefit) for income taxes (4 ) — — 311 — 307 Net income 2,865 1,618 2,949 2,506 (7,078 ) 2,860 Net loss attributable to noncontrolling interests — — — (5 ) — (5 ) Net income attributable to Medtronic 2,865 1,618 2,949 2,511 (7,078 ) 2,865 Other comprehensive loss, net of tax (1,011 ) (63 ) (1,011 ) (1,011 ) 2,085 (1,011 ) Total comprehensive income (loss) $ 1,854 $ 1,555 $ 1,938 $ 1,500 $ (4,993 ) $ 1,854 Consolidating Statement of Comprehensive Income Three Months Ended January 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 6,934 $ — $ 6,934 Costs and expenses: Cost of products sold — — — 2,141 — 2,141 Research and development expense — — — 546 — 546 Selling, general, and administrative expense 2 — — 2,315 — 2,317 Restructuring charges, net — — — 19 — 19 Acquisition-related items — — — 63 — 63 Amortization of intangible assets — — — 484 — 484 Other (income) expense, net 36 — — (27 ) — 9 Operating profit (loss) (38 ) — — 1,393 — 1,355 Interest income — (104 ) (174 ) (103 ) 282 (99 ) Interest expense 7 32 3 515 (282 ) 275 Interest expense (income), net 7 (72 ) (171 ) 412 — 176 Equity in net (income) loss of subsidiaries (1,137 ) (476 ) (966 ) — 2,579 — Income from operations before income taxes 1,092 548 1,137 981 (2,579 ) 1,179 Provision (benefit) for income taxes (3 ) — — 87 — 84 Net income 1,095 548 1,137 894 (2,579 ) 1,095 Other comprehensive income (loss), net of tax (1,494 ) (61 ) (1,494 ) (1,494 ) 3,049 (1,494 ) Total comprehensive income $ (399 ) $ 487 $ (357 ) $ (600 ) $ 470 $ (399 ) Consolidating Statement of Comprehensive Income Nine Months Ended January 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 21,266 $ — $ 21,266 Costs and expenses: Cost of products sold — — — 6,779 — 6,779 Research and development expense — — — 1,649 — 1,649 Selling, general, and administrative expense 7 — 3 7,099 — 7,109 Restructuring charges, net — — — 159 — 159 Certain litigation charges, net — — — 26 — 26 Acquisition-related items — — — 183 — 183 Amortization of intangible assets — — — 1,448 — 1,448 Other (income) expense, net 86 1 11 29 — 127 Operating profit (loss) (93 ) (1 ) (14 ) 3,894 — 3,786 Interest income — (421 ) (533 ) (329 ) 962 (321 ) Interest expense 12 98 6 1,751 (962 ) 905 Interest expense (income), net 12 (323 ) (527 ) 1,422 — 584 Equity in net (income) loss of subsidiaries (2,529 ) (558 ) (2,016 ) — 5,103 — Income from operations before income taxes 2,424 880 2,529 2,472 (5,103 ) 3,202 Provision (benefit) for income taxes (11 ) — — 778 — 767 Net income 2,435 880 2,529 1,694 (5,103 ) 2,435 Other comprehensive income (loss), net of tax (1,781 ) 767 (1,781 ) (1,781 ) 2,795 (1,781 ) Total comprehensive income $ 654 $ 1,647 $ 748 $ (87 ) $ (2,308 ) $ 654
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheet January 27, 2017 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 40 $ — $ 2,728 $ — $ 2,768 Investments — — — 8,690 — 8,690 Accounts receivable, net — — — 5,453 — 5,453 Inventories — 162 — 3,658 (100 ) 3,720 Intercompany receivable 48 — — 13,720 (13,768 ) — Other current assets 6 184 — 1,602 — 1,792 Total current assets 54 386 — 35,851 (13,868 ) 22,423 Property, plant, and equipment, net — 1,251 — 3,696 — 4,947 Goodwill — — — 41,224 — 41,224 Other intangible assets, net — 22 — 26,187 — 26,209 Tax assets — 675 — 809 — 1,484 Investment in subsidiaries 54,344 72,458 41,130 — (167,932 ) — Intercompany loans receivable 3,000 8,716 22,906 31,042 (65,664 ) — Other assets — 428 — 863 — 1,291 Total assets $ 57,398 $ 83,936 $ 64,036 $ 139,672 $ (247,464 ) $ 97,578 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Current debt obligations $ — $ 3,500 $ 1,099 $ 1,627 $ — $ 6,226 Accounts payable — 309 — 1,248 — 1,557 Intercompany payable 17 12,353 — 1,398 (13,768 ) — Accrued compensation 6 597 — 918 — 1,521 Accrued income taxes 12 26 — 783 — 821 Other accrued expenses — 579 — 1,968 — 2,547 Total current liabilities 35 17,364 1,099 7,942 (13,768 ) 12,672 Long-term debt — 23,617 — 2,306 — 25,923 Accrued compensation and retirement benefits — 1,185 — 425 — 1,610 Accrued income taxes 10 1,642 — 875 — 2,527 Long-term intercompany loans payable 7,966 10,235 15,595 31,868 (65,664 ) — Deferred tax liabilities — — — 3,643 — 3,643 Other liabilities — 198 — 1,512 — 1,710 Total liabilities 8,011 54,241 16,694 48,571 (79,432 ) 48,085 Shareholders’ equity 49,387 29,695 47,342 90,995 (168,032 ) 49,387 Noncontrolling interests — — — 106 — 106 Total equity 49,387 29,695 47,342 91,101 (168,032 ) 49,493 Total liabilities and equity $ 57,398 $ 83,936 $ 64,036 $ 139,672 $ (247,464 ) $ 97,578 Condensed Consolidating Balance Sheet April 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 55 $ — $ 2,821 $ — $ 2,876 Investments — — — 9,758 — 9,758 Accounts receivable, net — — — 5,562 — 5,562 Inventories — 162 — 3,511 (200 ) 3,473 Intercompany receivable 403 141,368 — 162,278 (304,049 ) — Other current assets 24 271 — 1,636 — 1,931 Total current assets 427 141,856 — 185,566 (304,249 ) 23,600 Property, plant, and equipment, net — 1,139 — 3,702 — 4,841 Goodwill — — — 41,500 — 41,500 Other intangible assets, net — 31 — 26,868 — 26,899 Tax assets — 690 — 693 — 1,383 Investment in subsidiaries 52,608 68,903 49,698 — (171,209 ) — Intercompany loans receivable 3,000 8,884 10,203 18,140 (40,227 ) — Other assets — 506 — 915 — 1,421 Total assets $ 56,035 $ 222,009 $ 59,901 $ 277,384 $ (515,685 ) $ 99,644 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Current debt obligations $ — $ 500 $ — $ 493 $ — $ 993 Accounts payable — 288 — 1,421 — 1,709 Intercompany payable — 151,687 — 152,362 (304,049 ) — Accrued compensation 32 616 — 1,064 — 1,712 Accrued income taxes 11 — — 555 — 566 Other accrued expenses 1 243 — 1,941 — 2,185 Total current liabilities 44 153,334 — 157,836 (304,049 ) 7,165 Long-term debt — 26,646 — 3,463 — 30,109 Accrued compensation and retirement benefits — 1,258 — 501 — 1,759 Accrued income taxes 10 1,422 — 1,471 — 2,903 Long-term intercompany loans payable 3,918 10,128 14,297 11,884 (40,227 ) — Deferred tax liabilities — — — 3,729 — 3,729 Other liabilities — 202 — 1,714 — 1,916 Total liabilities 3,972 192,990 14,297 180,598 (344,276 ) 47,581 Total shareholders' equity 52,063 29,019 45,604 96,786 (171,409 ) 52,063 Total liabilities and shareholders' equity $ 56,035 $ 222,009 $ 59,901 $ 277,384 $ (515,685 ) $ 99,644 Condensed Consolidating Balance Sheet January 27, 2017 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 81 $ — $ 2,687 $ — $ 2,768 Investments — — — 8,690 — 8,690 Accounts receivable, net — — — 5,453 — 5,453 Inventories — — — 3,720 — 3,720 Intercompany receivable 48 — 60 17 (125 ) — Other current assets 6 — — 1,786 — 1,792 Total current assets 54 81 60 22,353 (125 ) 22,423 Property, plant, and equipment, net — — — 4,947 — 4,947 Goodwill — — — 41,224 — 41,224 Other intangible assets, net — — — 26,209 — 26,209 Tax assets — — — 1,484 — 1,484 Investment in subsidiaries 54,344 21,293 39,803 — (115,440 ) — Intercompany loans receivable 3,000 5,639 24,173 19,444 (52,256 ) — Other assets — — — 1,291 — 1,291 Total assets $ 57,398 $ 27,013 $ 64,036 $ 116,952 $ (167,821 ) $ 97,578 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Current debt obligations $ — $ 1,188 $ 1,099 $ 3,939 $ — $ 6,226 Accounts payable — — — 1,557 — 1,557 Intercompany payable 17 — — 108 (125 ) — Accrued compensation 6 — — 1,515 — 1,521 Accrued income taxes 12 — — 809 — 821 Other accrued expenses — 32 — 2,515 — 2,547 Total current liabilities 35 1,220 1,099 10,443 (125 ) 12,672 Long-term debt — 2,139 — 23,784 — 25,923 Accrued compensation and retirement benefits — — — 1,610 — 1,610 Accrued income taxes 10 — — 2,517 — 2,527 Long-term intercompany loans payable 7,966 5,116 15,596 23,578 (52,256 ) — Deferred tax liabilities — — — 3,643 — 3,643 Other liabilities — — — 1,710 — 1,710 Total liabilities 8,011 8,475 16,695 67,285 (52,381 ) 48,085 Shareholders’ equity 49,387 18,538 47,341 49,561 (115,440 ) 49,387 Noncontrolling interests — — — 106 — 106 Total equity 49,387 18,538 47,341 49,667 (115,440 ) 49,493 Total liabilities and equity $ 57,398 $ 27,013 $ 64,036 $ 116,952 $ (167,821 ) $ 97,578 Condensed Consolidating Balance Sheet April 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 208 $ — $ 2,668 $ — $ 2,876 Investments — — — 9,758 — 9,758 Accounts receivable, net — — — 5,562 — 5,562 Inventories — — — 3,473 — 3,473 Intercompany receivable 403 — 61 — (464 ) — Other current assets 24 — — 1,907 — 1,931 Total current assets 427 208 61 23,368 (464 ) 23,600 Property, plant, and equipment, net — — 1 4,840 — 4,841 Goodwill — — — 41,500 — 41,500 Other intangible assets, net — — — 26,899 — 26,899 Tax assets — — — 1,383 — 1,383 Investment in subsidiaries 52,608 36,476 48,375 — (137,459 ) — Intercompany loans receivable 3,000 8,253 11,465 27,724 (50,442 ) — Other assets — — — 1,421 — 1,421 Total assets $ 56,035 $ 44,937 $ 59,902 $ 127,135 $ (188,365 ) $ 99,644 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities: Current debt obligations $ — $ — $ — $ 993 $ — $ 993 Accounts payable — — — 1,709 — 1,709 Intercompany payable — — — 464 (464 ) — Accrued compensation 32 — — 1,680 — 1,712 Accrued income taxes 11 — — 555 — 566 Other accrued expenses 1 24 — 2,160 — 2,185 Total current liabilities 44 24 — 7,561 (464 ) 7,165 Long-term debt — 3,382 — 26,727 — 30,109 Accrued compensation and retirement benefits — — — 1,759 — 1,759 Accrued income taxes 10 — — 2,893 — 2,903 Long-term intercompany loans payable 3,918 14,689 14,298 17,537 (50,442 ) — Deferred tax liabilities — — — 3,729 — 3,729 Other liabilities — — — 1,916 — 1,916 Total liabilities 3,972 18,095 14,298 62,122 (50,906 ) 47,581 Total shareholders' equity 52,063 26,842 45,604 65,013 (137,459 ) 52,063 Total liabilities and shareholders' equity $ 56,035 $ 44,937 $ 59,902 $ 127,135 $ (188,365 ) $ 99,644
Condensed Consolidating Statement of Cash Flows	Condensed Consolidating Statement of Cash Flows Nine Months Ended January 27, 2017 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 834 $ 933 $ 306 $ 3,034 $ — $ 5,107 Investing Activities: Acquisitions, net of cash acquired — (940 ) — (388 ) — (1,328 ) Additions to property, plant, and equipment — (257 ) — (667 ) — (924 ) Purchases of investments — — — (3,516 ) 162 (3,354 ) Sales and maturities of investments — 210 — 4,238 (162 ) 4,286 Net (increase) decrease in intercompany loans — 168 (2,703 ) (2,902 ) 5,437 — Capital contribution paid — (241 ) — — 241 — Other investing activities, net — — — 21 — 21 Net cash provided by (used in) investing activities — (1,060 ) (2,703 ) (3,214 ) 5,678 (1,299 ) Financing Activities: Acquisition-related contingent consideration — — — (58 ) — (58 ) Change in current debt obligations, net — — 1,099 19 — 1,118 Repayment of current debt obligations (maturities greater than 90 days) — — — (2 ) — (2 ) Proceeds from current debt obligations (maturities greater than 90 days) — — — 4 — 4 Issuance of long-term debt — — — 131 — 131 Payments on long-term debt — (29 ) — (332 ) — (361 ) Dividends to shareholders (1,782 ) — — — — (1,782 ) Issuance of ordinary shares 309 — — — — 309 Repurchase of ordinary shares (3,409 ) — — — — (3,409 ) Net intercompany loan borrowings (repayments) 4,048 107 1,298 (16 ) (5,437 ) — Capital contribution received — — — 241 (241 ) — Other financing activities — 34 — 46 — 80 Net cash provided by (used in) financing activities (834 ) 112 2,397 33 (5,678 ) (3,970 ) Effect of exchange rate changes on cash and cash equivalents — — — 54 — 54 Net change in cash and cash equivalents — (15 ) — (93 ) — (108 ) Cash and cash equivalents at beginning of period — 55 — 2,821 — 2,876 Cash and cash equivalents at end of period $ — $ 40 $ — $ 2,728 $ — $ 2,768 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 29, 2016 Medtronic Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (Medtronic, Inc.) Subsidiary Guarantor Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (15 ) $ 839 $ 525 $ 2,551 $ (8 ) $ 3,892 Investing Activities: Acquisitions, net of cash acquired — — — (1,132 ) — (1,132 ) Additions to property, plant, and equipment — (210 ) — (483 ) — (693 ) Purchases of investments — — — (4,509 ) — (4,509 ) Sales and maturities of investments — — — 4,017 — 4,017 Net (increase) decrease in intercompany loans — (975 ) (539 ) (2,544 ) 4,058 — Capital contribution paid — — (1,500 ) — 1,500 — Other investing activities, net — — — (11 ) — (11 ) Net cash provided by (used in) investing activities — (1,185 ) (2,039 ) (4,662 ) 5,558 (2,328 ) Financing Activities: Acquisition-related contingent consideration — — — (21 ) — (21 ) Change in current debt obligations, net — — 1,201 22 — 1,223 Repayment of current debt obligations (maturities greater than 90 days) — — (48 ) — — (48 ) Proceeds from current debt obligations (maturities greater than 90 days) — — 139 — — 139 Payments on long-term debt — (600 ) — (1,012 ) — (1,612 ) Dividends to shareholders (1,608 ) — — — — (1,608 ) Issuance of ordinary shares 360 — — — — 360 Repurchase of ordinary shares (2,170 ) — — — — (2,170 ) Net intercompany loan borrowings (repayments) 3,110 (96 ) 53 991 (4,058 ) — Intercompany dividend paid — — — (8 ) 8 — Capital contribution received — — — 1,500 (1,500 ) — Other financing activities 60 — — — — 60 Net cash (used in) provided by financing activities (248 ) (696 ) 1,345 1,472 (5,550 ) (3,677 ) Effect of exchange rate changes on cash and cash equivalents — — — (9 ) — (9 ) Net change in cash and cash equivalents (263 ) (1,042 ) (169 ) (648 ) — (2,122 ) Cash and cash equivalents at beginning of period 263 1,071 170 3,339 — 4,843 Cash and cash equivalents at end of period $ — $ 29 $ 1 $ 2,691 $ — $ 2,721 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 27, 2017 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 834 $ (53 ) $ 160 $ 4,166 $ — $ 5,107 Investing Activities: Acquisitions, net of cash acquired — — — (1,328 ) — (1,328 ) Additions to property, plant, and equipment — — — (924 ) — (924 ) Purchases of investments — — — (3,354 ) — (3,354 ) Sales and maturities of investments — — — 4,286 — 4,286 Net (increase) decrease in intercompany loans receivable — 2,614 (2,557 ) 1,774 (1,831 ) — Intercompany dividend received — 920 — — (920 ) — Capital contribution paid — (537 ) — — 537 — Other investing activities, net — — — 21 — 21 Net cash provided by (used in) investing activities — 2,997 (2,557 ) 475 (2,214 ) (1,299 ) Financing Activities: Acquisition-related contingent consideration — — — (58 ) — (58 ) Change in current debt obligations, net — — 1,099 19 — 1,118 Repayment of current debt obligations (maturities greater than 90 days) — — — (2 ) — (2 ) Proceeds from current debt obligations (maturities greater than 90 days) — — — 4 — 4 Issuance of long-term debt — — — 131 — 131 Payments on long-term debt — — — (361 ) — (361 ) Dividends to shareholders (1,782 ) — — — — (1,782 ) Issuance of ordinary shares 309 — — — — 309 Repurchase of ordinary shares (3,409 ) — — — — (3,409 ) Net intercompany loan borrowings (repayments) 4,048 (3,071 ) 1,298 (4,106 ) 1,831 — Intercompany dividend paid — — — (920 ) 920 — Capital contribution received — — — 537 (537 ) — Other financing activities — — — 80 — 80 Net cash provided by (used in) financing activities (834 ) (3,071 ) 2,397 (4,676 ) 2,214 (3,970 ) Effect of exchange rate changes on cash and cash equivalents — — — 54 — 54 Net change in cash and cash equivalents — (127 ) — 19 — (108 ) Cash and cash equivalents at beginning of period — 208 — 2,668 — 2,876 Cash and cash equivalents at end of period $ — $ 81 $ — $ 2,687 $ — $ 2,768 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 29, 2016 CIFSA Senior Notes (in millions) Parent Company Guarantor (Medtronic plc) Subsidiary Issuer (CIFSA) Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ (15 ) $ 3,316 $ 709 $ 2,932 $ (3,050 ) $ 3,892 Investing Activities: Acquisitions, net of cash acquired — — — (1,132 ) — (1,132 ) Additions to property, plant, and equipment — — — (693 ) — (693 ) Purchases of investments — — — (4,509 ) — (4,509 ) Sales and maturities of investments — — — 4,017 — 4,017 Net (increase) decrease in intercompany loans receivable — (2,749 ) (722 ) 7,160 (3,689 ) — Capital contributions paid — (570 ) (1,500 ) — 2,070 — Other investing activities, net — — — (11 ) — (11 ) Net cash provided by (used in) investing activities — (3,319 ) (2,222 ) 4,832 (1,619 ) (2,328 ) Financing Activities: Acquisition-related contingent consideration — — — (21 ) — (21 ) Change in current debt obligations, net — — 1,201 22 — 1,223 Repayment of current debt obligations (maturities greater than 90 days) — — (48 ) — — (48 ) Proceeds from current debt obligations (maturities greater than 90 days) — — 139 — — 139 Payments on long-term debt — (1,000 ) — (612 ) — (1,612 ) Dividends to shareholders (1,608 ) — — — — (1,608 ) Issuance of ordinary shares 360 — — — — 360 Repurchase of ordinary shares (2,170 ) — — — — (2,170 ) Net intercompany loan borrowings (repayments) 3,110 311 52 (7,162 ) 3,689 — Intercompany dividend paid — — — (3,050 ) 3,050 — Capital contributions received — — — 2,070 (2,070 ) — Other financing activities 60 — — — — 60 Net cash provided by (used in) financing activities (248 ) (689 ) 1,344 (8,753 ) 4,669 (3,677 ) Effect of exchange rate changes on cash and cash equivalents — — — (9 ) — (9 ) Net change in cash and cash equivalents (263 ) (692 ) (169 ) (998 ) — (2,122 ) Cash and cash equivalents at beginning of period 263 728 170 3,682 — 4,843 Cash and cash equivalents at end of period $ — $ 36 $ 1 $ 2,684 $ — $ 2,721

New Accounting Pronouncements (

New Accounting Pronouncements (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Jan. 27, 2017	Jan. 27, 2017	Apr. 29, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs	$ 124	$ 124	$ 138
Excess tax benefits recognized in additional paid-in capital	$ 5	$ 80
Long-term debt [Member] | Accounting Standards Update 2015-03 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs			138
Other assets [Member] | Accounting Standards Update 2015-03 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs			$ (138)

Acquisitions and Acquisition-41

Acquisitions and Acquisition-Related Items - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Jan. 27, 2017	Aug. 23, 2016	Aug. 05, 2016	Apr. 29, 2016
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill	$ 41,224			$ 41,500
Heartware International, Inc. [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets		$ 351
Property, plant, and equipment		13
Other intangible assets		625
Goodwill		479
Other assets		55
Total assets acquired		1,523
Current liabilities		144
Deferred tax liabilities		60
Long-term debt		245
Other liabilities		2
Total liabilities assumed		451
Net assets acquired		$ 1,072
Smith & Nephew's Gynecology Business [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets			$ 0
Property, plant, and equipment			3
Other intangible assets			167
Goodwill			180
Other assets			0
Total assets acquired			350
Current liabilities			0
Deferred tax liabilities			0
Long-term debt			0
Other liabilities			0
Total liabilities assumed			0
Net assets acquired			$ 350
All Other [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets	17
Property, plant, and equipment	4
Other intangible assets	65
Goodwill	113
Other assets	15
Total assets acquired	214
Current liabilities	9
Deferred tax liabilities	9
Long-term debt	0
Other liabilities	4
Total liabilities assumed	22
Net assets acquired	192
2017 Acquisitions [Member]
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets	368
Property, plant, and equipment	20
Other intangible assets	857
Goodwill	772
Other assets	70
Total assets acquired	2,087
Current liabilities	153
Deferred tax liabilities	69
Long-term debt	245
Other liabilities	6
Total liabilities assumed	473
Net assets acquired	$ 1,614

Acquisitions and Acquisition-42

Acquisitions and Acquisition-Related Items - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details) - USD ($) $ in Millions	9 Months Ended
	Jan. 27, 2017	Oct. 28, 2016	Apr. 29, 2016	Jan. 29, 2016	Oct. 30, 2015	Apr. 24, 2015
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration, fair value	$ 262	$ 285	$ 377	$ 371	$ 368	$ 264
Revenue-based payments [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration, fair value	$ 111
Revenue-based payments [Member] | Minimum [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs
Discount rate	11.00%
Probability of payment	30.00%
Revenue-based payments [Member] | Maximum [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs
Discount rate	32.50%
Probability of payment	100.00%
Product development-based payments [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration, fair value	$ 151
Product development-based payments [Member] | Minimum [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs
Discount rate	0.30%
Probability of payment	75.00%
Product development-based payments [Member] | Maximum [Member] | Recurring [Member] | Level 3 [Member] | Discounted cash flow [Member]
Fair Value Inputs
Discount rate	5.50%
Probability of payment	100.00%

Acquisitions and Acquisition-43

Acquisitions and Acquisition-Related Items - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments Associated with Acquisitions [Roll Forward]
Beginning Balance	$ 285	$ 368	$ 377	$ 264
Purchase price contingent consideration	(4)	14	28	149
Payments	(23)	(2)	(62)	(22)
Change in fair value	4	(9)	(81)	(20)
Ending Balance	$ 262	$ 371	$ 262	$ 371

Acquisitions and Acquisition-44

Acquisitions and Acquisition-Related Items - Narrative (Details) - USD ($) $ in Millions	Aug. 23, 2016	Aug. 05, 2016	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016	Oct. 28, 2016	Aug. 31, 2016	Apr. 29, 2016	Oct. 30, 2015	Apr. 24, 2015
Business Acquisition [Line Items]
Goodwill			$ 41,224		$ 41,224				$ 41,500
Acquisition-related items			68	$ 63	148	$ 183
Fair value of contingent consideration			262	$ 371	262	$ 371	$ 285		377	$ 368	$ 264
Other liabilities [Member]
Business Acquisition [Line Items]
Fair value of contingent consideration			200		200				311
Other accrued expenses [Member]
Business Acquisition [Line Items]
Fair value of contingent consideration			62		62				66
Bank borrowings [Member]
Business Acquisition [Line Items]
Long-term debt			142		142				$ 56
Heartware International, Inc. [Member]
Business Acquisition [Line Items]
Acquisition consideration	$ 1,100
Other intangible assets	625
Goodwill	479
Long-term debt	245
Debt redeemed								$ 203
Heartware International, Inc. [Member] | Bank borrowings [Member] | Debt due December 2017 [Member]
Business Acquisition [Line Items]
Long-term debt			$ 42		$ 42
Heartware International, Inc. [Member] | Customer-related and technology-related [Member]
Business Acquisition [Line Items]
Other intangible assets	$ 602
Estimated useful lives	15 years
Heartware International, Inc. [Member] | Tradenames [Member]
Business Acquisition [Line Items]
Other intangible assets	$ 23
Estimated useful lives	5 years
Smith & Nephew's Gynecology Business [Member]
Business Acquisition [Line Items]
Acquisition consideration		$ 350
Other intangible assets		$ 167
Estimated useful lives		13 years
Goodwill		$ 180
Long-term debt		$ 0

Special Charge (Details)

Special Charge (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016
Commitments and Contingencies Disclosure [Abstract]
Charitable cash contribution	$ 100,000,000		$ 100,000,000
Special charge	$ 100,000,000	$ 0	$ 100,000,000	$ 0

Restructuring Charges - Restruc

Restructuring Charges - Restructuring Reserve (Details) - Cost Synergies Initiative [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016
Restructuring Reserve [Roll Forward]
Beginning balance			$ 250
Restructuring charges	$ 56	$ 55	214	$ 208
Payments/write-downs			(213)
Reversal of excess accrual	(35)	$ (19)	(42)	$ (32)
Ending balance	209		209
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance			213
Restructuring charges			152
Payments/write-downs			(146)
Reversal of excess accrual			(40)
Ending balance	179		179
Asset Write-downs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance			0
Restructuring charges			18
Payments/write-downs			(18)
Reversal of excess accrual			0
Ending balance	0		0
Other Costs [Member]
Restructuring Reserve [Roll Forward]
Beginning balance			37
Restructuring charges			44
Payments/write-downs			(49)
Reversal of excess accrual			(2)
Ending balance	$ 30		$ 30

Restructuring Charges - Narrati

Restructuring Charges - Narrative (Details) - Cost Synergies Initiative [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 56	$ 55	$ 214	$ 208
Payments/write-downs			213
Accrual (reversal of accrual) for restructuring reserves	(35)	(19)	(42)	(32)
Impairment of property, plant and equipment [Member]
Restructuring Cost and Reserve [Line Items]
Payments/write-downs	$ 1	$ 3	8	13
Inventory write-offs [Member] | Cost of products sold [Member]
Restructuring Cost and Reserve [Line Items]
Payments/write-downs			10	$ 9
Covidien plc [Member]
Restructuring Cost and Reserve [Line Items]
Expected cost synergies			$ 850

Financial Instruments - Investm

Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details) - USD ($) $ in Millions	Jan. 27, 2017	Apr. 29, 2016
Available-for-sale securities:
Cost	$ 9,089	$ 10,000
Unrealized Gains	79	147
Unrealized Losses	(313)	(338)
Fair Value	8,855	9,809
Trading securities:
Cost		65
Unrealized Gains		15
Unrealized Losses		(1)
Fair Value		79
Cost method, equity method, and other investments:
Cost	589	506
Total investments [Abstract]
Cost	9,678	10,571
Unrealized Gains	79	162
Unrealized Losses	(313)	(339)
Fair Value	8,855	9,888
Investments [Member]
Available-for-sale securities:
Fair Value	8,690	9,679
Trading securities:
Fair Value		79
Cost method, equity method, and other investments:
Cost	0	0
Total investments [Abstract]
Fair Value	8,690	9,758
Other Assets [Member]
Available-for-sale securities:
Fair Value	165	130
Trading securities:
Fair Value		0
Cost method, equity method, and other investments:
Cost	589	506
Total investments [Abstract]
Fair Value	754	636
Level 1 [Member]
Available-for-sale securities:
Cost	679	867
Unrealized Gains	22	35
Unrealized Losses	(15)	(12)
Fair Value	686	890
Trading securities:
Cost		65
Unrealized Gains		15
Unrealized Losses		(1)
Fair Value		79
Level 1 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	566	805
Trading securities:
Fair Value		79
Level 1 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	120	85
Trading securities:
Fair Value		0
Level 2 [Member]
Available-for-sale securities:
Cost	8,362	9,085
Unrealized Gains	57	112
Unrealized Losses	(295)	(323)
Fair Value	8,124	8,874
Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	8,124	8,874
Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Level 3 [Member]
Available-for-sale securities:
Cost	48	48
Unrealized Gains	0	0
Unrealized Losses	(3)	(3)
Fair Value	45	45
Cost method, equity method, and other investments:
Cost	589	506
Level 3 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	0	0
Cost method, equity method, and other investments:
Cost	0	0
Level 3 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	45	45
Cost method, equity method, and other investments:
Cost	589	506
Corporate debt securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	4,637	3,935
Unrealized Gains	49	85
Unrealized Losses	(35)	(24)
Fair Value	4,651	3,996
Corporate debt securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	4,651	3,996
Corporate debt securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Corporate debt securities [Member] | Level 3 [Member]
Available-for-sale securities:
Cost	1	1
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	1	1
Corporate debt securities [Member] | Level 3 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	0	0
Corporate debt securities [Member] | Level 3 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	1	1
U.S. government and agency securities [Member] | Level 1 [Member]
Available-for-sale securities:
Cost	577	792
Unrealized Gains	1	14
Unrealized Losses	(12)	(1)
Fair Value	566	805
U.S. government and agency securities [Member] | Level 1 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	566	805
U.S. government and agency securities [Member] | Level 1 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
U.S. government and agency securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	973	902
Unrealized Gains	1	2
Unrealized Losses	(15)	0
Fair Value	959	904
U.S. government and agency securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	959	904
U.S. government and agency securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Marketable equity securities [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	120	85
Marketable equity securities [Member] | Level 1 [Member]
Available-for-sale securities:
Cost	102	75
Unrealized Gains	21	21
Unrealized Losses	(3)	(11)
Fair Value	120	85
Marketable equity securities [Member] | Level 1 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	0	0
Marketable equity securities [Member] | Level 1 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	120	85
Mortgage-backed securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	761	1,016
Unrealized Gains	6	17
Unrealized Losses	(20)	(18)
Fair Value	747	1,015
Mortgage-backed securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	747	1,015
Mortgage-backed securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Foreign government and agency securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	50
Unrealized Gains	0
Unrealized Losses	(1)
Fair Value	49
Foreign government and agency securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	49
Foreign government and agency securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0
Other asset-backed securities [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	198	192
Unrealized Gains	1	3
Unrealized Losses	0	0
Fair Value	199	195
Other asset-backed securities [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	199	195
Other asset-backed securities [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Debt funds [Member] | Level 2 [Member]
Available-for-sale securities:
Cost	1,743	3,040
Unrealized Gains	0	5
Unrealized Losses	(224)	(281)
Fair Value	1,519	2,764
Debt funds [Member] | Level 2 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	1,519	2,764
Debt funds [Member] | Level 2 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	0	0
Auction rate securities [Member] | Level 3 [Member]
Available-for-sale securities:
Cost	47	47
Unrealized Gains	0	0
Unrealized Losses	(3)	(3)
Fair Value	44	44
Auction rate securities [Member] | Level 3 [Member] | Investments [Member]
Available-for-sale securities:
Fair Value	0	0
Auction rate securities [Member] | Level 3 [Member] | Other Assets [Member]
Available-for-sale securities:
Fair Value	$ 44	44
Exchange traded funds [Member] | Level 1 [Member]
Trading securities:
Cost		65
Unrealized Gains		15
Unrealized Losses		(1)
Fair Value		79
Exchange traded funds [Member] | Level 1 [Member] | Investments [Member]
Trading securities:
Fair Value		79
Exchange traded funds [Member] | Level 1 [Member] | Other Assets [Member]
Trading securities:
Fair Value		$ 0

Financial Instruments - Availab

Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details) - USD ($) $ in Millions	Jan. 27, 2017	Apr. 29, 2016
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	$ 3,274	$ 1,975
Less than 12 months, Unrealized Losses	(75)	(64)
More than 12 months, Fair Value	1,351	1,940
More than 12 months, Unrealized Losses	(238)	(275)
Corporate debt securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	1,568	756
Less than 12 months, Unrealized Losses	(30)	(18)
More than 12 months, Fair Value	82	136
More than 12 months, Unrealized Losses	(5)	(6)
Auction rate securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	0	0
Less than 12 months, Unrealized Losses	0	0
More than 12 months, Fair Value	44	44
More than 12 months, Unrealized Losses	(3)	(3)
Mortgage-backed securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	402	196
Less than 12 months, Unrealized Losses	(8)	(5)
More than 12 months, Fair Value	133	92
More than 12 months, Unrealized Losses	(12)	(5)
U.S. government and agency securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	1,011	308
Less than 12 months, Unrealized Losses	(27)	(4)
More than 12 months, Fair Value	0	67
More than 12 months, Unrealized Losses	0	(5)
Foreign government and agency securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	49
Less than 12 months, Unrealized Losses	(1)
More than 12 months, Fair Value	0
More than 12 months, Unrealized Losses	0
Debt funds [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	227	670
Less than 12 months, Unrealized Losses	(8)	(26)
More than 12 months, Fair Value	1,091	1,601
More than 12 months, Unrealized Losses	(216)	(256)
Marketable equity securities [Member]
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	17	45
Less than 12 months, Unrealized Losses	(1)	(11)
More than 12 months, Fair Value	1	0
More than 12 months, Unrealized Losses	$ (2)	$ 0

Financial Instruments - Unobser

Financial Instruments - Unobservable Inputs, and Items Measured at Fair Value on a Recurring Basis that Used Significant Unobservable Inputs (Level 3) (Details) - Recurring [Member] - Level 3 [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 45	$ 103	$ 45	$ 106
Total unrealized gains (losses) included in other comprehensive income	0	0	0	(3)
Ending balance	45	103	45	103
Corporate debt securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	1	1	1	1
Total unrealized gains (losses) included in other comprehensive income	0	0	0	0
Ending balance	1	1	1	1
Auction rate securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	44	102	44	105
Total unrealized gains (losses) included in other comprehensive income	0	0	0	(3)
Ending balance	$ 44	$ 102	$ 44	$ 102
Discounted cash flow [Member] | Auction rate securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Years to principal recovery			3 years
Illiquidity premium			6.00%
Minimum [Member] | Discounted cash flow [Member] | Auction rate securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Years to principal recovery			2 years
Maximum [Member] | Discounted cash flow [Member] | Auction rate securities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Years to principal recovery			12 years

Financial Instruments - Activit

Financial Instruments - Activity Related to the Company's Investment Portfolio and Available-for-sale Debt Securities Contractual Maturities (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016
AFS Debt Maturities
Due in one year or less	$ 1,185		$ 1,185
Due after one year through five years	2,905		2,905
Due after five years through ten years	3,043		3,043
Due after ten years	83		83
Total	7,216		7,216
Debt [Member]
AFS Gross Realized Gain (Loss)
Proceeds from sales	661	$ 1,261	4,203	$ 3,979
Gross realized gains	10	2	74	11
Gross realized losses	(7)	(9)	(56)	(21)
Impairment losses recognized	0	0	0	0
Equity [Member]
AFS Gross Realized Gain (Loss)
Proceeds from sales	1	4	83	38
Gross realized gains	0	4	29	36
Gross realized losses	0	0	0	0
Impairment losses recognized	$ (10)	$ (2)	$ (20)	$ (43)

Financial Instruments - Narrati

Financial Instruments - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016	Apr. 29, 2016
Schedule of Investments [Line Items]
Marketable securities	$ 8,855		$ 8,855		$ 9,809
Cost	589		589		506
Other expense, net [Member]
Schedule of Investments [Line Items]
Impairment, cost method investments	10	$ 2	20	$ 23
Other assets [Member]
Schedule of Investments [Line Items]
Marketable securities	165		165		130
Cost	589		589		506
Debt securities [Member]
Schedule of Investments [Line Items]
Credit loss portion of other-than-temporary impairments	0		0		0
Reductions for available-for-sale securities sold	0	0	0	0
Other-than-temporary impairment losses on available-for-sale securities	0	0	0	0
Marketable equity securities [Member] | Other expense, net [Member]
Schedule of Investments [Line Items]
Impairment charges, marketable securities	0	$ 0	0	$ 20
Marketable equity securities [Member] | Other assets [Member]
Schedule of Investments [Line Items]
Marketable securities	$ 120		$ 120		$ 85

Financing Arrangements - Long-T

Financing Arrangements - Long-Term Debt (Details) - USD ($) $ in Millions	9 Months Ended
	Jan. 27, 2017	Apr. 29, 2016
Debt Instrument [Line Items]
Debt premium	$ 128	$ 214
Deferred financing costs	(124)	(138)
Long-term debt	$ 25,923	30,109
Senior notes [Member] | 6.000 percent ten-year 2008 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	6.00%
Term of debt instrument	10 years
Long-term Debt	$ 0	1,150
Senior notes [Member] | 1.500 percent three-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	1.50%
Term of debt instrument	3 years
Long-term Debt	$ 1,000	1,000
Senior notes [Member] | 1.375 percent five-year 2013 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	1.375%
Term of debt instrument	5 years
Long-term Debt	$ 1,000	1,000
Senior notes [Member] | 5.600 percent ten-year 2009 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	5.60%
Term of debt instrument	10 years
Long-term Debt	$ 400	400
Senior notes [Member] | 4.450 percent ten-year 2010 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.45%
Term of debt instrument	10 years
Long-term Debt	$ 766	766
Senior notes [Member] | 2.500 percent five-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	2.50%
Term of debt instrument	5 years
Long-term Debt	$ 2,500	2,500
Senior notes [Member] | Floating rate five-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Term of debt instrument	5 years
Long-term Debt	$ 500	500
Senior notes [Member] | 4.200 percent ten-year 2010 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.20%
Term of debt instrument	10 years
Long-term Debt	$ 600	600
Senior notes [Member] | 4.125 percent ten-year 2011 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.125%
Term of debt instrument	10 years
Long-term Debt	$ 500	500
Senior notes [Member] | 3.125 percent ten-year 2012 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.125%
Term of debt instrument	10 years
Long-term Debt	$ 675	675
Senior notes [Member] | 3.150 percent seven-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.15%
Term of debt instrument	7 years
Long-term Debt	$ 2,500	2,500
Senior notes [Member] | 3.200 percent ten-year 2012 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.20%
Term of debt instrument	10 years
Long-term Debt	$ 650	650
Senior notes [Member] | 2.750 percent ten-year 2013 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	2.75%
Term of debt instrument	10 years
Long-term Debt	$ 530	530
Senior notes [Member] | 2.950 percent ten-year 2013 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	2.95%
Term of debt instrument	10 years
Long-term Debt	$ 310	310
Senior notes [Member] | 3.625 percent ten-year 2014 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.625%
Term of debt instrument	10 years
Long-term Debt	$ 850	850
Senior notes [Member] | 3.500 percent ten-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	3.50%
Term of debt instrument	10 years
Long-term Debt	$ 4,000	4,000
Senior notes [Member] | 4.375 percent twenty-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.375%
Term of debt instrument	20 years
Long-term Debt	$ 2,382	2,382
Senior notes [Member] | 6.550 percent thirty-year 2008 CIFSA senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	6.55%
Term of debt instrument	30 years
Long-term Debt	$ 374	374
Senior notes [Member] | 6.500 percent thirty-year 2009 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	6.50%
Term of debt instrument	30 years
Long-term Debt	$ 300	300
Senior notes [Member] | 5.550 percent thirty-year 2010 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	5.55%
Term of debt instrument	30 years
Long-term Debt	$ 500	500
Senior notes [Member] | 4.500 percent thirty-year 2012 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.50%
Term of debt instrument	30 years
Long-term Debt	$ 400	400
Senior notes [Member] | 4.000 percent thirty-year 2013 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.00%
Term of debt instrument	30 years
Long-term Debt	$ 325	325
Senior notes [Member] | 4.625 percent thirty-year 2014 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.625%
Term of debt instrument	30 years
Long-term Debt	$ 650	650
Senior notes [Member] | 4.625 percent thirty-year 2015 senior notes [Member]
Debt Instrument [Line Items]
Stated interest rate	4.625%
Term of debt instrument	30 years
Long-term Debt	$ 4,000	4,000
Senior notes [Member] | Three-year term loan [Member]
Debt Instrument [Line Items]
Term of debt instrument	3 years
Long-term Debt	$ 0	3,000
Interest rate swaps [Member]
Debt Instrument [Line Items]
Long-term Debt	41	89
Capital lease obligations [Member]
Debt Instrument [Line Items]
Capital lease obligations	24	26
Bank borrowings [Member]
Debt Instrument [Line Items]
Long-term Debt	$ 142	$ 56

Financing Arrangements - Narrat

Financing Arrangements - Narrative (Details) - USD ($)	3 Months Ended	9 Months Ended
	Jan. 27, 2017	Jan. 27, 2017	Apr. 29, 2016
Debt Instrument, Fair Value Disclosure [Abstract]
Long-term debt, including the current portion, fair value	$ 28,600,000,000	$ 28,600,000,000	$ 29,800,000,000
Long-term debt, including the current portion, principal value	27,400,000,000	27,400,000,000	27,400,000,000
2015 Commercial Paper Program [Member] | Commercial Paper [Member]
Commercial Paper [Abstract]
Commercial paper, maximum borrowing amount	3,500,000,000	3,500,000,000
Commercial paper, amount outstanding	$ 1,100,000,000	$ 1,100,000,000	0
Weighted average original maturity	40 days	38 days
Weighted average interest rate	0.87%	0.82%
Amended and Restated Revolving Credit Agreement [Member] | Line of Credit [Member]
Line of Credit Facility
Line of credit, maximum capacity	$ 3,500,000,000	$ 3,500,000,000
Term of debt instrument		5 years
Line of credit, amount outstanding	$ 0	$ 0	$ 0

Derivatives and Currency Exch55

Derivatives and Currency Exchange Risk Management - Gains (Losses) on Derivatives and Amounts Reclassified into Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016
Cash flow hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in OCI	$ 190	$ 104	$ 378	$ 108
Recognized in Income	68	102	89	250
Currency exchange rate contracts [Member] | Cash flow hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in OCI	190	104	378	108
Other expense, net [Member] | Currency exchange rate contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Currency exchange rate contracts gains	67	19	27	35
Other expense, net [Member] | Currency exchange rate contracts [Member] | Cash flow hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in Income	$ 68	111	$ 89	295
Cost of products sold [Member] | Currency exchange rate contracts [Member] | Cash flow hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in Income		$ (9)		$ (45)

Derivatives and Currency Exch56

Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details) - USD ($) $ in Millions	Jan. 27, 2017	Apr. 29, 2016
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	$ 379	$ 248
Liability Derivatives, Fair Value	123	219
Currency exchange rate contracts [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	332	145
Liability Derivatives, Fair Value	86	166
Interest rate contracts [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	41	89
Liability Derivatives, Fair Value	26	48
Commodity derivatives [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value		1
Cross currency interest rate contracts [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	6	14
Liability Derivatives, Fair Value	11	4
Designated as hedging instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	337	221
Liability Derivatives, Fair Value	70	191
Designated as hedging instrument [Member] | Currency exchange rate contracts [Member] | Other current assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	217	123
Designated as hedging instrument [Member] | Currency exchange rate contracts [Member] | Other assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	79	9
Designated as hedging instrument [Member] | Currency exchange rate contracts [Member] | Other accrued expenses [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	33	89
Designated as hedging instrument [Member] | Currency exchange rate contracts [Member] | Other liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	11	54
Designated as hedging instrument [Member] | Interest rate contracts [Member] | Other assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	41	89
Designated as hedging instrument [Member] | Interest rate contracts [Member] | Other liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	26	48
Not designated as hedging instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	42	27
Liability Derivatives, Fair Value	53	28
Not designated as hedging instrument [Member] | Currency exchange rate contracts [Member] | Other current assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	35	13
Not designated as hedging instrument [Member] | Currency exchange rate contracts [Member] | Other accrued expenses [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	42	23
Not designated as hedging instrument [Member] | Commodity derivatives [Member] | Other current assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value		0
Not designated as hedging instrument [Member] | Commodity derivatives [Member] | Other accrued expenses [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value		1
Not designated as hedging instrument [Member] | Cross currency interest rate contracts [Member] | Other current assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	1
Not designated as hedging instrument [Member] | Cross currency interest rate contracts [Member] | Other assets [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	6	14
Not designated as hedging instrument [Member] | Cross currency interest rate contracts [Member] | Other accrued expenses [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	0
Not designated as hedging instrument [Member] | Cross currency interest rate contracts [Member] | Other liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	$ 11	$ 4

Derivatives and Currency Exch57

Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring [Member] - USD ($) $ in Millions	Jan. 27, 2017	Apr. 29, 2016
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	$ 331	$ 145
Derivative liabilities	86	166
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	48	103
Derivative liabilities	$ 37	$ 53

Derivatives and Currency Exch58

Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details) - USD ($) $ in Millions	Jan. 27, 2017	Apr. 29, 2016
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recorded Assets (Liabilities)	$ 379	$ 248
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(98)	(118)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	(129)	(1)
Derivative Assets, Net Amount	152	129
Derivative Liabilities, Gross Amount of Recorded Assets (Liabilities)	(123)	(219)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	98	119
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	26
Derivative Liabilities, Net Amount	(25)	(74)
Gross Amount of Recorded Assets (Liabilities)	256	29
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0	1
Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	(129)	25
Net Amount	127	55
Currency exchange rate contracts [Member]
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recorded Assets (Liabilities)	332	145
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(83)	(98)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	(123)	(1)
Derivative Assets, Net Amount	126	46
Derivative Liabilities, Gross Amount of Recorded Assets (Liabilities)	(86)	(166)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	71	85
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	26
Derivative Liabilities, Net Amount	(15)	(55)
Interest rate contracts [Member]
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recorded Assets (Liabilities)	41	89
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(12)	(20)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	(6)	0
Derivative Assets, Net Amount	23	69
Derivative Liabilities, Gross Amount of Recorded Assets (Liabilities)	(26)	(48)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	24	34
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	0
Derivative Liabilities, Net Amount	(2)	(14)
Cross currency interest rate contracts [Member]
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recorded Assets (Liabilities)	6	14
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(3)	0
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	0
Derivative Assets, Net Amount	3	14
Derivative Liabilities, Gross Amount of Recorded Assets (Liabilities)	(11)	(4)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	3	0
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	0
Derivative Liabilities, Net Amount	$ (8)	(4)
Commodity contracts [Member]
Offsetting Assets and Liabilities [Line Items]
Derivative Liabilities, Gross Amount of Recorded Assets (Liabilities)		(1)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments		0
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted		0
Derivative Liabilities, Net Amount		$ (1)

Derivatives and Currency Exch59

Derivatives and Currency Exchange Risk Management - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016	Apr. 29, 2016
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gains (losses) relating to ineffectiveness of foreign currency cash flow hedges	$ 0	$ 0	$ 0	$ 0
Gain (losses) relating to ineffectiveness of forward starting interest rate derivatives	0	0	0	0
After-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI	112,000,000		112,000,000		$ (90,000,000)
Cash flow hedge unrealized gains to be reclassified over the next 12 months			120,000,000
Gains (losses) relating to ineffectiveness of interest rate fair value hedges	0	0	0	0
Gains (losses) on firm commitments that no longer qualify as fair value hedges	0	0	0	0
Cash flow hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effective portion of net gains (losses) on derivative instruments reclassified from accumulated other comprehensive loss	68,000,000	102,000,000	89,000,000	250,000,000
Recognized in OCI	190,000,000	104,000,000	378,000,000	108,000,000
Currency exchange rate contracts [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	10,900,000,000		10,900,000,000		10,800,000,000
Currency exchange rate contracts [Member] | Cash flow hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Recognized in OCI	190,000,000	104,000,000	378,000,000	108,000,000
Currency exchange rate contracts [Member] | Not designated as hedging instrument [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	5,100,000,000		5,100,000,000		5,000,000,000
Currency exchange rate contracts [Member] | Designated as hedging instrument [Member] | Cash flow hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	5,700,000,000		$ 5,700,000,000		5,700,000,000
Maximum remaining maturity of foreign currency derivatives			3 years
Interest rate swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Unrealized gains (losses) on outstanding forward starting interest rate swap derivative instruments	(26,000,000)		$ (26,000,000)		(48,000,000)
Recognized in OCI	28,000,000	(14,000,000)	22,000,000	30,000,000
Interest rate swaps [Member] | Cash flow hedging [Member] | Interest expense, net [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effective portion of net gains (losses) on derivative instruments reclassified from accumulated other comprehensive loss	0	$ 0	0	$ 0
Interest rate swaps [Member] | Designated as hedging instrument [Member] | Cash flow hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	$ 300,000,000		$ 300,000,000
Weighted average fixed rate of interest rate derivatives	3.10%		3.10%
Interest rate swaps [Member] | Designated as hedging instrument [Member] | Fair Value Hedging [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	$ 1,200,000,000		$ 1,200,000,000		$ 1,200,000,000
Market value of outstanding interest rate swap agreements - net unrealized gain	41,000,000		41,000,000
Market value of hedged item - net unrealized loss	$ 41,000,000		$ 41,000,000

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jan. 27, 2017	Apr. 29, 2016
Inventory Disclosure [Abstract]
Finished goods	$ 2,381	$ 2,242
Work in-process	536	499
Raw materials	803	732
Total	$ 3,720	$ 3,473

Goodwill and Other Intangible61

Goodwill and Other Intangible Assets - Changes in the Carrying Amount of Goodwill (Details) $ in Millions	9 Months Ended
	Jan. 27, 2017USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 41,500
Goodwill as a result of acquisitions	772
Currency adjustment, net	(1,048)
Ending balance	41,224
Cardiac and Vascular Group [Member]
Goodwill [Roll Forward]
Beginning balance	6,243
Goodwill as a result of acquisitions	509
Currency adjustment, net	(55)
Ending balance	6,697
Minimally Invasive Therapies Group [Member]
Goodwill [Roll Forward]
Beginning balance	23,784
Goodwill as a result of acquisitions	230
Currency adjustment, net	(924)
Ending balance	23,090
Restorative Therapies Group [Member]
Goodwill [Roll Forward]
Beginning balance	9,620
Goodwill as a result of acquisitions	33
Currency adjustment, net	(69)
Ending balance	9,584
Diabetes Group [Member]
Goodwill [Roll Forward]
Beginning balance	1,853
Goodwill as a result of acquisitions	0
Currency adjustment, net	0
Ending balance	$ 1,853

Goodwill and Other Intangible62

Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($) $ in Millions	Jan. 27, 2017	Apr. 29, 2016
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	$ 31,826	$ 30,919
Accumulated Amortization	(6,224)	(4,741)
IPR&D [Member]
Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount, Non-Amortizable	607	721
Customer-related [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	18,708	18,596
Accumulated Amortization	(2,132)	(1,331)
Purchased technology and patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	12,208	11,397
Accumulated Amortization	(3,582)	(2,976)
Trademarks and tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	832	854
Accumulated Amortization	(471)	(403)
Other [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	78	72
Accumulated Amortization	$ (39)	$ (31)

Goodwill and Other Intangible63

Goodwill and Other Intangible Assets - Estimated Future Aggregate Amortization Expense of Amortizable Intangible Assets (Details) $ in Millions	Jan. 27, 2017USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining 2,017	$ 499
2,018	1,971
2,019	1,877
2,020	1,829
2,021	1,812
2,022	$ 1,768

Goodwill and Other Intangible64

Goodwill and Other Intangible Assets - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment	$ 0	$ 0	$ 0	$ 0
Impairment of definite-lived intangible assets	0	0	0	0
Impairment of indefinite-lived intangible assets	0	0	0	0
Amortization expense	$ 497,000,000	$ 484,000,000	$ 1,484,000,000	$ 1,448,000,000

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016	Apr. 29, 2016
Income Tax Disclosure [Abstract]
Effective tax rate	15.20%	7.10%	9.70%	24.00%
Charge associated with disallowance of utilization of net operating losses	$ 86
Charge associated with IRS resolution			$ 371
Charge in connection with redemption of an intercompany minority interest			29
Income tax expense (benefit) related to resolution of intercompany debt issues			(431)
Tax benefit associated with disposition of wholly owned U.S. subsidiary		$ 25
Net tax charge primarily related to internal reorganization				$ 417
Gross unrecognized tax benefits	2,000		2,000		$ 2,700
Accrued gross interest and penalties	345		345
Unrecognized tax benefits that would impact effective tax rate	$ 1,900		$ 1,900

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016
Numerator:
Net income attributable to ordinary shareholders	$ 821	$ 1,095	$ 2,865	$ 2,435
Denominator:
Basic weighted average shares outstanding (shares)	1,372.2	1,406.6	1,381.9	1,412.5
Effect of dilutive securities:
Employee stock options (shares)	7.9	12	9.2	12.5
Employee restricted stock units (shares)	3	3.5	3.4	4.1
Other (shares)	0	0.1	0.2	0.1
Diluted weighted average shares outstanding (shares)	1,383.1	1,422.2	1,394.7	1,429.2
Basic earnings per share (usd per share)	$ 0.60	$ 0.78	$ 2.07	$ 1.72
Diluted earnings per share (usd per share)	$ 0.59	$ 0.77	$ 2.05	$ 1.70
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	10	5	6	4

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 82	$ 81	$ 272	$ 290
Income tax benefits	(23)	(23)	(77)	(86)
Total stock-based compensation expense, net of tax	59	58	195	204
Cost of products sold [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	12	12	38	38
Research and development expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	10	8	32	28
Selling, general and administrative expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	55	47	179	162
Restructuring charges, net [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	0	2	2	16
Acquisition-related items [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	5	12	21	46
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	37	43	128	162
Restricted stock awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	40	33	128	113
Employee stock purchase plan shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 5	$ 5	$ 16	$ 15

Retirement Benefit Plans (Detai

Retirement Benefit Plans (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016
U.S. Pension Benefits [Member]
Net Periodic Benefit Cost
Service cost	$ 29	$ 30	$ 87	$ 90
Interest cost	27	31	81	93
Expected return on plan assets	(47)	(45)	(141)	(135)
Amortization of net actuarial loss	23	24	69	72
Net periodic benefit cost	32	40	96	120
Non-U.S. Pension Benefits [Member]
Net Periodic Benefit Cost
Service cost	19	22	57	66
Interest cost	6	9	18	27
Expected return on plan assets	(12)	(13)	(36)	(39)
Amortization of net actuarial loss	4	6	12	18
Net periodic benefit cost	$ 17	$ 24	$ 51	$ 72

Accumulated Other Comprehensi69

Accumulated Other Comprehensive (Loss) Income and Supplemental Equity Disclosure - Changes in AOCI (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance			$ 52,063
Other comprehensive loss	$ (551)	$ (1,494)	(1,011)	$ (1,781)
Balance	49,493		49,493
Unrealized Gain (Loss) on Available-for-Sale Securities [Member]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance			(107)	14
Other comprehensive income (loss) before reclassifications, before tax			(20)	(399)
Tax benefit (expense)			(5)	143
Other comprehensive income (loss) before reclassifications, net of tax			(25)	(256)
Reclassifications, before tax			(23)	(18)
Tax (expense) benefit			8	6
Reclassifications, net of tax			(15)	(12)
Other comprehensive loss			(40)	(268)
Balance	(147)	(254)	(147)	(254)
Cumulative Translation Adjustments [Member]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance			(474)	(277)
Other comprehensive income (loss) before reclassifications, before tax			(1,239)	(1,513)
Tax benefit (expense)			0	0
Other comprehensive income (loss) before reclassifications, net of tax			(1,239)	(1,513)
Reclassifications, before tax			0	0
Tax (expense) benefit			0	0
Reclassifications, net of tax			0	0
Other comprehensive loss			(1,239)	(1,513)
Balance	(1,713)	(1,790)	(1,713)	(1,790)
Net Change in Retirement Obligations [Member]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance			(1,197)	(1,131)
Other comprehensive income (loss) before reclassifications, before tax			0	2
Tax benefit (expense)			0	0
Other comprehensive income (loss) before reclassifications, net of tax			0	2
Reclassifications, before tax			81	90
Tax (expense) benefit			(15)	(30)
Reclassifications, net of tax			66	60
Other comprehensive loss			66	62
Balance	(1,131)	(1,069)	(1,131)	(1,069)
Unrealized Gain (Loss) on Derivatives [Member]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance			(90)	210
Other comprehensive income (loss) before reclassifications, before tax			400	134
Tax benefit (expense)			(145)	(50)
Other comprehensive income (loss) before reclassifications, net of tax			255	84
Reclassifications, before tax			(85)	(232)
Tax (expense) benefit			32	86
Reclassifications, net of tax			(53)	(146)
Other comprehensive loss			202	(62)
Balance	112	148	112	148
Total Accumulated Other Comprehensive (Loss) Income [Member]
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance			(1,868)	(1,184)
Other comprehensive income (loss) before reclassifications, before tax			(859)	(1,776)
Tax benefit (expense)			(150)	93
Other comprehensive income (loss) before reclassifications, net of tax			(1,009)	(1,683)
Reclassifications, before tax			(27)	(160)
Tax (expense) benefit			25	62
Reclassifications, net of tax			(2)	(98)
Other comprehensive loss			(1,011)	(1,781)
Balance	$ (2,879)	$ (2,965)	$ (2,879)	$ (2,965)

Accumulated Other Comprehensi70

Accumulated Other Comprehensive (Loss) Income and Supplemental Equity Disclosure - Supplemental Equity Schedule (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance			$ 52,063
Net income	$ 820	$ 1,095	2,860	$ 2,435
Other comprehensive loss	(551)	$ (1,494)	(1,011)	$ (1,781)
Dividends to shareholders			(1,782)
Issuance of shares under stock purchase and award plans			309
Repurchase of ordinary shares			(3,409)
Tax benefit from exercise of stock-based awards			80
Stock-based compensation			272
Additions of noncontrolling ownership interests			111
Balance	49,493		49,493
Total Shareholders' Equity [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance			52,063
Net income			2,865
Other comprehensive loss			(1,011)
Dividends to shareholders			(1,782)
Issuance of shares under stock purchase and award plans			309
Repurchase of ordinary shares			(3,409)
Tax benefit from exercise of stock-based awards			80
Stock-based compensation			272
Balance	49,387		49,387
Noncontrolling Interests [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance			0
Net income			(5)
Other comprehensive loss			0
Additions of noncontrolling ownership interests			111
Balance	$ 106		$ 106

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Mar. 01, 2017claim	Dec. 14, 2011patent	Jun. 29, 2007	Jul. 31, 2015USD ($)claim	Jan. 27, 2017USD ($)claimlandfill	Apr. 29, 2016USD ($)	Apr. 26, 2013USD ($)
Loss Contingencies [Line Items]
Accrued certain litigation charges | $					$ 1,200	$ 1,000
Covidien plc [Member]
Loss Contingencies [Line Items]
Tax sharing percentage, parent			42.00%
Tax sharing percentage, former parent			27.00%
Tax sharing percentage, former affiliate			31.00%
Orrington, Maine chemical manufacturing facility [Member]
Loss Contingencies [Line Items]
Number of landfills requiring removal | landfill					2
Number of landfills requiring capping | landfill					3
Indemnification agreement [Member] | Covidien plc [Member] | Tax Years Prior To 2013 [Member]
Loss Contingencies [Line Items]
Maximum potential loss for tax indemnification | $							$ 200
INFUSE [Member] | Product liability litigation [Member]
Loss Contingencies [Line Items]
Number of pending claims | claim					6,000
INFUSE [Member] | Product liability litigation [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of claims settled | claim	4,300
Pelvic mesh [Member] | Product liability litigation [Member]
Loss Contingencies [Line Items]
Number of pending claims | claim					15,800
Number of claims settled | claim				11,000
Settlement receivable | $				$ 121
Pelvic mesh [Member] | Product liability litigation [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Number of claims settled | claim	11,300
Ethicon [Member]
Loss Contingencies [Line Items]
Patents infringed | patent		1
Minimum [Member] | Penobscot River and Bay remediation [Member]
Loss Contingencies [Line Items]
Cost estimate for potential remediation | $					$ 25
Maximum [Member] | Penobscot River and Bay remediation [Member]
Loss Contingencies [Line Items]
Cost estimate for potential remediation | $					$ 235

Segment and Geographic Inform72

Segment and Geographic Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016
Segment Reporting Information [Line Items]
Net sales	$ 7,283,000,000	$ 6,934,000,000	$ 21,794,000,000	$ 21,266,000,000
Income before Income Taxes by Reportable Segment
Special charge	(100,000,000)	0	(100,000,000)	0
Restructuring charges, net	(21,000,000)	(19,000,000)	(162,000,000)	(159,000,000)
Certain litigation charges	(218,000,000)	0	(300,000,000)	(26,000,000)
Acquisition-related items	(68,000,000)	(63,000,000)	(148,000,000)	(183,000,000)
Interest expense, net	(180,000,000)	(176,000,000)	(532,000,000)	(584,000,000)
Income from operations before income taxes	967,000,000	1,179,000,000	3,167,000,000	3,202,000,000
Americas [Member]
Segment Reporting Information [Line Items]
Net sales	4,417,000,000	4,229,000,000	13,185,000,000	13,064,000,000
U.S. [Member]
Segment Reporting Information [Line Items]
Net sales	4,100,000,000	4,000,000,000	12,300,000,000	12,200,000,000
EMEA [Member]
Segment Reporting Information [Line Items]
Net sales	1,652,000,000	1,607,000,000	4,895,000,000	4,843,000,000
Asia Pacific [Member]
Segment Reporting Information [Line Items]
Net sales	818,000,000	729,000,000	2,530,000,000	2,235,000,000
Greater China [Member]
Segment Reporting Information [Line Items]
Net sales	396,000,000	369,000,000	1,184,000,000	1,124,000,000
Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	1,695,000,000	1,644,000,000	4,931,000,000	5,100,000,000
Segment Reconciling Items [Member]
Income before Income Taxes by Reportable Segment
Special charge	(100,000,000)	0	(100,000,000)	0
Impact of inventory step-up	0	0	(38,000,000)	(226,000,000)
Restructuring charges, net	(21,000,000)	(19,000,000)	(172,000,000)	(159,000,000)
Certain litigation charges	(218,000,000)	0	(300,000,000)	(26,000,000)
Acquisition-related items	(68,000,000)	(63,000,000)	(148,000,000)	(183,000,000)
Interest expense, net	(180,000,000)	(176,000,000)	(532,000,000)	(584,000,000)
Corporate, Non-Segment [Member]
Income before Income Taxes by Reportable Segment
Corporate	(141,000,000)	(207,000,000)	(474,000,000)	(720,000,000)
Cardiac and Vascular Group [Member]
Segment Reporting Information [Line Items]
Net sales	2,548,000,000	2,410,000,000	7,650,000,000	7,460,000,000
Cardiac and Vascular Group [Member] | Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	683,000,000	726,000,000	2,055,000,000	2,298,000,000
Minimally Invasive Therapies Group [Member]
Segment Reporting Information [Line Items]
Net sales	2,417,000,000	2,291,000,000	7,314,000,000	7,103,000,000
Minimally Invasive Therapies Group [Member] | Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	328,000,000	282,000,000	958,000,000	963,000,000
Restorative Therapies Group [Member]
Segment Reporting Information [Line Items]
Net sales	1,817,000,000	1,759,000,000	5,415,000,000	5,335,000,000
Restorative Therapies Group [Member] | Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	535,000,000	496,000,000	1,543,000,000	1,460,000,000
Diabetes Group [Member]
Segment Reporting Information [Line Items]
Net sales	501,000,000	474,000,000	1,415,000,000	1,368,000,000
Diabetes Group [Member] | Operating Segments [Member]
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	$ 149,000,000	$ 140,000,000	$ 375,000,000	$ 379,000,000

Guarantor Financial Informati73

Guarantor Financial Information - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016	Apr. 29, 2016	Apr. 24, 2015
Condensed Financial Statements, Captions [Line Items]
Equity in net (income) loss of subsidiaries	$ 0	$ 0	$ 0	$ 0
Investment in subsidiaries	0		0		$ 0
Shareholders’ equity	49,387		49,387		52,063
Intercompany payable	0		0		0
Intercompany receivable	0		0		0
Net cash provided by (used in) operating activities			5,107	3,892
Capital contribution paid			0	0
Capital contribution received			0	0
Net (increase) decrease in intercompany loans			0	0
Net intercompany loan borrowings (repayments)			0	0
Subsidiary Issuer [Member] | Medtronic Senior Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in net (income) loss of subsidiaries	(561)	(621)	(2,074)	(2,562)
Investment in subsidiaries	72,458		72,458		68,903
Shareholders’ equity	29,695		29,695		29,019
Intercompany payable	12,353		12,353		151,687
Intercompany receivable	0		0		141,368
Net cash provided by (used in) operating activities			933	839
Capital contribution paid			(241)	0
Capital contribution received			0	0
Net (increase) decrease in intercompany loans			168	(975)
Net intercompany loan borrowings (repayments)			107	(96)
Subsidiary Issuer [Member] | Medtronic Senior Notes [Member] | Error correction, equity in net (income) loss of subsidiaries [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in net (income) loss of subsidiaries		(7,100)		(7,100)
Subsidiary Issuer [Member] | Medtronic Senior Notes [Member] | Error correction, investment in subsidiaries [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries					5,100
Shareholders’ equity						$ 5,100
Subsidiary Issuer [Member] | Medtronic Senior Notes [Member] | Error correction, intercompany balances [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Shareholders’ equity						(20,500)
Intercompany receivable						(20,500)
Subsidiary Issuer [Member] | CIFSA Senior Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in net (income) loss of subsidiaries	(386)	(476)	(1,630)	(558)
Investment in subsidiaries	21,293		21,293		36,476
Shareholders’ equity	18,538		18,538		26,842
Intercompany payable	0		0		0
Intercompany receivable	0		0		0
Net cash provided by (used in) operating activities			(53)	3,316
Capital contribution paid			(537)	(570)
Capital contribution received			0	0
Net (increase) decrease in intercompany loans			2,614	(2,749)
Net intercompany loan borrowings (repayments)			(3,071)	311
Subsidiary Issuer [Member] | CIFSA Senior Notes [Member] | Error correction, equity in net (income) loss of subsidiaries [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in net (income) loss of subsidiaries		7,100		7,100
Subsidiary Issuer [Member] | CIFSA Senior Notes [Member] | Error correction, investment in subsidiaries [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries					(5,100)
Shareholders’ equity						(5,100)
Net cash provided by (used in) operating activities				(7,300)
Net (increase) decrease in intercompany loans				(7,300)
Subsidiary Issuer [Member] | CIFSA Senior Notes [Member] | Error correction, Intercompany capital contributions [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities				(2,100)
Capital contribution received				2,100
Subsidiary Guarantors [Member] | Medtronic Senior Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in net (income) loss of subsidiaries	(798)	(966)	(2,503)	(2,006)
Investment in subsidiaries	41,130		41,130		49,698
Shareholders’ equity	47,342		47,342		45,604
Intercompany payable	0		0		0
Intercompany receivable	0		0		0
Net cash provided by (used in) operating activities			306	525
Capital contribution paid			0	(1,500)
Capital contribution received			0	0
Net (increase) decrease in intercompany loans			(2,703)	(539)
Net intercompany loan borrowings (repayments)			1,298	53
Subsidiary Guarantors [Member] | Medtronic Senior Notes [Member] | Error correction, intercompany balances [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries						(20,500)
Shareholders’ equity						(20,500)
Subsidiary Guarantors [Member] | Medtronic Senior Notes [Member] | Error correction, Intercompany capital contributions [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities				1,500
Capital contribution paid				1,500
Subsidiary Guarantors [Member] | CIFSA Senior Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in net (income) loss of subsidiaries	(797)	(966)	(2,499)	(2,016)
Investment in subsidiaries	39,803		39,803		48,375
Shareholders’ equity	47,341		47,341		45,604
Intercompany payable	0		0		0
Intercompany receivable	60		60		61
Net cash provided by (used in) operating activities			160	709
Capital contribution paid			0	(1,500)
Capital contribution received			0	0
Net (increase) decrease in intercompany loans			(2,557)	(722)
Net intercompany loan borrowings (repayments)			1,298	52
Subsidiary Guarantors [Member] | CIFSA Senior Notes [Member] | Error correction, intercompany balances [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Investment in subsidiaries						(20,500)
Shareholders’ equity						(20,500)
Subsidiary Guarantors [Member] | CIFSA Senior Notes [Member] | Error correction, Intercompany capital contributions [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities				2,100
Capital contribution paid				(2,100)
Subsidiary Non-guarantors [Member] | Medtronic Senior Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in net (income) loss of subsidiaries	0	0	0	0
Investment in subsidiaries	0		0		0
Shareholders’ equity	90,995		90,995		96,786
Intercompany payable	1,398		1,398		152,362
Intercompany receivable	13,720		13,720		162,278
Net cash provided by (used in) operating activities			3,034	2,551
Capital contribution paid			0	0
Capital contribution received			241	1,500
Net (increase) decrease in intercompany loans			(2,902)	(2,544)
Net intercompany loan borrowings (repayments)			(16)	991
Subsidiary Non-guarantors [Member] | Medtronic Senior Notes [Member] | Error correction, Intercompany capital contributions [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities				(1,500)
Capital contribution received				1,500
Subsidiary Non-guarantors [Member] | CIFSA Senior Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in net (income) loss of subsidiaries	0	0	0	0
Investment in subsidiaries	0		0		0
Shareholders’ equity	49,561		49,561		65,013
Intercompany payable	108		108		464
Intercompany receivable	17		17		0
Net cash provided by (used in) operating activities			4,166	2,932
Capital contribution paid			0	0
Capital contribution received			537	2,070
Net (increase) decrease in intercompany loans			1,774	7,160
Net intercompany loan borrowings (repayments)			(4,106)	(7,162)
Subsidiary Non-guarantors [Member] | CIFSA Senior Notes [Member] | Error correction, investment in subsidiaries [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities				7,300
Net intercompany loan borrowings (repayments)				(7,300)
Subsidiary Non-guarantors [Member] | CIFSA Senior Notes [Member] | Error correction, intercompany balances [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Shareholders’ equity						(20,500)
Intercompany receivable						$ (20,500)
Subsidiary Non-guarantors [Member] | CIFSA Senior Notes [Member] | Error correction, Intercompany capital contributions [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities				(2,100)
Capital contribution received				2,100
Parent Company Guarantor (Medtronic plc) [Member] | Medtronic Senior Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in net (income) loss of subsidiaries	(937)	(1,137)	(2,949)	(2,529)
Investment in subsidiaries	54,344		54,344		52,608
Shareholders’ equity	49,387		49,387		52,063
Intercompany payable	17		17		0
Intercompany receivable	48		48		403
Net cash provided by (used in) operating activities			834	(15)
Capital contribution paid			0	0
Capital contribution received			0	0
Net (increase) decrease in intercompany loans			0	0
Net intercompany loan borrowings (repayments)			4,048	3,110
Parent Company Guarantor (Medtronic plc) [Member] | Medtronic Senior Notes [Member] | Error correction, intercompany balances [Member] | Restatement adjustment [Member]
Condensed Financial Statements, Captions [Line Items]
Intercompany payable					(20,500)
Parent Company Guarantor (Medtronic plc) [Member] | CIFSA Senior Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Equity in net (income) loss of subsidiaries	(937)	$ (1,137)	(2,949)	(2,529)
Investment in subsidiaries	54,344		54,344		52,608
Shareholders’ equity	49,387		49,387		52,063
Intercompany payable	17		17		0
Intercompany receivable	$ 48		48		$ 403
Net cash provided by (used in) operating activities			834	(15)
Capital contribution paid			0	0
Capital contribution received			0	0
Net (increase) decrease in intercompany loans			0	0
Net intercompany loan borrowings (repayments)			$ 4,048	$ 3,110

Guarantor Financial Informati74

Guarantor Financial Information - Consolidating Statement of Comprehensive Income (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016	Jan. 27, 2017	Jan. 29, 2016
Condensed Statement of Income Captions [Line Items]
Net sales	$ 7,283,000,000	$ 6,934,000,000	$ 21,794,000,000	$ 21,266,000,000
Costs and expenses:
Cost of products sold	2,268,000,000	2,141,000,000	6,855,000,000	6,779,000,000
Research and development expense	530,000,000	546,000,000	1,640,000,000	1,649,000,000
Selling, general, and administrative expense	2,388,000,000	2,317,000,000	7,232,000,000	7,109,000,000
Special charge	100,000,000	0	100,000,000	0
Restructuring charges, net	21,000,000	19,000,000	162,000,000	159,000,000
Certain litigation charges	218,000,000	0	300,000,000	26,000,000
Acquisition-related items	68,000,000	63,000,000	148,000,000	183,000,000
Amortization of intangible assets	497,000,000	484,000,000	1,484,000,000	1,448,000,000
Other expense, net	46,000,000	9,000,000	174,000,000	127,000,000
Operating profit	1,147,000,000	1,355,000,000	3,699,000,000	3,786,000,000
Interest income	(88,000,000)	(99,000,000)	(272,000,000)	(321,000,000)
Interest expense	268,000,000	275,000,000	804,000,000	905,000,000
Interest expense, net	180,000,000	176,000,000	532,000,000	584,000,000
Equity in net (income) loss of subsidiaries	0	0	0	0
Income from operations before income taxes	967,000,000	1,179,000,000	3,167,000,000	3,202,000,000
Provision for income taxes	147,000,000	84,000,000	307,000,000	767,000,000
Net income	820,000,000	1,095,000,000	2,860,000,000	2,435,000,000
Net loss attributable to noncontrolling interests	(1,000,000)	0	(5,000,000)	0
Net income attributable to Medtronic	821,000,000	1,095,000,000	2,865,000,000	2,435,000,000
Other comprehensive income (loss), net of tax	(551,000,000)	(1,494,000,000)	(1,011,000,000)	(1,781,000,000)
Comprehensive income (loss) attributable to Medtronic	270,000,000	(399,000,000)	1,854,000,000	654,000,000
Consolidating Adjustments [Member] | Medtronic Senior Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	(298,000,000)	(350,000,000)	(982,000,000)	(1,085,000,000)
Costs and expenses:
Cost of products sold	(312,000,000)	(362,000,000)	(996,000,000)	(1,063,000,000)
Research and development expense	0	0	0	0
Selling, general, and administrative expense	0	0	0	0
Special charge	0		0
Restructuring charges, net	0	0	0	0
Certain litigation charges	0		0	0
Acquisition-related items	0	0	0	0
Amortization of intangible assets	0	0	0	0
Other expense, net	0	0	0	0
Operating profit	14,000,000	12,000,000	14,000,000	(22,000,000)
Interest income	425,000,000	238,000,000	1,107,000,000	717,000,000
Interest expense	(425,000,000)	(238,000,000)	(1,107,000,000)	(717,000,000)
Interest expense, net	0	0	0	0
Equity in net (income) loss of subsidiaries	2,296,000,000	2,724,000,000	7,526,000,000	7,097,000,000
Income from operations before income taxes	(2,282,000,000)	(2,712,000,000)	(7,512,000,000)	(7,119,000,000)
Provision for income taxes	0	0	0	0
Net income	(2,282,000,000)		(7,512,000,000)
Net loss attributable to noncontrolling interests	0		0
Net income attributable to Medtronic	(2,282,000,000)	(2,712,000,000)	(7,512,000,000)	(7,119,000,000)
Other comprehensive income (loss), net of tax	1,108,000,000	3,084,000,000	1,928,000,000	3,994,000,000
Comprehensive income (loss) attributable to Medtronic	(1,174,000,000)	372,000,000	(5,584,000,000)	(3,125,000,000)
Consolidating Adjustments [Member] | CIFSA Senior Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	0	0	0	0
Special charge	0		0
Restructuring charges, net	0	0	0	0
Certain litigation charges	0		0	0
Acquisition-related items	0	0	0	0
Amortization of intangible assets	0	0	0	0
Other expense, net	0	0	0	0
Operating profit	0	0	0	0
Interest income	201,000,000	282,000,000	596,000,000	962,000,000
Interest expense	(201,000,000)	(282,000,000)	(596,000,000)	(962,000,000)
Interest expense, net	0	0	0	0
Equity in net (income) loss of subsidiaries	2,120,000,000	2,579,000,000	7,078,000,000	5,103,000,000
Income from operations before income taxes	(2,120,000,000)	(2,579,000,000)	(7,078,000,000)	(5,103,000,000)
Provision for income taxes	0	0	0	0
Net income	(2,120,000,000)		(7,078,000,000)
Net loss attributable to noncontrolling interests	0		0
Net income attributable to Medtronic	(2,120,000,000)	(2,579,000,000)	(7,078,000,000)	(5,103,000,000)
Other comprehensive income (loss), net of tax	1,184,000,000	3,049,000,000	2,085,000,000	2,795,000,000
Comprehensive income (loss) attributable to Medtronic	(936,000,000)	470,000,000	(4,993,000,000)	(2,308,000,000)
Parent Company Guarantor (Medtronic plc) [Member] | Medtronic Senior Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	4,000,000	2,000,000	9,000,000	7,000,000
Special charge	0		0
Restructuring charges, net	0	0	0	0
Certain litigation charges	0		0	0
Acquisition-related items	0	0	0	0
Amortization of intangible assets	0	0	0	0
Other expense, net	80,000,000	36,000,000	5,000,000	86,000,000
Operating profit	(84,000,000)	(38,000,000)	(14,000,000)	(93,000,000)
Interest income	0	0	0	0
Interest expense	32,000,000	7,000,000	74,000,000	12,000,000
Interest expense, net	32,000,000	7,000,000	74,000,000	12,000,000
Equity in net (income) loss of subsidiaries	(937,000,000)	(1,137,000,000)	(2,949,000,000)	(2,529,000,000)
Income from operations before income taxes	821,000,000	1,092,000,000	2,861,000,000	2,424,000,000
Provision for income taxes	0	(3,000,000)	(4,000,000)	(11,000,000)
Net income	821,000,000		2,865,000,000
Net loss attributable to noncontrolling interests	0		0
Net income attributable to Medtronic	821,000,000	1,095,000,000	2,865,000,000	2,435,000,000
Other comprehensive income (loss), net of tax	(551,000,000)	(1,494,000,000)	(1,011,000,000)	(1,781,000,000)
Comprehensive income (loss) attributable to Medtronic	270,000,000	(399,000,000)	1,854,000,000	654,000,000
Parent Company Guarantor (Medtronic plc) [Member] | CIFSA Senior Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	4,000,000	2,000,000	9,000,000	7,000,000
Special charge	0		0
Restructuring charges, net	0	0	0	0
Certain litigation charges	0		0	0
Acquisition-related items	0	0	0	0
Amortization of intangible assets	0	0	0	0
Other expense, net	80,000,000	36,000,000	5,000,000	86,000,000
Operating profit	(84,000,000)	(38,000,000)	(14,000,000)	(93,000,000)
Interest income	0	0	0	0
Interest expense	32,000,000	7,000,000	74,000,000	12,000,000
Interest expense, net	32,000,000	7,000,000	74,000,000	12,000,000
Equity in net (income) loss of subsidiaries	(937,000,000)	(1,137,000,000)	(2,949,000,000)	(2,529,000,000)
Income from operations before income taxes	821,000,000	1,092,000,000	2,861,000,000	2,424,000,000
Provision for income taxes	0	(3,000,000)	(4,000,000)	(11,000,000)
Net income	821,000,000		2,865,000,000
Net loss attributable to noncontrolling interests	0		0
Net income attributable to Medtronic	821,000,000	1,095,000,000	2,865,000,000	2,435,000,000
Other comprehensive income (loss), net of tax	(551,000,000)	(1,494,000,000)	(1,011,000,000)	(1,781,000,000)
Comprehensive income (loss) attributable to Medtronic	270,000,000	(399,000,000)	1,854,000,000	654,000,000
Subsidiary Issuer [Member] | Medtronic Senior Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	298,000,000	350,000,000	983,000,000	1,085,000,000
Costs and expenses:
Cost of products sold	214,000,000	245,000,000	706,000,000	753,000,000
Research and development expense	147,000,000	148,000,000	469,000,000	464,000,000
Selling, general, and administrative expense	264,000,000	245,000,000	828,000,000	756,000,000
Special charge	100,000,000		100,000,000
Restructuring charges, net	22,000,000	0	40,000,000	4,000,000
Certain litigation charges	0		0	0
Acquisition-related items	36,000,000	36,000,000	96,000,000	91,000,000
Amortization of intangible assets	3,000,000	3,000,000	9,000,000	9,000,000
Other expense, net	(498,000,000)	(574,000,000)	(1,830,000,000)	(1,502,000,000)
Operating profit	10,000,000	247,000,000	565,000,000	510,000,000
Interest income	(62,000,000)	(58,000,000)	(183,000,000)	(179,000,000)
Interest expense	397,000,000	408,000,000	1,203,000,000	1,307,000,000
Interest expense, net	335,000,000	350,000,000	1,020,000,000	1,128,000,000
Equity in net (income) loss of subsidiaries	(561,000,000)	(621,000,000)	(2,074,000,000)	(2,562,000,000)
Income from operations before income taxes	236,000,000	518,000,000	1,619,000,000	1,944,000,000
Provision for income taxes	(60,000,000)	(16,000,000)	(10,000,000)	(94,000,000)
Net income	296,000,000		1,629,000,000
Net loss attributable to noncontrolling interests	0		0
Net income attributable to Medtronic	296,000,000	534,000,000	1,629,000,000	2,038,000,000
Other comprehensive income (loss), net of tax	27,000,000	(80,000,000)	168,000,000	(337,000,000)
Comprehensive income (loss) attributable to Medtronic	323,000,000	454,000,000	1,797,000,000	1,701,000,000
Subsidiary Issuer [Member] | CIFSA Senior Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	0	0	1,000,000	0
Special charge	0		0
Restructuring charges, net	0	0	0	0
Certain litigation charges	0		0	0
Acquisition-related items	0	0	0	0
Amortization of intangible assets	0	0	0	0
Other expense, net	0	0	1,000,000	1,000,000
Operating profit	0	0	(2,000,000)	(1,000,000)
Interest income	(23,000,000)	(104,000,000)	(71,000,000)	(421,000,000)
Interest expense	26,000,000	32,000,000	81,000,000	98,000,000
Interest expense, net	3,000,000	(72,000,000)	10,000,000	(323,000,000)
Equity in net (income) loss of subsidiaries	(386,000,000)	(476,000,000)	(1,630,000,000)	(558,000,000)
Income from operations before income taxes	383,000,000	548,000,000	1,618,000,000	880,000,000
Provision for income taxes	0	0	0	0
Net income	383,000,000		1,618,000,000
Net loss attributable to noncontrolling interests	0		0
Net income attributable to Medtronic	383,000,000	548,000,000	1,618,000,000	880,000,000
Other comprehensive income (loss), net of tax	(82,000,000)	(61,000,000)	(63,000,000)	767,000,000
Comprehensive income (loss) attributable to Medtronic	301,000,000	487,000,000	1,555,000,000	1,647,000,000
Subsidiary Guarantors [Member] | Medtronic Senior Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	0	0	0	0
Special charge	0		0
Restructuring charges, net	0	0	0	0
Certain litigation charges	0		0	0
Acquisition-related items	0	0	0	0
Amortization of intangible assets	0	0	0	0
Other expense, net	0	0	0	0
Operating profit	0	0	0	0
Interest income	(157,000,000)	(174,000,000)	(477,000,000)	(531,000,000)
Interest expense	18,000,000	3,000,000	31,000,000	6,000,000
Interest expense, net	(139,000,000)	(171,000,000)	(446,000,000)	(525,000,000)
Equity in net (income) loss of subsidiaries	(798,000,000)	(966,000,000)	(2,503,000,000)	(2,006,000,000)
Income from operations before income taxes	937,000,000	1,137,000,000	2,949,000,000	2,531,000,000
Provision for income taxes	0	2,000,000	0	2,000,000
Net income	937,000,000		2,949,000,000
Net loss attributable to noncontrolling interests	0		0
Net income attributable to Medtronic	937,000,000	1,135,000,000	2,949,000,000	2,529,000,000
Other comprehensive income (loss), net of tax	(551,000,000)	(1,494,000,000)	(1,011,000,000)	(1,781,000,000)
Comprehensive income (loss) attributable to Medtronic	386,000,000	(359,000,000)	1,938,000,000	748,000,000
Subsidiary Guarantors [Member] | CIFSA Senior Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	0	0	2,000,000	3,000,000
Special charge	0		0
Restructuring charges, net	0	0	0	0
Certain litigation charges	0		0	0
Acquisition-related items	0	0	0	0
Amortization of intangible assets	0	0	0	0
Other expense, net	0	0	0	11,000,000
Operating profit	0	0	(2,000,000)	(14,000,000)
Interest income	(158,000,000)	(174,000,000)	(482,000,000)	(533,000,000)
Interest expense	18,000,000	3,000,000	30,000,000	6,000,000
Interest expense, net	(140,000,000)	(171,000,000)	(452,000,000)	(527,000,000)
Equity in net (income) loss of subsidiaries	(797,000,000)	(966,000,000)	(2,499,000,000)	(2,016,000,000)
Income from operations before income taxes	937,000,000	1,137,000,000	2,949,000,000	2,529,000,000
Provision for income taxes	0	0	0	0
Net income	937,000,000		2,949,000,000
Net loss attributable to noncontrolling interests	0		0
Net income attributable to Medtronic	937,000,000	1,137,000,000	2,949,000,000	2,529,000,000
Other comprehensive income (loss), net of tax	(551,000,000)	(1,494,000,000)	(1,011,000,000)	(1,781,000,000)
Comprehensive income (loss) attributable to Medtronic	386,000,000	(357,000,000)	1,938,000,000	748,000,000
Subsidiary Non-guarantors [Member] | Medtronic Senior Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	7,283,000,000	6,934,000,000	21,793,000,000	21,266,000,000
Costs and expenses:
Cost of products sold	2,366,000,000	2,258,000,000	7,145,000,000	7,089,000,000
Research and development expense	383,000,000	398,000,000	1,171,000,000	1,185,000,000
Selling, general, and administrative expense	2,120,000,000	2,070,000,000	6,395,000,000	6,346,000,000
Special charge	0		0
Restructuring charges, net	(1,000,000)	19,000,000	122,000,000	155,000,000
Certain litigation charges	218,000,000		300,000,000	26,000,000
Acquisition-related items	32,000,000	27,000,000	52,000,000	92,000,000
Amortization of intangible assets	494,000,000	481,000,000	1,475,000,000	1,439,000,000
Other expense, net	464,000,000	547,000,000	1,999,000,000	1,543,000,000
Operating profit	1,207,000,000	1,134,000,000	3,134,000,000	3,391,000,000
Interest income	(294,000,000)	(105,000,000)	(719,000,000)	(328,000,000)
Interest expense	246,000,000	95,000,000	603,000,000	297,000,000
Interest expense, net	(48,000,000)	(10,000,000)	(116,000,000)	(31,000,000)
Equity in net (income) loss of subsidiaries	0	0	0	0
Income from operations before income taxes	1,255,000,000	1,144,000,000	3,250,000,000	3,422,000,000
Provision for income taxes	207,000,000	101,000,000	321,000,000	870,000,000
Net income	1,048,000,000		2,929,000,000
Net loss attributable to noncontrolling interests	(1,000,000)		(5,000,000)
Net income attributable to Medtronic	1,049,000,000	1,043,000,000	2,934,000,000	2,552,000,000
Other comprehensive income (loss), net of tax	(584,000,000)	(1,510,000,000)	(1,085,000,000)	(1,876,000,000)
Comprehensive income (loss) attributable to Medtronic	465,000,000	(467,000,000)	1,849,000,000	676,000,000
Subsidiary Non-guarantors [Member] | CIFSA Senior Notes [Member]
Condensed Statement of Income Captions [Line Items]
Net sales	7,283,000,000	6,934,000,000	21,794,000,000	21,266,000,000
Costs and expenses:
Cost of products sold	2,268,000,000	2,141,000,000	6,855,000,000	6,779,000,000
Research and development expense	530,000,000	546,000,000	1,640,000,000	1,649,000,000
Selling, general, and administrative expense	2,384,000,000	2,315,000,000	7,220,000,000	7,099,000,000
Special charge	100,000,000		100,000,000
Restructuring charges, net	21,000,000	19,000,000	162,000,000	159,000,000
Certain litigation charges	218,000,000		300,000,000	26,000,000
Acquisition-related items	68,000,000	63,000,000	148,000,000	183,000,000
Amortization of intangible assets	497,000,000	484,000,000	1,484,000,000	1,448,000,000
Other expense, net	(34,000,000)	(27,000,000)	168,000,000	29,000,000
Operating profit	1,231,000,000	1,393,000,000	3,717,000,000	3,894,000,000
Interest income	(108,000,000)	(103,000,000)	(315,000,000)	(329,000,000)
Interest expense	393,000,000	515,000,000	1,215,000,000	1,751,000,000
Interest expense, net	285,000,000	412,000,000	900,000,000	1,422,000,000
Equity in net (income) loss of subsidiaries	0	0	0	0
Income from operations before income taxes	946,000,000	981,000,000	2,817,000,000	2,472,000,000
Provision for income taxes	147,000,000	87,000,000	311,000,000	778,000,000
Net income	799,000,000		2,506,000,000
Net loss attributable to noncontrolling interests	(1,000,000)		(5,000,000)
Net income attributable to Medtronic	800,000,000	894,000,000	2,511,000,000	1,694,000,000
Other comprehensive income (loss), net of tax	(551,000,000)	(1,494,000,000)	(1,011,000,000)	(1,781,000,000)
Comprehensive income (loss) attributable to Medtronic	$ 249,000,000	$ (600,000,000)	$ 1,500,000,000	$ (87,000,000)

Guarantor Financial Informati75

Guarantor Financial Information - Condensed Consolidating Balance Sheet (Details) - USD ($) $ in Millions	Jan. 27, 2017	Apr. 29, 2016	Jan. 29, 2016	Apr. 24, 2015
Current assets:
Cash and cash equivalents	$ 2,768	$ 2,876	$ 2,721	$ 4,843
Investments	8,690	9,758
Accounts receivable, net	5,453	5,562
Inventories	3,720	3,473
Intercompany receivable	0	0
Other current assets	1,792	1,931
Total current assets	22,423	23,600
Property, plant, and equipment, net	4,947	4,841
Goodwill	41,224	41,500
Other intangible assets, net	26,209	26,899
Tax assets	1,484	1,383
Investment in subsidiaries	0	0
Intercompany loans receivable	0	0
Other assets	1,291	1,421
Total assets	97,578	99,644
Current liabilities:
Current debt obligations	6,226	993
Accounts payable	1,557	1,709
Intercompany payable	0	0
Accrued compensation	1,521	1,712
Accrued income taxes	821	566
Other accrued expenses	2,547	2,185
Total current liabilities	12,672	7,165
Long-term debt	25,923	30,109
Accrued compensation and retirement benefits	1,610	1,759
Accrued income taxes	2,527	2,903
Long-term intercompany loans payable	0	0
Deferred tax liabilities	3,643	3,729
Other liabilities	1,710	1,916
Total liabilities	48,085	47,581
Shareholders’ equity	49,387	52,063
Noncontrolling interests	106	0
Total equity	49,493	52,063
Total liabilities and equity	97,578	99,644
Consolidating Adjustments [Member] | Medtronic Senior Notes [Member]
Current assets:
Cash and cash equivalents	0	0	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories	(100)	(200)
Intercompany receivable	(13,768)	(304,049)
Other current assets	0	0
Total current assets	(13,868)	(304,249)
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	(167,932)	(171,209)
Intercompany loans receivable	(65,664)	(40,227)
Other assets	0	0
Total assets	(247,464)	(515,685)
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	(13,768)	(304,049)
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	0	0
Total current liabilities	(13,768)	(304,049)
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Long-term intercompany loans payable	(65,664)	(40,227)
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	(79,432)	(344,276)
Shareholders’ equity	(168,032)	(171,409)
Noncontrolling interests	0
Total equity	(168,032)
Total liabilities and equity	(247,464)	(515,685)
Consolidating Adjustments [Member] | CIFSA Senior Notes [Member]
Current assets:
Cash and cash equivalents	0	0	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	(125)	(464)
Other current assets	0	0
Total current assets	(125)	(464)
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	(115,440)	(137,459)
Intercompany loans receivable	(52,256)	(50,442)
Other assets	0	0
Total assets	(167,821)	(188,365)
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	(125)	(464)
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	0	0
Total current liabilities	(125)	(464)
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Long-term intercompany loans payable	(52,256)	(50,442)
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	(52,381)	(50,906)
Shareholders’ equity	(115,440)	(137,459)
Noncontrolling interests	0
Total equity	(115,440)
Total liabilities and equity	(167,821)	(188,365)
Parent Company Guarantor (Medtronic plc) [Member] | Medtronic Senior Notes [Member]
Current assets:
Cash and cash equivalents	0	0	0	263
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	48	403
Other current assets	6	24
Total current assets	54	427
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	54,344	52,608
Intercompany loans receivable	3,000	3,000
Other assets	0	0
Total assets	57,398	56,035
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	17	0
Accrued compensation	6	32
Accrued income taxes	12	11
Other accrued expenses	0	1
Total current liabilities	35	44
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	10	10
Long-term intercompany loans payable	7,966	3,918
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	8,011	3,972
Shareholders’ equity	49,387	52,063
Noncontrolling interests	0
Total equity	49,387
Total liabilities and equity	57,398	56,035
Parent Company Guarantor (Medtronic plc) [Member] | CIFSA Senior Notes [Member]
Current assets:
Cash and cash equivalents	0	0	0	263
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	48	403
Other current assets	6	24
Total current assets	54	427
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	54,344	52,608
Intercompany loans receivable	3,000	3,000
Other assets	0	0
Total assets	57,398	56,035
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	17	0
Accrued compensation	6	32
Accrued income taxes	12	11
Other accrued expenses	0	1
Total current liabilities	35	44
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	10	10
Long-term intercompany loans payable	7,966	3,918
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	8,011	3,972
Shareholders’ equity	49,387	52,063
Noncontrolling interests	0
Total equity	49,387
Total liabilities and equity	57,398	56,035
Subsidiary Issuer [Member] | Medtronic Senior Notes [Member]
Current assets:
Cash and cash equivalents	40	55	29	1,071
Investments	0	0
Accounts receivable, net	0	0
Inventories	162	162
Intercompany receivable	0	141,368
Other current assets	184	271
Total current assets	386	141,856
Property, plant, and equipment, net	1,251	1,139
Goodwill	0	0
Other intangible assets, net	22	31
Tax assets	675	690
Investment in subsidiaries	72,458	68,903
Intercompany loans receivable	8,716	8,884
Other assets	428	506
Total assets	83,936	222,009
Current liabilities:
Current debt obligations	3,500	500
Accounts payable	309	288
Intercompany payable	12,353	151,687
Accrued compensation	597	616
Accrued income taxes	26	0
Other accrued expenses	579	243
Total current liabilities	17,364	153,334
Long-term debt	23,617	26,646
Accrued compensation and retirement benefits	1,185	1,258
Accrued income taxes	1,642	1,422
Long-term intercompany loans payable	10,235	10,128
Deferred tax liabilities	0	0
Other liabilities	198	202
Total liabilities	54,241	192,990
Shareholders’ equity	29,695	29,019
Noncontrolling interests	0
Total equity	29,695
Total liabilities and equity	83,936	222,009
Subsidiary Issuer [Member] | CIFSA Senior Notes [Member]
Current assets:
Cash and cash equivalents	81	208	36	728
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	0	0
Other current assets	0	0
Total current assets	81	208
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	21,293	36,476
Intercompany loans receivable	5,639	8,253
Other assets	0	0
Total assets	27,013	44,937
Current liabilities:
Current debt obligations	1,188	0
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	32	24
Total current liabilities	1,220	24
Long-term debt	2,139	3,382
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Long-term intercompany loans payable	5,116	14,689
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	8,475	18,095
Shareholders’ equity	18,538	26,842
Noncontrolling interests	0
Total equity	18,538
Total liabilities and equity	27,013	44,937
Subsidiary Guarantors [Member] | Medtronic Senior Notes [Member]
Current assets:
Cash and cash equivalents	0	0	1	170
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	0	0
Other current assets	0	0
Total current assets	0	0
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	41,130	49,698
Intercompany loans receivable	22,906	10,203
Other assets	0	0
Total assets	64,036	59,901
Current liabilities:
Current debt obligations	1,099	0
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	0	0
Total current liabilities	1,099	0
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Long-term intercompany loans payable	15,595	14,297
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	16,694	14,297
Shareholders’ equity	47,342	45,604
Noncontrolling interests	0
Total equity	47,342
Total liabilities and equity	64,036	59,901
Subsidiary Guarantors [Member] | CIFSA Senior Notes [Member]
Current assets:
Cash and cash equivalents	0	0	1	170
Investments	0	0
Accounts receivable, net	0	0
Inventories	0	0
Intercompany receivable	60	61
Other current assets	0	0
Total current assets	60	61
Property, plant, and equipment, net	0	1
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	39,803	48,375
Intercompany loans receivable	24,173	11,465
Other assets	0	0
Total assets	64,036	59,902
Current liabilities:
Current debt obligations	1,099	0
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	0	0
Total current liabilities	1,099	0
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Long-term intercompany loans payable	15,596	14,298
Deferred tax liabilities	0	0
Other liabilities	0	0
Total liabilities	16,695	14,298
Shareholders’ equity	47,341	45,604
Noncontrolling interests	0
Total equity	47,341
Total liabilities and equity	64,036	59,902
Subsidiary Non-guarantors [Member] | Medtronic Senior Notes [Member]
Current assets:
Cash and cash equivalents	2,728	2,821	2,691	3,339
Investments	8,690	9,758
Accounts receivable, net	5,453	5,562
Inventories	3,658	3,511
Intercompany receivable	13,720	162,278
Other current assets	1,602	1,636
Total current assets	35,851	185,566
Property, plant, and equipment, net	3,696	3,702
Goodwill	41,224	41,500
Other intangible assets, net	26,187	26,868
Tax assets	809	693
Investment in subsidiaries	0	0
Intercompany loans receivable	31,042	18,140
Other assets	863	915
Total assets	139,672	277,384
Current liabilities:
Current debt obligations	1,627	493
Accounts payable	1,248	1,421
Intercompany payable	1,398	152,362
Accrued compensation	918	1,064
Accrued income taxes	783	555
Other accrued expenses	1,968	1,941
Total current liabilities	7,942	157,836
Long-term debt	2,306	3,463
Accrued compensation and retirement benefits	425	501
Accrued income taxes	875	1,471
Long-term intercompany loans payable	31,868	11,884
Deferred tax liabilities	3,643	3,729
Other liabilities	1,512	1,714
Total liabilities	48,571	180,598
Shareholders’ equity	90,995	96,786
Noncontrolling interests	106
Total equity	91,101
Total liabilities and equity	139,672	277,384
Subsidiary Non-guarantors [Member] | CIFSA Senior Notes [Member]
Current assets:
Cash and cash equivalents	2,687	2,668	$ 2,684	$ 3,682
Investments	8,690	9,758
Accounts receivable, net	5,453	5,562
Inventories	3,720	3,473
Intercompany receivable	17	0
Other current assets	1,786	1,907
Total current assets	22,353	23,368
Property, plant, and equipment, net	4,947	4,840
Goodwill	41,224	41,500
Other intangible assets, net	26,209	26,899
Tax assets	1,484	1,383
Investment in subsidiaries	0	0
Intercompany loans receivable	19,444	27,724
Other assets	1,291	1,421
Total assets	116,952	127,135
Current liabilities:
Current debt obligations	3,939	993
Accounts payable	1,557	1,709
Intercompany payable	108	464
Accrued compensation	1,515	1,680
Accrued income taxes	809	555
Other accrued expenses	2,515	2,160
Total current liabilities	10,443	7,561
Long-term debt	23,784	26,727
Accrued compensation and retirement benefits	1,610	1,759
Accrued income taxes	2,517	2,893
Long-term intercompany loans payable	23,578	17,537
Deferred tax liabilities	3,643	3,729
Other liabilities	1,710	1,916
Total liabilities	67,285	62,122
Shareholders’ equity	49,561	65,013
Noncontrolling interests	106
Total equity	49,667
Total liabilities and equity	$ 116,952	$ 127,135

Guarantor Financial Informati76

Guarantor Financial Information - Condensed Consolidating Statement of Cash Flows (Details) - USD ($) $ in Millions	9 Months Ended
	Jan. 27, 2017	Jan. 29, 2016
Operating Activities:
Net cash provided by (used in) operating activities	$ 5,107	$ 3,892
Investing Activities:
Acquisitions, net of cash acquired	(1,328)	(1,132)
Additions to property, plant, and equipment	(924)	(693)
Purchases of investments	(3,354)	(4,509)
Sales and maturities of investments	4,286	4,017
Net (increase) decrease in intercompany loans	0	0
Intercompany dividend received	0
Capital contribution paid	0	0
Other investing activities, net	21	(11)
Net cash used in investing activities	(1,299)	(2,328)
Financing Activities:
Acquisition-related contingent consideration	(58)	(21)
Change in current debt obligations, net	1,118	1,223
Repayment of short-term borrowings (maturities greater than 90 days)	(2)	(48)
Proceeds from short-term borrowings (maturities greater than 90 days)	4	139
Issuance of long-term debt	131	0
Payments on long-term debt	(361)	(1,612)
Dividends to shareholders	(1,782)	(1,608)
Issuance of ordinary shares	309	360
Repurchase of ordinary shares	(3,409)	(2,170)
Net intercompany loan borrowings (repayments)	0	0
Intercompany dividend paid	0	0
Capital contribution received	0	0
Other financing activities	80	60
Net cash used in financing activities	(3,970)	(3,677)
Effect of exchange rate changes on cash and cash equivalents	54	(9)
Net change in cash and cash equivalents	(108)	(2,122)
Cash and cash equivalents at beginning of period	2,876	4,843
Cash and cash equivalents at end of period	2,768	2,721
Consolidating Adjustments [Member] | Medtronic Senior Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	0	(8)
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	162	0
Sales and maturities of investments	(162)	0
Net (increase) decrease in intercompany loans	5,437	4,058
Capital contribution paid	241	1,500
Other investing activities, net	0	0
Net cash used in investing activities	5,678	5,558
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Repayment of short-term borrowings (maturities greater than 90 days)	0	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0	0
Issuance of long-term debt	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(5,437)	(4,058)
Intercompany dividend paid		8
Capital contribution received	(241)	(1,500)
Other financing activities	0	0
Net cash used in financing activities	(5,678)	(5,550)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Consolidating Adjustments [Member] | CIFSA Senior Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	0	(3,050)
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Net (increase) decrease in intercompany loans	(1,831)	(3,689)
Intercompany dividend received	(920)
Capital contribution paid	537	2,070
Other investing activities, net	0	0
Net cash used in investing activities	(2,214)	(1,619)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Repayment of short-term borrowings (maturities greater than 90 days)	0	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0	0
Issuance of long-term debt	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	1,831	3,689
Intercompany dividend paid	920	3,050
Capital contribution received	(537)	(2,070)
Other financing activities	0	0
Net cash used in financing activities	2,214	4,669
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Parent Company Guarantor (Medtronic plc) [Member] | Medtronic Senior Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	834	(15)
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Net (increase) decrease in intercompany loans	0	0
Capital contribution paid	0	0
Other investing activities, net	0	0
Net cash used in investing activities	0	0
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Repayment of short-term borrowings (maturities greater than 90 days)	0	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0	0
Issuance of long-term debt	0
Payments on long-term debt	0	0
Dividends to shareholders	(1,782)	(1,608)
Issuance of ordinary shares	309	360
Repurchase of ordinary shares	(3,409)	(2,170)
Net intercompany loan borrowings (repayments)	4,048	3,110
Intercompany dividend paid		0
Capital contribution received	0	0
Other financing activities	0	60
Net cash used in financing activities	(834)	(248)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	(263)
Cash and cash equivalents at beginning of period	0	263
Cash and cash equivalents at end of period	0	0
Parent Company Guarantor (Medtronic plc) [Member] | CIFSA Senior Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	834	(15)
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Net (increase) decrease in intercompany loans	0	0
Intercompany dividend received	0
Capital contribution paid	0	0
Other investing activities, net	0	0
Net cash used in investing activities	0	0
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0	0
Issuance of long-term debt	0
Payments on long-term debt	0	0
Dividends to shareholders	(1,782)	(1,608)
Issuance of ordinary shares	309	360
Repurchase of ordinary shares	(3,409)	(2,170)
Net intercompany loan borrowings (repayments)	4,048	3,110
Intercompany dividend paid	0	0
Capital contribution received	0	0
Other financing activities	0	60
Net cash used in financing activities	(834)	(248)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	(263)
Cash and cash equivalents at beginning of period	0	263
Cash and cash equivalents at end of period	0	0
Subsidiary Issuer [Member] | Medtronic Senior Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	933	839
Investing Activities:
Acquisitions, net of cash acquired	(940)	0
Additions to property, plant, and equipment	(257)	(210)
Purchases of investments	0	0
Sales and maturities of investments	210	0
Net (increase) decrease in intercompany loans	168	(975)
Capital contribution paid	(241)	0
Other investing activities, net	0	0
Net cash used in investing activities	(1,060)	(1,185)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Repayment of short-term borrowings (maturities greater than 90 days)	0	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0	0
Issuance of long-term debt	0
Payments on long-term debt	(29)	(600)
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	107	(96)
Intercompany dividend paid		0
Capital contribution received	0	0
Other financing activities	34	0
Net cash used in financing activities	112	(696)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	(15)	(1,042)
Cash and cash equivalents at beginning of period	55	1,071
Cash and cash equivalents at end of period	40	29
Subsidiary Issuer [Member] | CIFSA Senior Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	(53)	3,316
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Net (increase) decrease in intercompany loans	2,614	(2,749)
Intercompany dividend received	920
Capital contribution paid	(537)	(570)
Other investing activities, net	0	0
Net cash used in investing activities	2,997	(3,319)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Repayment of short-term borrowings (maturities greater than 90 days)	0	0
Proceeds from short-term borrowings (maturities greater than 90 days)	0	0
Issuance of long-term debt	0
Payments on long-term debt	0	(1,000)
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(3,071)	311
Intercompany dividend paid	0	0
Capital contribution received	0	0
Other financing activities	0	0
Net cash used in financing activities	(3,071)	(689)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	(127)	(692)
Cash and cash equivalents at beginning of period	208	728
Cash and cash equivalents at end of period	81	36
Subsidiary Guarantors [Member] | Medtronic Senior Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	306	525
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Net (increase) decrease in intercompany loans	(2,703)	(539)
Capital contribution paid	0	(1,500)
Other investing activities, net	0	0
Net cash used in investing activities	(2,703)	(2,039)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	1,099	1,201
Repayment of short-term borrowings (maturities greater than 90 days)	0	(48)
Proceeds from short-term borrowings (maturities greater than 90 days)	0	139
Issuance of long-term debt	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	1,298	53
Intercompany dividend paid		0
Capital contribution received	0	0
Other financing activities	0	0
Net cash used in financing activities	2,397	1,345
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	(169)
Cash and cash equivalents at beginning of period	0	170
Cash and cash equivalents at end of period	0	1
Subsidiary Guarantors [Member] | CIFSA Senior Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	160	709
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Net (increase) decrease in intercompany loans	(2,557)	(722)
Intercompany dividend received	0
Capital contribution paid	0	(1,500)
Other investing activities, net	0	0
Net cash used in investing activities	(2,557)	(2,222)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	1,099	1,201
Repayment of short-term borrowings (maturities greater than 90 days)	0	(48)
Proceeds from short-term borrowings (maturities greater than 90 days)	0	139
Issuance of long-term debt	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	1,298	52
Intercompany dividend paid	0	0
Capital contribution received	0	0
Other financing activities	0	0
Net cash used in financing activities	2,397	1,344
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	(169)
Cash and cash equivalents at beginning of period	0	170
Cash and cash equivalents at end of period	0	1
Subsidiary Non-guarantors [Member] | Medtronic Senior Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	3,034	2,551
Investing Activities:
Acquisitions, net of cash acquired	(388)	(1,132)
Additions to property, plant, and equipment	(667)	(483)
Purchases of investments	(3,516)	(4,509)
Sales and maturities of investments	4,238	4,017
Net (increase) decrease in intercompany loans	(2,902)	(2,544)
Capital contribution paid	0	0
Other investing activities, net	21	(11)
Net cash used in investing activities	(3,214)	(4,662)
Financing Activities:
Acquisition-related contingent consideration	(58)	(21)
Change in current debt obligations, net	19	22
Repayment of short-term borrowings (maturities greater than 90 days)	(2)	0
Proceeds from short-term borrowings (maturities greater than 90 days)	4	0
Issuance of long-term debt	131
Payments on long-term debt	(332)	(1,012)
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(16)	991
Intercompany dividend paid		(8)
Capital contribution received	241	1,500
Other financing activities	46	0
Net cash used in financing activities	33	1,472
Effect of exchange rate changes on cash and cash equivalents	54	(9)
Net change in cash and cash equivalents	(93)	(648)
Cash and cash equivalents at beginning of period	2,821	3,339
Cash and cash equivalents at end of period	2,728	2,691
Subsidiary Non-guarantors [Member] | CIFSA Senior Notes [Member]
Operating Activities:
Net cash provided by (used in) operating activities	4,166	2,932
Investing Activities:
Acquisitions, net of cash acquired	(1,328)	(1,132)
Additions to property, plant, and equipment	(924)	(693)
Purchases of investments	(3,354)	(4,509)
Sales and maturities of investments	4,286	4,017
Net (increase) decrease in intercompany loans	1,774	7,160
Intercompany dividend received	0
Capital contribution paid	0	0
Other investing activities, net	21	(11)
Net cash used in investing activities	475	4,832
Financing Activities:
Acquisition-related contingent consideration	(58)	(21)
Change in current debt obligations, net	19	22
Repayment of short-term borrowings (maturities greater than 90 days)	(2)	0
Proceeds from short-term borrowings (maturities greater than 90 days)	4	0
Issuance of long-term debt	131
Payments on long-term debt	(361)	(612)
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(4,106)	(7,162)
Intercompany dividend paid	(920)	(3,050)
Capital contribution received	537	2,070
Other financing activities	80	0
Net cash used in financing activities	(4,676)	(8,753)
Effect of exchange rate changes on cash and cash equivalents	54	(9)
Net change in cash and cash equivalents	19	(998)
Cash and cash equivalents at beginning of period	2,668	3,682
Cash and cash equivalents at end of period	$ 2,687	$ 2,684